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Chapter 1
The incidence of cryptococcosis, initially considered unusual, began to increase with 
the arrival of acquired immunodeficiency syndrome (AIDS) in the 1980s to become 
one of the most important mycoses worldwide. After the advent of highly effective 
antiretroviral therapy in the mid-1990, its frequency started to decline in developed 
countries. However, cryptococcal meningitis remained the most common life-
threatening opportunistic fungal infection with an estimated annual mortality of 
625,000 persons, which ranks cryptococcosis as fourth among the most common causes 
of death due to infections in sub-Saharan Africa, higher than tuberculosis. (Armstrong 
et al. 2014; Park et al., 2009; La Hoz and Papas, 2013). Additionally, it has been reported 
that up to 6% of people with impaired cellular immunity due to other causes, are at risk 
of developing clinically apparent infections due to Cryptococcus (Bratton et al., 2012).
From discovery of the causative agent of cryptococcosis to its current 
taxonomy
Probably the first case of cryptococcosis was descrited in 1861 by Zenker. However 
because of the lack of microbiological evidence, the first case description is usually 
attributed to doctors Otto Busse and Abraham Buschke from Germany. In 1894 they 
reported the isolation of a microorganism from an injury in a 31-year-old woman and 
named it Saccharomyces hominis. Almost simultaneously, Sanfelice described the 
presence of encapsulated yeasts obtained from fermented peach juice; he demonstrated 
its pathogenicity in laboratory animals and called it Saccharomyces neoformans. 
Sanfelice shortly afterwards recovered a similar agent from the lymph node in an ox and 
called it Saccharomyces lithogenes because there were particular differences between 
this organism and the first one (Casadevall and Perfect, 1998, Bovers et al., 2008a).
A year after the first cryptococcosis case report by Busse and Buschke, Curtis Ferdinand 
in France, described a “plant parasite” yeast as an etiologic agent of an ulcerating abscess 
in a young Frenchman with an unremarkable medical history. Based on different 
morphological features in comparison with the previous described isolates (elongated 
or oval yeasts) and its affinity for subcutaneous tissue shown in animal models, Curtis 
labelled this agent Saccharomyces subcutaneous tumefaciens. Despite the absence of 
epidemiological data, it is currently considered the first report of an autochthonous 
infection by C. gattii in France (Hagen et al., 2012; Kwon-Chung et al., 2011).
These findings demonstrated three cardinal aspects: i) the ability to cause infection 
in humans and in animals, ii) this, added to the demonstration of Koch’s postulates 
by Sanfelice and Curtis, showed its pathogenic potential and iii) the fact that it can 
be recovered from natural sources revealed its saprophytic nature. However, the 
different denominations received yielded confusion about the true nature of this agent 
(Casadevall and Perfect, 1998; Bovers et al., 2008a).
The genus Cryptococcus was first established in 1833 by Kützing to “accommodate” 
a new microorganism described as “globose hyaline microscopic organism with 
undetermined taxonomic position that produces whitish mucoid colonies”. Later, 
in 1901, Vuillemin argued that the microorganisms isolated by Busse and Sanfelice 
in 1894 actually belong to this genus. Thereafter, its definition underwent multiple 
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proposed amendments until the gender name Cryptococcus Vuillemin and pointed C. 
neoformans as the type species. Nowadays, the genus includes about 100 pathogenic 
and non-pathogenic species (Kwon-Chung et al., 2011).
One of the main contributions to the current taxonomy of C. neoformans, was the 
recognition of its sexual stage. In 1975 the first teleomorph, Filobasidiella neoformans, 
was obtained by mating compatible isolates of serotypes A and D. The second species, 
Filobasidiella bacillispora was achieved by crosslinking compatible cells of serotypes 
B and C (Kwon-Chung, 1975). The correlation between the different serotypes and 
teleomorph states indicated that differences between isolates were not restricted to 
their antigenic properties. Subsequent studies showed that both species differ in their 
ecological niches, epidemiology, biochemistry, association with different host immune 
states, phylogeny and genomic arrangements (Kwon-Chung and Varma, 2006; Kwon-
Chung et al., 2011).
Studies about this agent and the disease it causes, led to its current classification. What 
once was considered a “complex species”, is now recognized as a “species complex” 
(Fonseca et al., 2011). The F. bacillispora anamorph state which comprises serotypes B 
and C was raised to the upper level and named Cryptococcus bacillisporus; later on this 
denomination was replaced by C. neoformans var. gattii and it is currently recognized as 
the species C. gattii. On the other hand, the F. neoformans anamorph state (serotype A, 
D and AD), named as C. neoformans was reclassified as C. neoformans var. neoformans, 
however, based on it phylogenetic characteristics, this nomenclature changed as well. 
The latter variety today has been raised to species level that comprises C. neoformans 
var. grubii corresponding to serotype A, C. neoformans var. neoformans corresponding 
to serotype D and the intervarietal state C. neoformans corresponding to serotype AD 
(table 1) (Kwon-Chung and Varma, 2006; Ngamskulrungroj et al., 2009).
Table 1. Accepted nomenclature for the C. neoformans/C. gattii species complex
Division Basidiomycota
Class Hymenomycetes
Order Tremellales
Family Tremellaceae
Genus Filobasidiella
Species, 
varieties 
and 
serotypes
Teleomorph Anamorph
F. bacillispora C. gattii (serotype B and C)
F. neoformans C. neoformans
C. neoformans  
var. grubii  
(serotype A)
C. neoformans 
var. neoformans 
(serotype D)
C. neoformans 
intervarietal state 
(serotype AD)
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Cryptococcosis – What is it and what is the cause?
Cryptococcosis, formerly known as Busse and Buschke disease, European blastomycosis 
or torulosis is the infection caused by the encapsulated yeast C. neoformans species 
complex which are ubiquitous microorganisms able to affect humans and animals. 
Although infection mostly occurs after inhalation of infective particles, the most 
frequent clinical presentation is not a pneumonia, but meningitis and disseminated 
disease (Lin and Heitman, 2006). Nearly 100 species have been described within 
the genus Cryptococcus, the C. neoformans/C. gattii species complex being primary 
responsible for cryptococcal infections in both humans and animals (Fonseca et 
al., 2011). The literature includes a budding number of case reports on infections 
due to Cryptococcus albidus and Cryptococcus laurentii, as the etiological cause of 
approximately 80% of infections due to other species different from C. neoformans 
species complex (Khawcharoenporn et al., 2007). Other members of this genus occur 
less frequently and are usually related to severe immunosuppression (Casadevall and 
Perfect, 1998; Khawcharoenporn et al. 2007; Kwon-Chung et al., 2011). 
Correct identification of Cryptococcus different from the C. neoformans/C. gattii 
species complex has high clinical relevance, as they might have a different pattern 
of susceptibility to antifungal agents (Pfaller et al., 2009). However, for practical 
purposes, C. neoformans/C. gattii species complex is considered to be the only one that 
consistently produces disease (Kwon-Chung et al., 2011).
Yeasts belonging to the C. neoformans/C. gattii species complex are characterized by 
4 to 6 μm rounded-oval cells, surrounded by a polysaccharide capsule of variable size: 
isolates recovered from environmental sources have a virtual or unapparent capsule (≤ 
4 μm) while those from clinical sources used to show a wide capsule (≥ 30 μm). Based 
on antigenic differences in their structure, seven serotypes were identified: A, B, C, 
D, AD, AB and BD that, together with the biochemical, ecological, epidemiological 
and genetic divergences, permitted discrimination of the existing species from varieties 
that set up the complex (Casadevall and Perfect, 1998; Kronstad et al., 2011). 
What are the sources of it causative agents?
The C. neoformans/C. gattii species complex comprises of free-living saprophytic yeasts 
which can survive in diverse niches. Numerous studies have been carried out in order to 
achieve a better understanding of its life cycle in nature (Casadevall and Perfect, 1998; 
Randhawa et al., 2010; Kwon-Chung et al., 2011).
C. neoformans and C. gattii have been isolated ubiquitous worldwide from variable 
natural sources (soil, air, water, raw milk and its derivatives, citrus, vegetables such as 
green beans, beets, cabbage, radishes, lettuce , tomatoes and some tubers including 
potatoes). However, poultry manure, especially from domestic pigeons (Columba livia) 
has been identified as the most notorious source of infection-related isolates (Casadevall 
and Perfect, 1998; Cabral, 1999; Kwon-Chung et al., 2011). In the accumulated faeces 
protected from the sun’s ultraviolet rays up to 2-3 x 106 cells/g can be detected, which 
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can survive for more than a year (Hamasha et al., 2004). The low concentration of C. 
neoformans in the peak, belly, legs and intestines of these birds suggests that pigeons are 
not its main reservoir in nature. These facts combined with the increased C. neoformans 
reports from more than 22 tree species of different families and genera indicated that 
plants could be the primary ecological niche (Lazera et al., 2000; Randhawa et al., 2008; 
Randhawa et al., 2010). This hypothesis is supported by the potential of the yeast to 
degrade lignin which serves as growth substrate by using its phenoloxidase enzyme 
(Lazera et al., 2000).
On the other hand, C. gattii used to have a more restricted distribution to tropical 
and subtropical climates. However, more recently, the outbreak at the west coast of 
North America indicates a drastic change in the adaptation of this organism to other 
environments (Chowdhary et al., 2012a; Galanis and Macdougall, 2010; Hagen et al., 
2013; Kidd et al., 2007; MacDougall et al., 2011). Until 1990 the ecological niche of this 
species was a mystery when the Australian researchers Ellis and Pfeiffer described 
its association with Eucalyptus camaldulensis. They confirmed the presence of 
basidiospores, suspended in the air near these trees and suggested that in this reservoir 
sexual reproduction with subsequent propagule dissemination to the environment could 
occur (Ellis and Pfeiffer, 1990). Subsequent reports have shown that this association is 
not limited to Eucalyptus trees or a particular geographic area contributing to a better 
understanding of the diversity of its natural sources that, interestingly, do not include 
poultry manure or contaminated soil (Chowdhary et al. 2012b; Ellis, 1987; Hamasha et 
al., 2004; Kidd et al., 2007; Lazera et al., 2000).
How do we become sick from these yeasts?
Circumstantial evidence suggests that infection by the C. neoformans/C. gattii species 
complex usually develops after inhalation of infectious propagules (Velagapudi et al., 
2009). This can also occur in various species of animals but proof of person to person 
and animal to person transmission or laboratory-acquired disease are scarce. Other 
routes are less common and include organ transplants from infected donors and 
traumatic cutaneous inoculation (Török et al., 2010).
Serologic studies in the open population indicate a high prevalence of infections due to 
this yeast, which seems to be acquired already from childhood onwards. Despite this, 
whether a person/individual will became sick or not depends on three main factors: 
the state of the host defence mechanisms, the virulence of the infecting strain and the 
inoculum count (Casadevall, 2010).
Once inhaled, the infectious agent reaches the lungs where it meets the first line of 
defence that consists of nonspecific phagocytic effector cells: alveolar macrophages, 
neutrophils, natural killer cells and lymphocytes. Macrophages phagocytose the yeasts, 
express on their surface the processed antigen bound to the major histocompatibility 
complex class II and present it to CD4+ T cells responsible for triggering a specific 
immune response. In most immunocompetent subjects the response is able to 
eliminate the infection and the microorganism does not extend beyond the pulmonary 
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focus with little or no symptoms. However, the ability of these cells to remove the yeast 
is limited. By consequence a large inoculum can overcome this defence mechanism 
allowing fungal multiplication and dissemination (Casadevall et al., 1993; Olszewski 
et al., 2010).
Cryptococcosis is more common in individuals with impaired cell-mediated immunity, 
being HIV infection the most important predisposing condition (Byrnes et al., 2009; 
Galanis and MacDougall, 2010). Other well known risk factors are steroid treatment, 
solid organ transplantation, chronic obstructive pulmonary disease, diabetes, 
lymphoma, leukemia, sarcoidosis, cirrhosis and connective tissue diseases (e.g. lupus 
erythematosus and rheumatoid arthritis) (Baddley et al., 2011; Bratton et al., 2012; La Hoz 
and Pappas, 2013; Pappas, 2013). Besides, the hypothesis that an intact immune system 
is able to control the infection has been challenged. On one hand, documented cases 
prior to the AIDS epidemic, show that this agent is able to cause disease in individuals 
without apparent predisposing factors (Mitchell and Perfect, 1995) while, on the other 
hand, it has been widely demonstrated that C. gattii species is the main responsible 
agent of cryptococcosis in HIV-negative patients (Casadevall, 2010).
Unlike potent toxins released by pathogenic bacteria, the C. neoformans/C. gattii species 
complex does not seem to produce abundant products that directly contribute to the 
clinical manifestations of the infection. Cryptococcal pathogenesis largely depends on 
the integrity of the various host defence components in the compromised immune 
system (Casadevall et al., 2003; Idnurm et al., 2005; Kozubowski and Heitman, 2011).
The polysaccharide capsule and its constituents as well as melanin and extracellular 
enzymes (urease, superoxide dismutase, proteases, esterases and lipases) are among 
the most studied virulence factors of C. neoformans/C. gattii species complex that 
contribute to the seriousness of the disease (Rodriguez et al., 2009; Kronstad et al., 
2011). More recently additional factors such as morphologic changes (development of 
filaments during mating as well as the expansion of the capsule and cell size in response 
to specific host factors during infection) and biofilm formation have been recognized 
that amplify the pathogenic power of these yeasts (Martínez et al. 2008; Lin, 2009; 
Kozubowski and Heitman, 2011; Kronstad et al., 2011).
Both, C. neoformans and C.gattii share the main adaptation and virulence mechanisms, 
which corroborates the classification of both species as true pathogens. Extrapulmonary 
dissemination is invariably associated with disease, meningoencephalitis being the most 
common clinical presentation. The basis of C. neoformans/C. gattii species complex 
neurotropism are not clear, but this propensity could be associated with the abundant 
presence of catecholamines (excellent substrates for the phenoloxidase enzyme) 
and the selective evasion of host defences. Protein molecules such as antibodies and 
complement factors, essential for efficient fungal opsonization, are effectively shut out 
by the blood-brain barrier. It indeed has been suggested that phagocytic cells resident 
in the central nervous system (CNS) are effective against the fungus, but their activity 
is critically depend on opsonins (Feldmesser et al., 2000; Casadevall, 2010; Charlier et 
117
General Introduction
al., 2010; Liu et al., 2012). 
C. neoformans and C. gattii are able to survive in the hostile phagosome environment. 
The development of these structures with large numbers of yeasts inside, suggests 
that early stages of the replication of the organism does occur within these vesicles 
subsequent to the escape through a non-destructive removal process (Johnston and 
May, 2010). In fact, such an expulsion is preceded by the phago-lysosome fusion, which 
seems to be coordinated by or dependent on the pathogen, since this phenomenon 
does not occur in the presence of dead yeasts (Alvarez and Casadevall, 2006). The 
development of giant phago-lysosomes led to speculate that C. neoformans/C. gattii 
species complex is able of altering the cytoplasmic membrane properties of these 
organelles, the pathogen to prevent death of the host cell and the activation of the 
inflammatory response. Furthermore, it has been demonstrated that yeasts can be 
transported between macrophages, a process that may contribute to the persistence or 
latency of the pathogen in the host (Ma et al., 2007; Johnston and May, 2010).
Several investigations assessed the mechanism of persistence of Cryptococcus. 
Olszewski et al. provided a full summary of this complex phenomenon. According 
to these researchers, a small number of yeasts may persist for long periods or even 
forever within host tissues. In this case, the modulatory effects on the innate and 
adaptive immune response, the high adaptability to extreme conditions, and the 
development of tolerance to treatment, although insufficient to promote disease in 
most immunocompetent hosts, explains persistence and reactivation or relapse of 
subclinical infection (Olszewski et al., 2010).
What are the clinical manifestations of infection?
The clinical picture is related to the affected organ. Although the load of yeasts at the 
affected sites is significantly higher in immunocompromised patients, the clinical 
manifestations are similar regardless of the host immune status. However, infections 
due to C. gattii can be distinguished from C. neoformans given a higher tendency to 
produce tumorous lesions and neurological involvement because of a slower response 
to treatment (Török et al., 2010; Pappas, 2013).
After more than 100 years of clinical experience, it has become clear that lungs are 
the first organ that the C. neoformans/C. gattii species complex face, but most cases 
stay asymptomatic. Clinical manifestations, if any, consist of coughing, fever, pleural 
pain, malaise and weight loss. Unlike infections with Histoplasma capsulatum, tissue 
calcification occurs exceptionally. This feature, combined with the unavailability of 
reliable intradermal tests, makes the diagnosis of infection due to this agent difficult 
(Harrison 2009; Török et al., 2010).
Most cases remain undiagnosed unless neurological signs and symptoms, usually quite 
insidiously appear. A wide range of CNS symptoms can be present, headache and fever 
(38-39 °C) being the most prominent. Since the clinical presentation is nonspecific, it 
is important to consider the diagnosis of cryptococcal meningitis in every HIV-positive 
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patient with fever. Supplemented by monitoring for this possibility at regular intervals, 
even when the initial investigations are negative because brain and meningeal infection 
is the most frequent cause of death due to cryptococcal infection (Casadevall and 
Perfect, 1998; Harrison, 2009). C. neoformans can invade a single site or multiple organs 
simultaneously during dissemination. Other sites such as skin and prostate are often 
affected; the latter is considered an important yeast reservoir in males. (Casadevall and 
Perfect, 1998; Török et al., 2010).
How can the infection be established? 
Microbiological diagnosis of cryptococcosis is based on direct microscopic examination 
of a clinical sample as well as isolation and identification of the yeast using biochemical 
and serological tests. However, these methods have some disadvantages (Huston and 
Mody, 2009). Phenotypic methods for example, are laborious, time consuming and 
sometimes imprecise because of the subjectivity in result interpretation (Wengenack 
and Binniker, 2009). Automatic and semi-automatic methods such as API 20C AUX 
and Vitek respectively allow obtaining results within approximately 72 h. These tests, 
however, have their own limitations as they depend on complementary tests for final 
identification (Gündeş et al., 2001; Massonete et al., 2004). 
Matrix-Assisted Laser Desorption Ionization-Time-of-Flight Mass Spectrometry 
(MALDI-TOF MS) is a rapid identification tool for the correct recognition of the two 
currently recognized human pathogenic Cryptococcus species and offers a simple 
method for the separation of the eight major molecular types and the detection of 
hybrid strains within this species complex in the clinical laboratory (Firacative et al., 
2012; McTaggart et al., 2011; Stevenson et al., 2010). 
For serological testing, false positive results due to cross-reactions with rheumatoid 
factor and Trichosporon spp. or false negative results because a pro-zone phenomenon 
have been described (Huston and Mody, 2009). In 2009, a lateral flow immunoassay (LFA) 
for the detection of cryptococcal antigen was developed by IMMY (ImmunoMycologics, 
U.S.A.) as a potential test for the diagnosis of cryptococcal infection (Jarvis et al., 2011). 
This system seems to be stable at room temperature, has a rapid turnaround time, 
requires very little technical skill, and can be performed with minimal laboratory 
infrastructure (McMullan et al., 2012). Beside these advantages, it has been shown that 
it is a sensitive test as compared with the gold standard (culture), and it has a high level 
of overlap with enzyme immunoassay (EIA) (Lindsley et al., 2011). However agreement 
between titres, which was more often observed in sera with low EIA optical density 
values was imperfect possibly reflecting the presence of low levels of circulating antigen 
(Lindsley et al., 2011; McMullan et al., 2012).
Although not suited for routine diagnosis, molecular methods are available for the 
detection of specific genetic sequences of C. neoformans/C. gattii species complex from 
specimens and cultures (Bovers et al., 2007; Wengenack and Binnicker, 2009). These 
tools provide identification of C. neoformans/C. gattii species complex and other less 
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frequently encountered species such as C. laurentii, and offer more complete results 
than conventional diagnostic procedures. They contribute to a better understanding 
of epidemiology and natural history of cryptococcosis. These tests can also be used to 
determine the presence of certain genotypes in a given population, allowing the study 
of the species diversity in the environment (Leaw et al., 2006). Some of the most used 
techniques are described below:
DNA-DNA hybridization: Based on the intrinsic property of the complementarity of 
the nitrogenous bases. It is a powerful tool for the development of specific primers 
currently used in research centers to identify genetic variations among isolates from 
different geographical areas (Hu et al., 2008, Costa et al., 2010).
Electrokaryotyping: This was the first technique used for the chromosomal analysis 
of C. neoformans. It consists in the separation of large DNA fragments through their 
re-orientation on agarose gel under the action of electric alternating fields. Lebens 
and Polacheck were the first to visualize C. neoformans and C. gattii chromosomes by 
this system and revealed that these two species differ in the number of chromosomal 
bands. Due to high complexity its current use in C. neoformans studies is very limited 
(Polacheck and Lebens, 1989).
Polymerase chain reaction (PCR): Among the many tools to manipulate and gather data 
from DNA, this technique facilitates the production of multiple copies of small, specific 
segments of the genome. This technique accelerates the diagnosis of cryptococcosis 
with satisfactory specificity and sensitivity by detecting minimum amounts of 
specimens. The main advantages are i) rapidly and easily executable, ii) less expensive 
than hybridization, iii) can be fully automated, iv) applicable to contaminated samples 
or mixed cultures and v) can be used in combination with other techniques making it a 
useful tool for molecular epidemiology studies. Widely used variants for C. neoformans 
and C. gattii identification are conventional PCR and multiplex (real-time) PCR. The 
most commonly used target sequences are CAP59, IGS1, PLB1, URA5, M13 and ITS (18S, 
5.8S and 28S). Particularly due to its high variability and the presence of about 100 
copies per haploid genome, the latter are the most widely used for genomic sequence 
studies (Hsu et al., 2003; Pryce et al., 2006).
PCR-fingerprinting is based on the detection of hypervariable repetitive DNA sequences. 
It is considered to be one of the fastest molecular techniques for the detection of band 
patterns. It has been applied to confirm a particular molecular type in sporadic cases 
or for molecular epidemiological studies. By using short primers founded in arbitrary 
sequences it is not necessary to have prior knowledge of the sequence. As for many 
molecular methods, PCR fingerprinting has an enhanced discrimination power 
compared to biochemical and serological tests. Its high sensitivity and specificity for 
detecting differences allows rapid differentiation of C. neoformans and C. gattii isolates. 
Within the field of fungal taxonomy the ribosomal DNA targets 18S, 5.8S and 28S are 
frequently used, but for the C. gattii/C. neoformans species complex several other 
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genetic markers have been applied to study the genetic diversity and include CAP59, 
CAP64, IGS1, LAC1, PBL1, URA5. Studies based on genetic fingerprinting facilitate the 
classification of clinical and environmental isolates in eight major molecular types, 
but an exact correlation between serotype and molecular types of C. gattii does not 
exist (Meyer et al., 2003, 2009; Chen et al., 2008; Hagen et al., 2010; Hagen et al., 2012; 
Mueller and Wolfenbarger, 1999; Kidd et al., 2007).
Random amplification of polymorphic DNA (RAPD) is a technique that involves the 
amplification of genomic DNA by simple arbitrary primers. It detects polymorphisms 
without knowledge about the genome. This method allows the differentiation among 
varieties, serotypes and molecular types of major pathogenic species of the genus. It 
is used to determine cryptococcal genetic profiles from different sources of strains 
obtained from patients in a particular geographic region or from different anatomical 
sites. At present, it use has been replaced by newer methods that have a higher resolution 
(García-Hermoso et al., 1999; Hagen et al., 2010; Hagen et al., 2012; Litvintseva et al., 
2005).
Restriction fragment length polymorphism (RFLP) or PCR-RFLP can be applied for the 
rapid determination of molecular types of C. gattii and C. neoformans. First, a specific 
region of interest is amplified, for C. gattii/C. neoformans the PLB1 and URA5-loci are 
widely used. The basic difference between both techniques is that PCR-RFLP needs 
specific primers that amplify the genetic region of interest followed by an enzymatic 
digestion. Molecular epidemiological studies have revealed that PCR-RFLP can be 
applied to determine the relationship between clinical and environmental cryptococcal 
isolates (Kidd et al., 2007; Meyer et al., 2003; Meyer et al., 2009).
Amplified Fragment Length Polymorphism (AFLP) is one of the most advanced 
techniques to efficiently obtain fingerprint data from large numbers of cryptococcal 
isolates. It is more efficient than PCR-RFLP, combining high resolution and high 
sampling power. Additionally, it is excellent in the detection of genetic variability as 
it explores the presence or absence of polymorphisms in restriction sites in greater 
detail. By this method it is possible to group C. neoformans and C. gattii species 
complex in thirteen molecular types and to compare the obtained results with other 
typing techniques (e.g. serotyping). Among its main limitations are the multiple stages 
involved in the process, expensive reagents and laboratory equipment and requirement 
of high quality DNA. Recently it was demonstrated that isolates with certain AFLP 
genotypes are associated with increased virulence (Mueller and Wolfenbarger, 1999; 
Boekhout et al., 2001; Barreto de Oliveira et al., 2004; Enache-Angoulvant et al., 2007; 
Bovers et al., 2008b; Leal et al., 2008; Litvintseva and Mitchell, 2009; Byrnes et al., 
2009; Hagen et al., 2010; Hagen et al., 2012).
Multi-locus sequence typing (MLST) is currently one of the important tools for global 
epidemiological and population biological studies. It is based on the variation of the 
nucleotide sequence of multiple genes such as those encoding the capsule, urease, 
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phospholipase, and laccase production. It is remarkably valuable for determining 
circulating genotypes in different parts of the world. Its advantages include a high 
reproducibility, and the possibility to perform analysis through specific software that 
can be exchanged between laboratories. Moreover, the generated data can be used 
to differentiate isolates and to investigate evolutionary relationships. Recently the 
International Society for Human and Animal Mycology published a consensus MLST 
scheme for genotyping of C. neoformans and C. gattii (Litvintseva et al., 2006; Hagen 
et al., 2012; Meyer et al., 2009; Urwin and Maiden, 2003).
Short tandem repeat (STR) analysis was initially developed for forensic and paternity 
studies but the advantages favoured its expansion into other research fields. STR is 
actually the analysis of DNA fragment sizes of DNA-repeats that have a length of one to 
six nucleotides. The variation in the number of repeats creates different allele sizes. STRs 
are usually found in non-coding DNA regions and have a high mutation rate, making it 
highly polymorphic. As for MLST, STR has highly reproducible and readily comparable 
results intra-and inter-laboratory (Hanafy et al., 2008; de Valk et al., 2009).
Currently, molecular typing of microorganisms plays a much broader role than simply 
performing epidemiological studies. The development of these techniques introduced 
new possibilities to the fields of taxonomy, identification and diagnosis, as well as to that 
of clarification of the phylogeny and evolution. The accumulation of data generated by 
these methods is expected to have a positive impact on the control of resistant isolates 
and better management of the disease (Costa et al., 2010; Kwon-Chung et al., 2011).
What are the options for the management of the infection? 
Cryptococcal infection treatment has been one of the most studied among mycosis 
diseases, but there are still many unresolved aspects. Despite medical advances, the 
mortality rate during the first three months of treatment for neurocryptococcosis 
exceeds 20% and approaches 100% in patients who do not receive proper management 
(Perfect et al., 2010). Papers published on this subject agree that the application of 
an induction phase, among the evaluated schemes, is the most effective followed by 
consolidation and a maintenance phase (Perfect et al., 2010; Török et al., 2010).
The recommended treatment during the induction phase is based on a combination 
of two or more drugs. Amphotericin B (0.7 to 1 mg/kg/d) and 5-fluorocytosine (100 
mg/kg/day) during 2 weeks are first choice. Alternatives are liposomal amphotericin 
B formulations and in cases of unavailability of, or intolerance, to any of the listed 
drugs, fluconazole (800-400 mg/d) or itraconazole (400 mg/d) (Perfect et al., 2010). 
It is recommended to use 8 weeks of fluconazole (400 mg/d) during the consolidation 
phase. In the next phase the dose can be halved for not less than a year or as long as 
patients exhibit CD4+ lymphocyte counts ≤ 200 cells/mL. Itraconazole (400 mg/d) and 
amphotericin B (1 mg/kg/week), as alternatives have also been evaluated (Perfect et al., 
2010). 
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Reduction or cessation of steroid treatment when possible, administration of interferon 
gamma and intrathecal or intraventricular amphotericin B, as well as surgical excision 
of the lesions, have been used for rescue of therapeutic failures (Perfect et al., 2010; 
Török et al., 2010). The optimal strategy for the management of intracranial pressure 
is not well established, but there is some evidence that the drainage of cerebrospinal 
fluid (CSF) by various methods produces the best results (Casadevall and Perfect, 
1998; Török et al., 2010). Nevertheless, the high incidence of therapeutic failures and 
relapses hint at the lack of an optimum approach to control this infection. A wide array 
of therapeutic options, ranging from immunization to assessment of new antifungal 
compounds, have been tested (Mondon et al., 1999; Espinel-Ingroff, 2003; Thompson 
et al., 2008; Pfaller et al., 2009; Thompson et al., 2009; Saylo et al., 2010; Chow and 
Casadevall, 2011).
Although some recently developed antifungals already have been licensed for use 
in humans, it remains problematic to treat some patients effectively. Therefore it is 
necessary to continue the search for alternative therapies. A new generation of azoles 
such as isavuconazole are currently in different phases of development (Guinea and 
Bouza, 2008; Fera et al., 2009). The antifungal spectrum of isavuconazol appears 
to be similar to that of voriconazole and posaconazole with potent in vitro activity 
against Candida spp., Aspergillus spp., Scedosporium spp., Blastomyces dermatitidis, 
Histoplasma capsulatum, zygomycetes as well as against less frequent, pigmented fungi 
(Exophiala spp., and Phialophora spp.). Moreover, cross-resistance with fluconazole 
has not been reported (Hagen et al., 2010; Thompson et al., 2009; Thompson and 
Wiederhold, 2010; Yamazaki et al., 2010). In addition, the pharmacokinetic profile of 
this drug has advantage over that of other antifungals allowing oral and parenteral 
administration (Thompson and Wiederhold, 2010). This drug is currently tested in 
clinical phase III trials of therapy for candidosis and aspergillosis (Guinea and Bouza, 
2008; Guinea et al., 2010).
Testing the in vitro activity of antifungal compounds 
With the increase in number of available antifungals, a need for reliable methods for 
determining antifungal susceptibility testing has become apparent. Susceptibility 
testing became important in medical mycology when the AIDS epidemic began. 
The use of fluconazole, generally given at subtherapeutic doses for the treatment of 
oropharyngeal candidosis, led to the emergence of resistance (Tapia, 2009).
The first reports of resistance were questioned on the basis of the use of different 
methodologies with low intra- and inter- laboratory reproducibility. Subsequent work 
showed the importance of adjusting the test conditions (inoculum, culture medium 
composition, pH, temperature and incubation time) because of their respective impact 
on inhibitory concentration values (MIC). 
The first optimized and standardized method for the study of yeasts susceptibility 
was a macrodilution technique. This was developed by the National Committee for 
Clinical Laboratory Standards (NCCLS), now the Institute for Clinical Laboratory 
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Standards (CLSI). Afterward, this method was adapted to a microdilution plate format, 
which currently is the most widely accepted reference test (Johnson et al., 2008; CLSI, 
2008a). The European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
has promoted modifications, which in practical terms made the broth microdilution 
test less laborious, easier to interpret (especially with isolates showing trailing) and 
faster, with definitive results at 24 h for Candida spp. and 48 hours for Cryptococcus 
spp. Although according to published studies both methods correlate well, it should be 
taken into account that they have their own individual standard cutoff (Espinel-Ingroff 
et al., 2005; Rodriguez-Tudela et al., 2007; Rodriguez-Tudela et al., 2010). Sensitire 
YeastOne® (TREK Diagnostic Systems Ltd., UK) is the closest approach to the reference 
methodology (Johnson et al., 2008).
Etest (Biodisk AB, Sweden) was recently developed and is one of the most attractive 
alternatives currently on the market. It is a simple method based on the application of 
a plastic strip with a gradient concentration of antifungal on a previously inoculated 
agar surface with the isolate for testing. After incubation the inhibition zone indicates 
the MIC as the point where the inhibition ellipse intersects the strip. Once the operator 
gains experience in reading and interpreting, the test is a reliable and reproducible 
method that correlates well with the reference method (Johnson et al., 2008; Tapia et 
al., 2009). Detection of resistant species usually should be checked by a second method, 
which constitutes a drawback of this method. This is particularly important for Candida 
tropicalis isolates and Cryptococcus spp. as a result of relatively poor growth on the 
recommended medium. The use of Etest also provides a much wider range of MIC 
values than those obtained by other methods. Hence, susceptible isolates tend to show 
lower MIC values while less susceptible isolates tend to have higher MIC values than 
those obtained by reference methods. The technique has been standardized for yeasts 
and filamentous fungi and is currently available for amphotericin B, 5-fluorocytosine, 
fluconazole, itraconazole, voriconazole, posaconazole and caspofungin (Johnson et al., 
2008).
Disk diffusion is a simple and economical method to test the susceptibility of water-
soluble antifungals such as 5-fluorocytosine, fluconazole and voriconazole. This is 
described by the CLSI standards for application and interpretation and is more useful 
for Candida (CLSI, 2008c; Johnson et al., 2008). The test provides an inhibition zone 
diameter that correlates with MIC values obtained by the reference method based on the 
evaluation of thousands of different isolates (Pfaller et al., 2004). Addition of methylene 
blue to the culture medium (0.5 mg/mL) gives a sharper demarcation of the inhibition 
zone that improves readability of the test (CLSI, 2008c). Susceptibility tests may 
predict the clinical response to treatment. However, within the framework of invasive 
fungal infections, there are still a large number of possibly ambiguous factors when 
one is trying to interpret the in vitro activity of antifungal agents. Pharmacodynamic 
and pharmacokinetic analyses in conjunction with the identification of resistance 
mechanisms have been useful in establishing cutoff values for at least some of the 
systemic antifungal agents (Tapia, 2009).
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Due to the relatively low frequency of resistant isolates and the multiple concurrent 
factors involved in invasive fungal infections, it is difficult to validate cutoff values. 
The interaction between antifungal drugs - host, fungus - host and drug - fungus is a 
complex process, so that the in vitro susceptibility tests constitutes only a small part of 
the information needed to predict treatment outcome. 
Aim of this thesis
The Cryptococcus neoformans/Cryptococus gattii species complex is a saprophytic 
encapsulated globally distributed yeast. Although the primary route of cryptococcal-
host entry is through the inhalation of fungal conidia and/or desiccated yeast forms, 
meningitis is the commonest and more severe clinical form of disease. About one million 
new cases are reported annually and despite appropriate antifungal therapy, mortality 
remains high with death rates of up to 70% in HIV/AIDS patients resulting in at least 
625 000 deaths per year. Understanding the ecology, epidemiology and pathogenesis of 
C. neoformans/C. gattii species complex as well as its susceptibility profile to old and 
new antifungal compounds may contribute to a better management and control of this 
important mycosis. With these aims we did the following investigations. 
Part I includes three chapters (2-4) that deal with the application of molecular biological 
techniques to the study of clinical and environmental C. neoformans/C. gattii species 
complex isolates from Cuba and the Netherlands. Chapter 2 describes a novel approach 
for high resolution molecular subtyping of C. neoformans var. grubii based on nine 
microsatellite markers selected from the available genomic sequences of H99 strain. 
The panel of markers was applied to 190 Cuban Cryptococcus isolates, which included 
122 clinical strains, all collected from different patients between 1987 and 2007 
(mainly from cerebrospinal fluid representing almost every province of Cuba) and 68 
environmental isolates from pigeon guano gathered in the period 1998 to 2007 from 
different locations across the island. AFLP was used to confirm the identification of the 
isolates as C. neoformans var. grubii, and to validate the typing result of the microsatellite 
analysis. Chapter 3 describes the study of 300 Dutch C. neoformans isolates, obtained 
from 237 patients during 1977 to 2007. For this purpose, relevant information about the 
strains was obtained from the database of the Netherlands Reference Laboratory for 
Bacterial Meningitis (Academic Medical Center, Amsterdam, The Netherlands). Four 
categories were determined based on the predisposing factors that may have influenced 
the onset of the Cryptococcus infection: HIV/AIDS-related immunodeficiency, non-
HIV/AIDS-related immunodeficiency (e.g., immunosuppressive therapy and organ 
transplantation), immunocompetent individuals, and a category for which the 
presence or absence of predisposing factors was unknown. Isolates were molecularly 
characterized with PCR (mating- and sero- type), AFLP and microsatellite. Correlation 
between genotype and susceptibility to seven antifungal compounds was investigated. 
In chapter 4, 19 C. neoformans var. grubii isolates from seven Cuban patients with 
recurrent infection were studied using the microsatellite set of nine markers previously 
mentioned. Isolates were recovered at different time intervals from cerebrospinal 
fluid (n = 16), blood, urine and semen (one each). Patients (6 HIV-positive and 1 HIV-
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negative) were admitted at Tropical Medicine Institute “Pedro Kourí” between 1995 
and 2001, just before HAART was introduced in Cuba. Additionally, mating- and 
serotyping as well as in vitro susceptibility to amphotericin B, flucytosine, fluconazole, 
itraconazole, voriconazole, posaconazole and isavuconazole by broth microdilution 
method were performed. 
Part II encloses also three chapters (5-7) mainly devoted to antifungal susceptibility 
studies. Chapter 5 describes the largest study up to now on antifungal susceptibility 
of Cuban C. neoformans/C. gattii species complex isolates collected over 25 years. It 
was also the first study to report the in vitro susceptibility of C. neoformans var. grubii 
to isavuconazole. Chapter 6 is dedicated to the study of a worldwide collection of 350 
Cryptococcus gattii isolates representing clinical (n = 215; 61.4%), veterinary (n = 57; 
16.3%), environmental (n = 73; 20.9%) and unknown sources (n = 5; 1.4%). According 
to their geographical origin, the strains were grouped as Africa (n = 28; 8.0%), Asia 
(n = 22; 6.3%), Australia (n = 20; 5.7%), Europe (n = 101; 28.9%), North America (n 
= 95; 27.1%), South America (n = 81; 23.1%) and unknown origin (n = 3; 0.9%). The 
North American group contained 75 (24.1%) C. gattii isolates related to the Vancouver 
Island outbreak. Clusters obtained using AFLP fingerprinting, were correlated with the 
antifungal susceptibility profile for seven antifungal drugs including isavuconazole. 
Chapter 7 is based on an international study of wild-type (WT) susceptibility endpoint 
distributions and epidemiological cutoff values (ECVs) of fluconazole, itraconazole, 
posaconazole and voriconazole. The aggregated MIC distributions of the four triazoles 
(2,985 to 5,733 MICs for C. neoformans and 705 to 975 MICs for C. gattii gathered in 
15 to 24 laboratories) were used. The ECV was based on MIC distributions (obtained 
in at least three laboratories) and defined as the highest WT cutoff susceptible value. 
In the absence of clinical breakpoints the obtained values may help in the detection of 
isolates with acquired resistance mechanisms.
Part III (chapers 8-11) involves the study of possible sources of infection from trees, the 
description of the first C. gattii isolates in Cuba, as well as some of the possible immune 
mechanisms involved in host defense against C. neoformans and C. gattii infections. In 
chapter 8, different species of trees in Havana, Cuba were sampled to identify potential 
sources of C. neoformans/C. gattii species complex. A total of 662 samples were 
collected from 331 trees and cacti (65 Indian almond trees, 65 flamboyant trees, 65 Ficus 
spp. (mainly Indian laurel trees), 60 cacti of different species, 60 casuarins, five blue 
mahoe trees, three ceiba, two seagrape, and one each of copey, yellow oleander, yellow 
flamboyant, wallnut, caribbean pine and roble. Initial selection of the isolates was 
carried out by conventional techniques and further characterized using a combination 
of AFLP and DNA sequencing analysis. Chapters 9 and 10 describe the first veterinary 
and human cases of cryptococcosis due C. gattii in Cuba. In both settings the strains 
were identified using macro- and micro-morphological characteristics. The strains 
were subsequently studied by PCR (for mating- and serotype), AFLP as well as MLST 
using the standard loci (CAP59, GPD1, IGS1, LAC1, PLB1, SOD1), URA5, CAP10, MPD1 
and TEF1 to compare the results with the data of other isolates with the same genotype. 
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A bootstrap Maximum Likelihood phylogenetic analysis was performed using the 
settings as being used for a previously published C. gattii MLST study. Additionally, 
susceptibility testing using a broth microdilution method was performed in accordance 
with CLSI document M27-A3 guidelines. Chapter 11 highlights differences in the 
cytokine profile of human peripheral blood mononuclear cells of healthy individuals 
after in vitro stimulation with 40 different well-defined heat-killed isolates of C. gattii, 
C. neoformans and several hybrid isolates obtained from different sources. In addition, 
the involvement of TLR2, TLR4 and TLR9 in the pro-inflammatory cytokine response 
to C. gattii was investigated. Finally, the main results from this thesis are integrated and 
discussed in chapter 12 with suggestions for future research.
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Abstract
Background: Human cryptococcal infections have been associated with bird droppings as a likely source of infection.
Studies toward the local and global epidemiology of Cryptococcus spp. have been hampered by the lack of rapid,
discriminatory, and exchangeable molecular typing methods.
Methodology/Principal Findings: We selected nine microsatellite markers for high-resolution fingerprinting from the
genome of C. neoformans var. grubii. This panel of markers was applied to a collection of clinical (n = 122) and environmental
(n = 68; from pigeon guano) C. neoformans var. grubii isolates from Cuba. All markers proved to be polymorphic. The
average number of alleles per marker was 9 (range 5–51). A total of 104 genotypes could be distinguished. The
discriminatory power of this panel of markers was 0.993. Multiple clusters of related genotypes could be discriminated that
differed in only one or two microsatellite markers. These clusters were assigned as microsatellite complexes. The majority of
environmental isolates (.70%) fell into 1 microsatellite complex containing only few clinical isolates (49 environmental
versus 2 clinical). Clinical isolates were segregated over multiple microsatellite complexes.
Conclusions/Significance: A large genotypic variation exists in C. neoformans var. grubii. The genotypic segregation
between clinical and environmental isolates from pigeon guano suggests additional source(s) of human cryptococcal
infections. The selected panel of microsatellite markers is an excellent tool to study the epidemiology of C. neoformans var.
grubii.
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Introduction
Cryptococcosis ranks as one of the three common life-
threatening opportunistic infections in persons with AIDS [1].
Global estimates indicate more than 900,000 annual cases, causing
an estimated 624,700 deaths [2]. Other patient groups with
impaired T-cell function have an up to 6% lifetime risk of
developing clinically manifest cryptococcosis [3]. Seventy species
belonging to the genus Cryptococcus have been described, but only
members of the C. neoformans complex are mostly associated with
human infections. This species complex has been considered to
contain two pathogenic species: C. neoformans involving the varieties
neoformans (serotype D) and grubii (serotype A), and C. gattii
(serotypes B and C) [4–7]. Six monophyletic lineages have been
identified that also may represent species [4,5,8] as well as some
hybrids [9–12].
In the Caribbean the disease appears to be not very common
with an estimated 7800 patients and 4300 casualties reported
annually [2]. In Cuba the disease was first reported in the early
1950s [13]. Since then sporadic cases of cryptococcosis were
associated with alcoholism, organ transplants and immunological
disorders. Since the first cases of AIDS in Cuba in 1986, the
number of patients infected by this fungus has increased over the
years. The annual number of infected individuals ranged from 8 to
15 cases per year [14] while a study of 211 serial autopsies of
patients with HIV/AIDS infection in Cuba over a period of 10
years, showed that systemic or central nervous system cryptococ-
cosis was a serious and common disorder in 29% of cases [15]. Up
to now all clinical isolates from patients in Cuba have been
identified as C. neoformans var. grubii [16].
Multiple molecular typing methods have been described to
study the epidemiology of C. neoformans complex. The most
commonly used approaches to date involve AFLP, PCR
fingerprinting and or PCR-RFLP approaches as well as mating-
and/or serotype-specific PCRs [17–23]. These techniques have
proven useful to discriminate between the different sero- and
mating types but have not been shown to be very useful for
discrimination within specific C. neoformans complex members and
varieties. Multi-locus sequence typing (MLST) has been applied to
collections of C. neoformans and C. gattii from various origins
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[5,24,25] but this technique is laborious, has a long turn-around
time and is associated with significant costs. Microsatellites are
increasingly popular molecular typing targets since they provide
cost-effective genotyping with fast turn-around times. On a
theoretical basis, and, as has been shown for other fungi,
molecular typing by using microsatellites is more discriminatory
than by using MLST [26]. Like MLST data, microsatellite typing
data is transportable and exchangeable [27]. Here we describe the
use of a 9-marker microsatellite panel consisting of 3 dinucleotide
repeat markers, 3 trinucleotide repeat markers and 3 tetranucle-
otide repeat markers. Each panel of 3 markers was amplified using
a multiplex multicolor PCR approach. Amplified products were
analyzed on a high resolution capillary electrophoresis platform
allowing precise determination of repeat numbers in each marker.
We applied this panel to a collection of clinical and environmental
C. neoformans var. grubii isolates from Cuba. Part of this work was
presented at the 46th Interscience Conference on Antimicrobial
Agents and Chemotherapy (ICAAC), San Francisco, 2006, Abstr.
M904.
Materials and Methods
Ethics Statement
This research was approved by the Institutional Scientific and
Ethical Committee of the Instituto Pedro Kouri, Havana, Cuba.
All data were analyzed anonymously.
Isolates
A total of 190 clinical and environmental Cryptococcus isolates
from the collection of the mycology laboratory at the Tropical
Medicine Institute ‘‘Pedro Kourı´’’, were included in the study.
Clinical strains (n = 122) were collected between 1987 and 2007,
the large majority (91%) of isolates were from cerebrospinal fluid.
The remaining isolates were from urine, blood, tissue biopsy and
bronchoalveolar lavage samples. For ,70% of all clinical isolates,
information about the origin of the patients was available. Most
patients (,65%) were from Havana City. The remaining patients
inhabited almost every province of Cuba (Figure 1). Approxi-
mately 77% of all patients were HIV positive. All clinical isolates
were from different patients. Environmental isolates (n = 68) were
isolated from pigeon guano collected in the period 1998 to 2007
from well distributed locations across Cuba (Figure 1). In case an
environmental sample yielded multiple different colony morphol-
ogies suspected of being Cryptococcus, these were analyzed
separately.
Species identification was initially performed by standard
mycological methods [28] and confirmed with a commercial
identification system (Auxacolor 2; Bio-Rad, Marnes-la-Coquette,
France) as well as by using AFLP analysis.
DNA Isolation
A suspension of freshly grown cells was prepared in lysis buffer
(Roche Diagnostics, Almere, The Netherlands) and subjected to
mechanical lysis in a MagNA Lyser for 30 s at 6500 rpm (Roche
Diagnostics). Next, DNA was purified using a MagNAPure LC
instrument in combination with a MagNAPure LC DNA Isolation
Kit III as recommended (Roche Diagnostics). DNA yield and
purity were estimated by UV absorbance measurements.
Microsatellite Analysis
Candidate short tandem repeat markers were identified in the
available genomic sequences from the H99 strain using the
Tandem Repeats Finder software [29]. A 9 marker microsatellite
panel consisting of 3 dinucleotide repeat markers, 3 trinucleotide
repeat markers and 3 tetranucleotide repeat markers was selected
from the candidate markers using previously described criteria
[30]. PCR amplification primers for each of the markers are
according to Table 1. Three subpanels (CNA2, CNA3 and CNA4
respectively) of 3 markers each were amplified using a multicolor
multiplex PCR approach. Within each panel, one of the
amplification primers carried a fluorescent label consisting of
either FAM (6-carboxyfluorescein), HEX (hexachlorofluorescein)
or TET (tetrachlorofluorescein). In addition to the amplification
primers, each 50 ml amplification reaction contained approxi-
mately 1 ng of genomic DNA, 1 U FastStart Taq DNA
polymerase (Roche diagnostics), 2 mM MgCl2 and 0.2 mM
dNTP’s in 1x reaction buffer (Roche diagnostics). The amplifica-
tion profile consisted of a 10 min denaturation/activation step
followed by 35 cycles of 94uC for 30 s, 60uC for 30 s and 72uC for
1 min. After an additional 10 min incubation at 72uC, the
reactions were cooled to room temperature.
AFLP Analysis
Approximately 50 ng of genomic DNA was subjected to a
combined restriction-ligation procedure containing 5 pmol of
EcoR I adapter, 50 pmol Mse I adapter, 2 U of EcoR I (New
England Biolabs, Beverly, MA, USA), 2 U of Mse I (New England
Biolabs) and 1 U of T4 DNA ligase (Promega, Leiden, The
Netherlands) in a total volume of 20 ml of 1x reaction buffer for
1 hour at 20uC. Next, the mixture was diluted five times with
10 mM Tris/HCl pH 8.3 buffer. Adapters were made by mixing
equimolar amounts of complementary oligonucleotides (59-
CTCGTAGACTGCGTACC-39 and 59-AATTGGTACGCAG-
TC-39 for EcoR I; 59-GACGATGAGTCCTGAC-39 and 59-
TAGTCAGGACTCAT–39 for Mse I) and heating to 95uC,
subsequently followed by cooling slowly to ambient temperature.
One microliter of the diluted restriction-ligation mixture was used
for amplification in a volume of 25 ml under the following
conditions: 1 mM EcoR I primer with two selective residues (59-
Flu-GTAGACTGCGTACCCGTAC-39), 1 mM MseI primer
with one selective residues (59-GATGAGTCCTGACTAAG-39),
0.2 mM each dNTP and 1 U of Taq DNA polymerase (Roche
Diagnostics) in 1x reaction buffer containing 1.5 mM MgCl2.
Amplification was done as follows. After an initial denaturation
step for 4 min at 94uC in the first 20 cycles a touch down
procedure was applied: 15 s denaturation at 94uC; 15 s annealing
at 66uC with the temperature for each successive cycle lowered by
0.5uC and 1 min of extension at 72uC. Cycling was then
continued for further 30 cycles with an annealing temperature of
56uC. After completion of the cycles an additional incubation at
72uC for 10 min was performed before the reactions were cooled
to room temperature. The amplicons were then combined with
the ET400-R size standard (GE Healthcare, Diegem, Belgium)
and analyzed on a MegaBACE 500 automated DNA platform
(GE Healthcare), according to the manufacturer’s instructions.
Capillary Electrophoresis
Following amplification, the reaction products were diluted 10-
fold with distilled water. One ml of diluted products was combined
with 0.25 ml of ET-ROX 550 size marker and 8.75 ml of distilled
water. After a 1 min denaturation step at 94uC, the samples were
quickly cooled to room temperature and injected onto a
MegaBACE 500 automated DNA analysis platform equipped
with a 48 capillary array as recommended by the manufacturer
(GE Healthcare). Electropherograms were analyzed using Frag-
ment Profiler 1.2 software (GE Healthcare). Assignment of repeat
numbers was relative to the results obtained using the H99 strain,
which was used as a control strain in all experiments. According to
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Figure 1. Origin of samples and relationships between genotypes. A: Map of Cuba. Colored dots indicate provinces from which clinical and/
or environmental samples were available. B: Minimum spanning tree (MST) based on a multistate categorical analysis representing the genotypes of
190 C. neoformans var. grubii isolates from Cuba. Each circle represents a unique genotype. The size of the circle corresponds to the number of
isolates with that genotype. Genotypes are linked to their closest relative. Numbers and connecting lines correspond to the number of different
markers between genotypes. Genotypes with identical colors and connected by a shaded background are part of a microsatellite complex (MC). In
yellow are unique genotypes that are not part of a MC. C: Same as B, but now showing cross-links between all genotypes that differ in no more than 2
markers. D: Same MST as in B, but now showing genotypes obtained from clinical and environmental samples.
doi:10.1371/journal.pone.0009124.g001
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the genomic sequence, the genotype of the H99 strain was 27-20-
20-57-17-14-55-19-16 for markers 2A-2B-2C-3A-3B-3C-4A-4B-
4C respectively.
Data Analysis
Typing data was imported into BioNumerics v5.0 software
(Applied Maths, Sint-Martens-Latem, Belgium). Microsatellite
data was analyzed using the multistate categorical similarity
coefficient. Microsatellite complexes (MC’s) were defined as
groups of 2 or more genotypes differing by a maximum of 2
markers. AFLP data was analyzed by UPGMA clustering using
the Pearson correlation coefficient.
Results
A selection of 9 microsatellite markers was made from genomic
sequences from Cryptococcus neoformans var. grubii strain H99. All
markers proved to be polymorphic displaying a minimum of 5 and
up to 51 different alleles per marker (Table 1). The specificity of
the markers was tested by including C. neoformans var. neoformans
isolates (serotype D) as well as C. gattii isolates (serotype B). None of
these isolates yielded amplification products confirming the
specificity of these primers for C. neoformans var. grubii.
In Table 2, the discriminatory power for each of the individual
markers, panels and entire set of markers were calculated. When
all markers are combined, the nine marker microsatellite panel
yielded a discriminatory power of greater than 0.993. With this
collection of 190 isolates, 104 different genotypes could be
discriminated. The AFLP analysis confirmed that all isolates were
C. neoformans var. grubii (not shown) in line with previous
observations [16]. This panel of markers thus provides a highly
discriminatory typing assay for C. neoformans var. grubii. The
relationship between the different genotypes is illustrated in
Figure 1. Within the large diversity of genotypes, complexes of
closely related genotypes are recognized and indicated as
microsatellite complexes (MC’s). Within the MC’s most of the
genotypic variation is the result from variations in few microsat-
ellite markers (Table 3). The most discriminatory marker was
marker CNA4a. Elimination of this marker from the dataset
resulted in a reduction of the number of different genotypes by
approximately 50%, but did not affect the distribution of the
isolates over the different MC’s nor did it affect the segregation
between the different MC’s (results not shown). Eleven MC’s are
recognized containing up to 51 isolates each. Nine further
genotypes (from 18 isolates) were observed that did not belong
to a microsatellite complex, bringing the total number of different
genogroups to 20. Four MC’s (MC1-MC4) were the most
prevalent and contain more than 70% of all isolates.
Not all markers yielded a PCR product with all of the isolates,
especially markers CNA3a scored negative on a substantial part
(85%) of the isolates. When a negative result was obtained, the
particular marker was reamplified in a monoplex PCR reaction.
When still negative, the marker was scored as ‘‘0’’. Exclusion of
marker CNA3a from the microsatellite panel did not influence the
clustering of the isolates over the different MC’s (not shown).
The distribution of the clinical and environmental isolates over
the different MC’s is shown in Table 4. Very interestingly, MC1
contained a large majority of isolates from environmental origin
(.96% from pigeon guano) and only few human clinical isolates.
This difference was highly significant (p,0,001). Though small in
size, MC9 also exclusively contained isolates from environmental
origin . The non environmental MC’s were all found in HIV
positive patients with one exception: MC6 contained 3 isolates and
those were obtained from HIV negative patients.
The temporal distribution of the largest MC’s with clinical
isolates showed their presence over prolonged periods of time since
Table 1. Basic characteristics of the selected microsatellite markers.
Panel Marker Chr: position
Repeat
unit
Labeled primer
sequence (59-39)
Unlabeled primer
sequence (59-39)*
Conc.
(mM)
No. alleles
(range)
CNA2 CNA2A 11: 389201–389350 CT FAM- CGAGGTCATGTTGTGAGTCC GTGACCGTCTCGTTCTTCTCA 0.3 15 (10–60)
CNA2B 9: 191563–191711 TG HEX- TCGTCAACGATGCAAGTCTC GGGCCTGGGAAATAGGTAGA 0.3 6 (8–21)
CNA2C 10: 307773–306912 TA TET- AGAAGCACATGGGGAAAGG GCGCAGTTTGAAGATGAGAA 1.0 16 (8–44)
CNA3 CNA3A 11: 1281429–12814716 CTA FAM- ACCCCCTGCCCATCATA GCACAGGCATAAAGCTAAGTGTGA 0.3 9 (19–69)
CNA3B 4: 339525–339664 TCT HEX- TGGGGATATCGATTCCTTCTC GATTGGTATGGGAAGCGTTG 0.3 5 (5–17)
CNA3C 7: 285123–285270 CCA TET- TGGAAGAGGATGGAGCGTAT GCATAGTTTATCGTTTTCTCTTTTC 0.3 10 (8–38)
CNA4 CNA4A 5: 233120–233445 TTAT FAM- CGTCGAAGACTGCACAAAAA GTTCTGTATGACAGGTCGCAAA 1.0 51 (15–119)
CNA4B 4: 1021855–1022020 ATCC HEX- CGGATGAGATGGAAAGAAGG GTGCGTCTGTCAAAAGATTGC 0.3 10 (5–25)
CNA4C 14: 131866–132031 TATT TET- AGATGTCCTGGCGATGTTG GAGGAGCAAGCAATCAAACC 0.3 11 (1–18)
*The underlined residue(s) are not a match to the genomic sequence. These were introduced to minimize the formation of minus A peaks, a well known PCR artifact that
may complicate interpretation of the results [34].
doi:10.1371/journal.pone.0009124.t001
Table 2. Overview of the discriminatory power of the
individual markers, panels of markers and the entire set of
markers. Calculated values are based on the Simpson’s index
of diversity and are expressed in a value of ‘D’ [35].
Marker D Panel D Set D
CNA2a 0.842 CNA2 0.906 CNA 0.993
CNA2b 0.789
CNA2c 0.828
CNA3a 0.282 CNA3 0.868
CNA3b 0.618
CNA3c 0.819
CNA4a 0.972 CNA4 0.992
CNA4b 0.712
CNA4c 0.688
doi:10.1371/journal.pone.0009124.t002
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they were found repeatedly since the early years of the study and
thus have been present for almost 2 decades.
Discussion
A 9-marker microsatellite panel is described for high resolution
sub typing of C. neoformans var. grubii isolates, one of the members
of the C. neoformans complex, in particular serotype A isolates. This
panel of markers provides a highly discriminatory panel allowing
excellent discrimination between isolates from various origins. The
numerical typing result allows easy storage into global databases as
well as portability of the results.
From the results, it is obvious that certain genotypes appear to
be more closely related to each other than to other genotypes.
MC’s were arbitrarily defined by genotypes differing in up to 2
microsatellite markers from each other. Within each MC, the
amount of variation is attributable to only one or two
microsatellite markers as the likely result of instability of these
specific markers. This mostly involved the markers CNA2a,
CNA2c and CNA4a. Not surprisingly, these are among the most
discriminatory markers from the entire set (Table 2). Likewise,
within an MC, there was very limited to no variation in the less
discriminatory markers (Table 3). The difference between the
MC’s is attributable to multiple microsatellite markers ($3
markers difference). Although MC1 and MC2 could be connected
to each other by sequential genotypes differing in only 2
microsatellite markers, there appears to be no close relationship
between these MC’s (Figure 1C; Table 3) and these were therefore
considered to reflect different unrelated MC’s.
One marker that was selected from the H99 genome (CNA3a)
did not yield an amplification product in 85% of all tested isolates.
This could be the result of an actual deletion of this locus in the
genome from these isolates or it could be the result of one or more
sequence polymorphisms underneath either of the two amplifica-
tion primers. Alternatively, the size of the amplified fragment
could be beyond the reach of the size marker on the capillary
electrophoresis runs. This was not further investigated. Whether or
not this observation is specific for the Cuban population of C.
neoformans var. grubii, which may very well be explained by the
geopolitical isolation of this country, remains to be established.
In our study, the large majority of environmental isolates from
pigeon droppings co-clustered in one MC (MC1) containing only
very few isolates from human clinical samples. This MC was
widespread in multiple environmental locations across Cuba. Vice
versa, several of the other MC’s predominantly contained isolates
from human clinical samples and only few from environmental
origin. Possibly, isolates from MC1 are more adapted to the
pigeon host and may be less pathogenic for humans. Several MC’s
were identified that contained only clinical isolates and were never
found in environmental samples which suggests the presence of
additional niches of C. neoformans var. grubii that may cause human
infections. One MC was identified (MC6) containing only isolates
Table 3. Signature profiles of the 4 most prevalent microsatellite complexes and the reference isolate H99 upon whose genome
the selection of markers was made.
CNA2a CNA2b CNA2c CNA3a CNA3b CNA3c CNA4a CNA4b CNA4c
MC1 53–60 11 9 0 13 35–38 85–108 8 5
MC2 11 8 22–25 0 14 16 30–37 8 5
MC3 10 12 10 0 14 14 66–78 6 9–11
MC4 12 10 8 0 5 8 103–119 5 1
H99 27 20 20 57 17 14 55 19 16
doi:10.1371/journal.pone.0009124.t003
Table 4. Distribution of isolates from clinical (including HIV status) or environmental origin over the 11 microsatellite complexes.
Complex Total number of isolates Env. Clin. HIV pos. HIV neg. HIV status unknown
MC1 51 49 2 2 0 0
MC2 32 2 30 16 6 8
MC3 39 2 37 27 9 1
MC4 14 0 14 14 0 0
MC5 8 2 6 5 0 1
MC6 3 0 3 0 3 0
MC7 9 5 4 4 0 0
MC8 4 1 3 3 0 0
MC9 3 3 0 0 0 0
MC10 2 0 2 1 1 0
MC11 7 0 7 4 1 2
other 18 4 14 9 5 0
Total 190 68 122 85 25 12
Env.: Environmental isolates; Clin.: Clinical isolates; pos.: positive; neg.: negative.
doi:10.1371/journal.pone.0009124.t004
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from humans without HIV infection. This may indicate that this
particular genotype may be more virulent to humans but this
clearly needs more confirmation. However, despite careful
selection of multiple colonies from environmental samples, we
cannot rule out the possibility that there could have been a
sampling bias towards genotypes that are more abundantly present
in pigeon guano.
In this study, we used AFLP analysis for a dual purpose. Firstly
to confirm the identification of the isolates as C. neoformans var.
grubii, and secondly to validate the typing result of the
microsatellite analysis. The specific combination of restriction
enzymes and selective residues used here was reported before [17].
Interestingly, we found only limited genetic variation in this
collection of isolates. AFLP showed no segregation between the
isolates in MC1 and the majority of the other isolates (results not
shown). On the other hand, a relatively small number of clinical
isolates (11%) did indeed segregate into a separate AFLP cluster.
This subdivision is fully supported by the microsatellite data since
this AFLP cluster is recognized as a separate MC (MC4, Figure 1),
well separated from the other MC’s. Since AFLP analysis amplifies
fragments from multiple random locations in the genome, this may
point to relatively few or small genomic differences between MC1
isolates and the majority of the other isolates versus substantial
genomic differences between the majority of the isolates and those
from MC4. Probably, the discriminatory power of the AFLP
analysis can be increased by testing other combinations of
restriction enzymes and/or selective residues but this was not
attempted.
C. neoformans var. grubii has since long been associated with bird
droppings: according to the Centers for Disease Control and
Prevention, people with weakened immune systems should avoid
areas contaminated with bird droppings and contact with birds
[31]. However, this assumed link has received little attention using
molecular typing studies. Our results suggest that certain clinical
isolates may originate from additional ecological niche(s). This is
supported by recent evidence from Litvintseva et al. that
environmental isolates from pigeon excreta were less pathogenic
in a mouse model than isolates from human clinical samples [32].
In this prior work, neither AFLP nor MLST proved useful to
distinguish between these clinical and environmental isolates.
Instead, a retrotransposon based Southern blotting procedure
enabled them to distinguish between individual isolates with
identical AFLP/MLST genotypes. However, analysis of serial
cultures showed that the genotypes were not stable over time,
limiting the usefulness of this approach. In addition, the authors
did not report specific genotypes being associated with either
clinical or environmental isolates. Our results confirm the
superiority of this panel of microsatellite markers as molecular
typing targets for C. neoformans var. grubii and simultaneously allow
distinguishing between isolates from clinical and environmental
origin. The lack of temporal and spatial (east to west Cuba is
1000 km) variability suggest a clonal relationship between the
majority (.70%) of isolates from pigeon guano in Cuba. This too
may be explained by the isolated location of the country. In
contrast, most clinical cases were from Havana City and these
involved multiple different MC’s additionally suggesting the
presence of alternative sources for human infections.
The use of microsatellite markers in typing studies with C.
neoformans var. grubii was reported before. Hanafy et al. reported a
selection of 15 microsatellite markers for C. neoformans var. grubii of
which only 3 proved to be polymorphic [33]. The PCR products
were analyzed by agarose gel electrophoresis. This technique
suffers from insufficient resolution and does not allow use of the
full potential of microsatellite markers as molecular typing targets.
In summary, we have developed a novel approach for high
resolution molecular sub typing of C. neoformans var. grubii. This will
help the study of the global epidemiology of this opportunistic
pathogenic yeast. We also show that microsatellites are excellent
multilevel genotyping targets allowing recognition of individual
genotypes as well as clusters of related genotypes. The selected
microsatellite markers are sufficiently stable for use in long-term
longitudinal studies. Finally, our results point to additional sources
other than bird droppings as origin of human infections.
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A set of 300 Dutch Cryptococcus neoformans isolates, obtained from 237 patients during 1977 to 2007, was investigated by deter-
mining the mating type, serotype, and AFLP andmicrosatellite genotype and susceptibility to seven antifungal compounds. Al-
most half of the studied cases were fromHIV-infected patients, followed by a patient group of individuals with other underlying
diseases and immunocompetent individuals. The majority of the isolates were mating type� and serotype A, followed by�D
isolates and other minor categories. The most frequently observed genotype was AFLP1, distantly followed by AFLP2 and
AFLP3. Microsatellite typing revealed a high genetic diversity among serotype A isolates but a lower diversity within the serotype
D set of isolates. One patient was infected by multiple AFLP genotypes. Fluconazole and flucytosine had the highest geometric
meanMICs of 2.9 and 3.5�g/ml, respectively, while amphotericin B (0.24�g/ml), itraconazole (0.08�g/ml), voriconazole (0.07
�g/ml), posaconazole (0.06�g/ml), and isavuconazole (0.03�g/ml) hadmuch lower geometric meanMICs. One isolate had a
high flucytosine MIC (>64�g/ml), while decreased susceptibility (>16�g/ml) for flucytosine and fluconazole was found in 9
and 10 C. neoformans isolates, respectively.
The encapsulated basidiomycetous yeast Cryptococcus neofor-mans, the causative agent of cryptococcosis, can cause life-
threatening infections, such as severe lung infections and menin-
goencephalitis. This fungal disease was rarely seen until the early
1980s, but this changed due to the HIV pandemic (5, 42, 44).
Annually nearly one million HIV-infected subjects develop cryp-
tococcosis, mainly in sub-Saharan Africa, where the majority of
patients die due to ineffective treatment or a lack of treatment
options (35, 44). Besides a high incidence of cryptococcosis
among HIV-infected patients, individuals with other underlying
diseases might be at risk due to immune disorders or immuno-
suppressive therapy (e.g., organ transplant recipients and individ-
uals receiving anti-cancer therapy) (5, 35, 44).
According to the current taxonomic classiﬁcation, the genus
Cryptococcus contains more than 100 species (19). However, only
C. neoformans and C. gattii are frequent causes of cryptococcal
disease in humans and animals. Cryptococcus gattii has been rec-
ognized as a primary pathogen, and C. neoformans is mainly an
opportunistic infection. The latter is currently divided into two
varieties, C. neoformans variety grubii (serotype A) and C. neofor-
mans variety neoformans (serotype D) (5). Cryptococcus neofor-
mans variety gattii (serotype B and C), was raised to a separate
species named C. gattii (5, 28).
PCR ﬁngerprinting, restriction fragment length polymor-
phism analysis of the PLB1 and URA5 loci, ampliﬁed fragment
length polymorphism (AFLP) ﬁngerprint analysis, and several
multilocus sequence typing (MLST) studies divided C. neofor-
mans and C. gattii into 10 distinct genotypes (4, 6, 26, 30, 33).
Within C. neoformans variety grubii, three genotypes can be dis-
cerned (named AFLP1/VNI, AFLP1A/VNB/VNII, and AFLP1B/
VNII), C. neoformans variety neoformans has one genotype
(AFLP2/VNIV), and the C. neoformans intervariety serotype AD
hybrid has one (AFLP3/VNIII). Cryptococcus gattii can be divided
into ﬁve genotypes: AFLP4/VGI, AFLP6/VGII, and AFLP10/
VGIV with serotype B isolates, and AFLP5/VGIII and AFLP7/
VGIV are represented by serotype C isolates (21, 30). Several in-
terspecies hybrids have been described. C. neoformans variety
neoformans AFLP2/VNIV � C. gattii AFLP4/VGI is known as
AFLP8 and C. neoformans variety grubii AFLP1/VNI � C. gattii
AFLP4/VGI has been designatedAFLP9 (7, 8). A third interspecies
variety has recently been described and was found to be a hybrid
between C. neoformans var. grubii AFLP1/VNI and C. gattii
AFLP6/VGII (1).
A retrospective survey of HIV-infected patients in the Nether-
lands identiﬁed 268 patients with cryptococcosis during 1986 to
1999 (42). A major increase in the incidence of the disease was
observed since 1987, which correlatedwith the increasing number
of HIV/AIDS patients. The introduction of highly active antiret-
roviral therapy (HAART) in 1996 resulted in a signiﬁcant decrease
of cryptococcosis patients in the Netherlands (42). A clinical epi-
demiological analysis was made of the patient characteristics, but
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a genotypic analysis of the involved C. neoformans isolates has not
been performed (42). In this study, we investigated Dutch C. neo-
formans isolates that were collected during a 30-year period (1977
to 2007) to investigate the genetic diversity. AFLP ﬁngerprinting,
microsatellite typing, and mating type and serotype analyses were
performed by using PCRs to assess the genetic diversity among
Dutch clinical Cryptococcus strains. Antifungal susceptibility pro-
ﬁleswere determined for the antifungal compounds amphotericin
B, ﬂucytosine, ﬂuconazole, itraconazole, and the three novel tria-
zoles, posaconazole, voriconazole, and isavuconazole.
MATERIALS AND METHODS
Patient-related data. Clinically relevant information was extracted from
the database of the Netherlands Reference Laboratory for Bacterial Men-
ingitis (Academic Medical Center, Amsterdam, The Netherlands) and
included the source and date of Cryptococcus isolation, date of birth, gen-
der, andplace of residence of the patient. Patient datawere requested from
the contributing clinicians or hospitals in the case that no or limited data
were available. Relapses of cryptococcal infections were deﬁned by a pe-
riod between two positive cultures of more than 90 days. Four patient
categories were determined based on the predisposing factors that may
have inﬂuenced the onset of the Cryptococcus infection, namely, HIV/
AIDS-related immunodeﬁciency, non-HIV/AIDS-related immunodeﬁ-
ciency (e.g., immunosuppressive therapy and organ transplantation), im-
munocompetent individuals, and a patient category for which the
presence or absence of predisposing factors was unknown.
Cryptococcal isolates andmedia.Cryptococcal isolates (n� 328; 300
were viable) were revived from the collection of the Netherlands Refer-
ence Laboratory for Bacterial Meningitis (held at�80°C; AcademicMed-
ical Center, Amsterdam, The Netherlands) or were requested from par-
ticipating Dutch hospitals. Isolates were cultured on 1% yeast extract, 1%
peptone, 2% D-glucose agar (YPGA)medium and incubated at 25°C for 2
days.
Genomic DNA extraction. Isolates were subcultured for 2 days at
30°C on YPGA media supplemented with 0.5 M NaCl to prevent the
formation of polysaccharide capsules. Genomic DNA was extracted as
described previously by Hagen et al. (21). The purity and quantity of the
genomic DNA solution was measured using a Nanodrop ND-1000 spec-
trophotometer (Nanodrop, Wilmington, DE), and ﬁnal work solutions
with a concentration of 100 ng/�l were prepared.
Determining mating type and serotype by PCR and AFLP genotyp-
ing. The mating type and serotype determination of the isolates was per-
formed as described previously (2). Reference strains 125.91 (CBS10512;
mating type aA; AFLP1), H99 (CBS8710; �A; AFLP1), JEC20 (CBS10511;
aD; AFLP2), and JEC21 (CBS10513; �D; AFLP2) were included as con-
trols. Isolates that failed to yield an amplicon subsequently were subjected
to a set of two PCRs to amplify theC. gattiimating type STE12a or STE12�
allele (7, 21). For these PCRs, the reference strains CBS1930 (aB; AFLP6)
and WM276 (�B; AFLP4) were included as controls.
The genotype was determined using AFLP ﬁngerprint analysis as de-
scribed previously by Boekhout et al. (4). Reference strains for each of the
genotypes were included according to Hagen et al. (21).
Microsatellite amplification and analysis. The genetic relatedness of
C. neoformans variety grubii (serotype A) isolates was further investigated
using nine short tandem repeatmarkers (STRs) as described recently (25).
The C. neoformans var. grubii genome-sequenced reference strain H99
(CBS8710) was used as a control. Fragment analysis on a MegaBACE 500
capillary electrophoresis platform (GE Healthcare Life Sciences, Diegem,
Belgium) was carried out as described by Illnait-Zaragozi et al. (25).
Bionumerics version 6.1 (Applied Maths, Sint-Martens-Latem, Belgium)
was used to calculate a minimum spanning tree. A multistate categorical
similarity coefﬁcient was used, and microsatellite complexes (MCs) were
deﬁned by a minimum group of two genotypes that contain at least ﬁve
isolates and with a maximum neighbor distance of a two-locus difference
among the nine loci studied (25).
To characterize the genetic structure of C. neoformans variety neofor-
mans (serotype D) isolates, a microsatellite panel was developed based on
the genome sequence of reference strain JEC21 (CBS10513) using the
Tandem Repeats Finder software package (3). This panel consists of two
dinucleotide repeat loci, four trinucleotide repeat loci, and one tet-
ranucleotide repeat locus (Table 1) that are all speciﬁc for isolates harbor-
ing serotype D; no cross-speciﬁcity was observed when tested with C.
neoformans var. grubii or C. gattii isolates (data not provided). For each
locus, one of the ampliﬁcation primers was labeled with a ﬂuorescent dye
(FAM, 6-carboxyﬂuorescein; HEX, hexachloroﬂuorescein; or TET, tetra-
chloroﬂuorescein). The C. neoformans var. grubii genome-sequenced ref-
erence strain JEC21 was used as a control. Ampliﬁcation conditions, the
processing of amplicons, and data analysis were identical to the methods
and conditions used for the analysis of the C. neoformans variety grubii
microsatellite panel.
Antifungal susceptibility testing. The MICs of amphotericin B (Bristol
Myers Squibb, Woerden, The Netherlands), ﬂucytosine (Valeant Pharma-
ceuticals, Zoetermeer, Netherlands), ﬂuconazole and voriconazole (Pﬁzer
Central Research, Sandwich, Kent, United Kingdom), itraconazole (Janssen
Cilag, Tilburg, The Netherlands), posaconazole (Schering-Plough Corp.
[now Merck], Kenilworth, NJ), and isavuconazole (Basilea Pharmaceutica
[now Astellas], Basel, Switzerland) were determined using a broth microdi-
lutionmethod in accordance with CLSI documentM27-A3 (13). The proce-
dure was performed as described by Hagen et al. (21).
Statistical analysis. The 50 and 90%minimum inhibitory concentra-
tions (MIC50 and MIC90, respectively) were determined by ordering the
MIC values for each antifungal in ascending order and selecting the me-
dian and 90th quantile, respectively, of the MIC distribution. Geometric
mean MICs were calculated using Ofﬁce Excel 2007 (Microsoft, Red-
mond,WA), for which purpose values “�X” were set equal to “0.5X” and
“�Y” values were set equal to “2Y”. A two-tailed Mann-Whitney-Wil-
coxon test was performed to compare the MIC values between different
groups (e.g., patient categories versus AFLP genotypes or microsatellite
cluster), and a P value of �0.05 was regarded as statistically signiﬁcant.
Signiﬁcant correlations betweenCryptococcus characteristics versus any of
the other values were calculated using a chi-square test. Statistical analyses
were performed using the SAS software package (SAS, Cary, NC).
The discriminatory power of the microsatellite typing experiments
was calculated according to Simpson (37) using the software package
Haplotype Analysis v1.05 (18).
RESULTS
Cryptococcal isolates, patients, and patient categories.Detailed
data of the total number of Cryptococcus isolates and the number
TABLE 1 Primer sequences for microsatellite typing of C. neoformans
var. neoformansa
Name Sequence Target
CND2-1 Fwd FAM-AATCCTGAGACGGTTTGTGG CND2A
CND2-1 Rvd GAACATTGTGCCCGACTTTT
CND2-4 Fwd TET-ATCGAAGGTCTCGTCGTCTG CND2B
CND2-4 Rvd GAATGCTCTGGATGGAAGGA
CND3-1 Fwd FAM-TGCTGAGCTTGTTGAGGTTG CND3A
CND3-1 Rvd GAATGGCGCACTAATCTACCC
CND3-2 Fwd HEX-AGGCAAGACTGACGTTGAGC CND3B
CND3-2 Rvd GCAACTTCCTCCCCTCTTTCC
CND3-3 Fwd GTTGGTCTGTCTCCCTCGAT CND3C
CND3-3 Rvd TET-TTTCAAAGATGCTTGATGAGGA
CND3-4 Fwd GTCGGTAAGGTTTTGGGTTGA CND3D
CND3-4 Rvd HEX-AGCACCAAAAGATGGGTACAA
CND4-3 Fwd GCGCCGCTCTTAGAATGAAGA CND4A
CND4-3 Rvd TET-TCTCCGTCTGTCGTCTTTTG
a The primer sequences for the seven microsatellite serotype D-speciﬁc primer pairs are
given. Primer sequences for the nine microsatellite serotype A-speciﬁc primer pairs are
from Illnait-Zaragozi et al. (25).
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of patients included, as well as number of isolates per deﬁned
patient category, are listed in Table 2. The isolates were isolated
from cerebrospinal ﬂuid (CSF) (n � 201; 67%), blood (n � 45;
15%), lung (n � 28; 9.3%), bone (n � 5; 1.7%), spleen, urine
(each n � 2; 0.67%), pus, neck gland (each n � 1; 0.33%), and
unknown sources (n� 15; 5%).
The 300 isolates originated from237 patients, of whom45were
female (19.0%), 188 were male (79.3%), and 4 were of unknown
gender (1.7%). The male-to-female ratio was 4.2 to 1 with an
overall age distribution of 14 to 83 years and male and female age
distributions of 17 to 83 and 14 to 78 years, respectively. The
average age at which the 237 patients developed cryptococcosis
was 43.2 years with a median of 41 years.
Almost half the studied cases of cryptococcosis occurred in
HIV-infected patients (n � 115; 48.5%), followed by the group
with other underlying diseases (n� 50; 21.1%) and immunocom-
petent individuals (n � 18; 7.6%). Fifty-four (22.8%) of the epi-
sodes occurred in patients for which no clinical data were avail-
able. Two or more isolates were available from 42 patients
(17.7%), and 2 of these patients had a relapse of cryptococcosis.
Mating type, serotype, and AFLP genotype determinations.
Detailed data on the mating type, serotype, and AFLP genotype
distribution among investigatedCryptococcus spp. isolates per pa-
tient category are listed in Table 3. The PCR-based determination
of mating type and serotype revealed that the majority of the 300
isolates were �A (n � 219; 73.0%). Thirty-eight isolates (12.7%)
were serotype D, of which 32 were mating type � and 6 mating
type a. The remaining isolates belonged tominormating type and
serotype categories as listed in Table 3.
The mating type and serotype of 11 isolates (3.7%) could not
be determined, and these were subsequently subjected to a C. gat-
tii-speciﬁc PCR. This resulted in two (0.7%) isolates that were C.
gattii mating type �, while the remaining nine (3%) isolates re-
mained untypeable.
AFLP ﬁngerprinting divided the isolates into six AFLP
groups. The majority of isolates (n � 245; 81.7%) clustered
together with reference strains for genotype AFLP1, which rep-
resents C. neoformans var. grubii (serotype A) and includes
seven (2.3%) isolates that belong to the minor genotype cluster
AFLP1B. Thirty-six isolates clustered together with the refer-
ence strain for genotype AFLP2 (n� 36; 12%), representing C.
neoformans var. neoformans (serotype D), and 14 clustered to-
gether in genotype AFLP3 (n� 14; 4.7%), which represents the
serotype AD hybrids. The remaining isolates belonged to mi-
nor AFLP genotypes, as listed in Table 3.
Some discrepancies between the conventional methods for de-
termining mating type and serotype versus AFLP ﬁngerprinting
were observed. Four isolates (1.2%) were determined by PCRs for
mating type and serotype as �A or aD, but AFLP genotyping re-
vealed that they were actually hybrid serotype AD isolates (geno-
TABLE 2 Cryptococcosis patient dataa
Cryptococcus isolate and
patient parameter Total HIV/AIDS positive
Other predisposing
factors Immunocompetent Unknown immune status
Isolates
No. (%) of strainsb 300 (100) 137 (45.7) 68 (22.7) 24 (8) 71 (23.7)
No. (%) of CSF culturesc 201 (67) 105 (76.6) 37 (54.4) 13 (54.2) 46 (64.8)
No. (%) of blood culturesc 44 (14.7) 20 (14.6) 7 (10.3) 4 (16.7) 13 (18.3)
No. (%) of other sourcesc 55 (18.3) 12 (8.8) 24 (35.3) 7 (29.2) 12 (16.9)
Patients
All
No. (%)b 237 (100) 115 (48.5)d,e 50 (21.1)d 18 (7.6) 54 (22.8)f
Male/female ratio 4.2:1 8.4:1 1.8:1 3.5:1 3.5: 1
Age distribution (yr) 14–83 20–63d 17–78d 15–83 14�69
Avg age (yr) 43.2 38.2d 53.9d 50.8 41.2
Median age (yr) 41 37d 60d 48 38
Male
No. (%)b 188 (100) 101 (53.7)e 31 (16.5) 14 (7.4) 42 (22.3)f
Age distribution (yr) 17–83 20–63 17–75 27–83 19–69
Avg age (yr) 42.7 39.0 52.7 53.1 40.6
Median age (yr) 41 38 59 48 35
Female
No. (%)b 45 (100) 12 (26.7) 17 (37.8) 4 (8.9) 12 (26.7)
Age distribution (yr) 14–78 23–43 30–78 15–73 14–69
Avg age (yr) 45.4 31.0 53.8 43.0 42.9
Median age (yr) 42 32.8 60 42 49
a The number of included C. neoformans isolates is listed for the categories HIV/AIDS patients, patients with other predisposing factors, immunocompetent patients, and patients
with unknown immune status. Data are divided into four sections, providing the source of isolation of the Cryptococcus isolates, data related to the patient, and patient-related data
for male and female patients.
b Numbers and percentages indicated in these patient categories are the cumulative numbers and percentages indicated in the column Total.
c Numbers and percentages of isolates per source (CSF, blood, or other source) are the cumulative numbers and percentages of isolates applied to that patient category.
d Including two patients without known gender.
e Including one male patient without known age.
f Including three male patients without known age.
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type AFLP3) that lack either the serotype A or D genetic back-
ground. Three isolates that were determined by mating type and
serotype PCR as aD were identiﬁed by AFLP genotyping as inter-
species hybrids between C. neoformans var. neoformans and C.
gattii that were assigned to AFLP8 (7). A signiﬁcant correlation
between the genotypic AFLP1 and AFLP2 groups versus the im-
mune status of the patients was observed (P� 0.029).
Microsatellite (STR) genotyping of serotypeA isolates.Based
on serotype and AFLP ﬁngerprint analysis, a set of 259 C. neofor-
mans isolates was further investigated using a serotype A-speciﬁc
microsatellite panel. This included 245 serotype A isolates belong-
ing to genotypeAFLP1 and 14 serotypeADhybrid isolates belong-
ing to genotype AFLP3 (Table 3).
When all nine serotype A-speciﬁc microsatellite markers were
combined, 196 different microsatellite genotypes and 11 MCs
could be distinguished among 259 isolates (Fig. 1). Using the
Simpson’s diversity index (D), the discriminatory power for the
complete set of nine microsatellite markers was 0.994, and that of
the three separate panels was 0.929, 0.953, and 0.985 for CNA2,
CNA3, and CNA4, respectively. Among the nine studied micro-
satellite loci, CNA4A had the highest genotypic diversity with 59
types (D � 0.967), while locus CNA3B had the lowest genotypic
diversity with nine types (D � 0.649). However, locus CNA3C
showed the lowest resolution, with a D value of 0.578.
Microsatellite loci CNA3A and CNA4A showed a relatively
high degree of negative results for 35 and 6% of the investigated
isolates, respectively, whereas the other microsatellite markers
showed only the occasional absence of a microsatellite locus.
However, the assignment ofMCs remained intact whenmicrosat-
ellite loci CNA3A and CNA4A were discarded from the analysis
(data not shown). A step-by-step removal of themost discrimina-
tory microsatellite loci showed that the backbone structure of the
microsatellite cluster analysis was found to be represented by the
microsatellite loci CNA3B, CNA3C, and CNA4C, which all had a
low genotypic diversity and low discriminatory power. Statistical
analysis revealed no signiﬁcant differences between theMCs com-
pared to the clinical origin, date of isolation, AFLP genotype, or
geographic locality (data not shown).
Microsatellite (STR) genotyping of serotype D isolates. A set
of 53C. neoformans isolates that included 36 serotypeD (genotype
AFLP2), 14 serotype AD (genotype AFLP3), and 3 serotype BD
(genotype AFLP8) isolates (Table 3) was studied by serotype D-
speciﬁcmicrosatellite analysis.When all sevenmicrosatellite CND
markers were combined, 32 different microsatellite proﬁles could
be distinguished among 53 isolates (Fig. 2).Nomicrosatellite clus-
ters could be determined due to the number of isolates used for
analysis with this novel microsatellite typing panel. The discrimi-
natory power for the complete set of seven microsatellite markers
was found to be 0.966. Among the seven studied microsatellite
loci, CND2A and CND2B had the highest genotypic diversity,
with nine alleles (D � 0.813 and 0.73, respectively), while locus
CND3C had the lowest genotypic diversity and the lowest resolu-
tion, with three alleles (D� 0.466). There were no cross-reactions
observed when the serotype D microsatellite typing was per-
formed on a set of non-serotype D C. neoformans and C. gattii
isolates (data not shown). Statistical analysis revealed no signiﬁ-
cant differences between theMCs compared to the clinical origin,
date of isolation, AFLP genotype, or geographic locality.
Mixed C. neoformans infections determined by AFLP and
microsatellite typing. Multiple isolates were available from 38
patients. The majority of these isolates were sampled on the same
day but from different clinical specimens. While microsatellite
proﬁles of most of these isolates were found to be identical, a few
TABLE 3 Genetic background of Cryptococcus neoformans isolates per patient category based on mating type, serotype, and genotypea
Typing method and strain Total HIV/AIDS
Other predisposing
factors Immunocompetent Unknown immune status
PCR-based mating type and
serotype determination
No. (%) of �A strains 219 (73) 95 (69.3) 47 (69.1) 20 (83.3) 57 (80.3)
No. (%) of aD strains 6 (2) 3 (2.2) 2 (2.9) 1 (1.4)
No. (%) of �D strains 32 (10.7) 9 (6.6) 13 (19.1) 1 (4.2) 9 (12.7)
No. (%) of �A-aA strains 21 (7) 14 (10.2) 2 (2.9) 2 (8.3) 3 (4.2)
No. (%) of �A-�D strains 1 (0.3) 1 (0.7)
No. (%) of �A-aD strains 6 (2) 5 (3.6) 1 (1.5)
No. (%) of �D-aA strains 4 (1.3) 4 (2.9)e
No. (%) of C. gattii (�) isolates 2 (0.7) 1 (0.7) 1 (1.5)
No. (%) of unknown isolates 9 (3) 5 (3.6) 2 (2.9) 1 (4.2) 1 (1.4)
AFLP genotyping (no. [%] positive)
AFLP1 245 (81.7) 111 (81)d 51 (75)c 21 (87.5)b 62 (87.3)
AFLP2 36 (12) 13 (9.5)e 13 (19.1) 2 (8.3) 8 (11.3)
AFLP3 14 (4.7) 12 (8.8) 1 (1.5) 1 (4.2)
AFLP4 1 (0.3) 1 (0.7)
AFLP6 1 (0.3) 1 (1.5)
AFLP8 3 (1) 2 (2.9) 1 (1.4)
a The numbers and percentages of C. neoformans isolates per patient category are given for the mating type and/or serotyping results and AFLP genotyping. Percentages are
cumulative for the PCR-based mating type and serotype determination group and the AFLP genotyping group.
b Includes one isolate with genotype AFLP1B.
c Includes two isolates with genotype AFLP1B.
d Includes four isolates with genotype AFLP1B.
e One isolate was found to be �D-aA by conventional PCR mating type and serotype determination, while AFLP genotyping revealed that this isolate was AFLP2.
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showedminor differences of one to three repeat units between one
and two of the nine microsatellite loci studied.
Some patients were found to be infected with multiple C. neo-
formans strains. One immunosuppressed patient yielded nine se-
rotype A isolates during a period of 2 weeks, and two showed
major differences in three out of the nine microsatellite loci stud-
ied. A three-locus difference was also observed between isolates
sampled on the same day from CSF and blood of one patient. The
two isolates obtained from a patient that experienced a cryptococ-
cosis relapse were found to be different for six loci and were a mix
of minor (1 or 2) and major (�10) changes in repeat numbers.
This pattern of minor and major differences in repeat numbers
was also observed between two isolates sampled on the same day
from a patient that was also found to be infected with C. neofor-
mans serotype D, which was isolated 21 days prior and 24 days
after the isolation of the two serotype A isolates. These two sero-
type D isolates were found to belong to two different genotypes of
C. neoformans var. neoformans based on microsatellite typing,
since they differed for six of the seven microsatellite loci. Two
interspecies hybrid isolates of C. neoformans var. neoformans and
C. gattii (genotype AFLP8) were cultured with an 88-day interval
from an immunocompromised patient and were found to differ
for ﬁve of the seven serotype D microsatellite loci.
Antifungal susceptibility testing. MIC ranges, MIC50s,
MIC90s, and geometric mean MICs of seven antifungal com-
pounds are presented in Table 4. Susceptibility data for each of the
seven antifungal compounds are presented for all 300 Cryptococ-
cus spp. isolates as well as for the three major genotypes AFLP1
(n� 245), AFLP2 (n� 36), and AFLP3 (n� 14). For all four of
these groups, the MIC50 and the geometric mean MIC values dif-
fered by less than 1 log2 dilution step, except for ﬂuconazole and
itraconazole.
The overall MIC ranges for each of the seven antifungal com-
pounds were 0.063 to 1 �g/ml for amphotericin B, 0.125 to �64
�g/ml for ﬂucytosine, 0.25 to 64 �g/ml for ﬂuconazole, 0.016 to
0.5�g/ml for itraconazole and posaconazole, 0.016 to 1�g/ml for
voriconazole, and �0.016 to 0.5 �g/ml for isavuconazole. Flu-
conazole and ﬂucytosine had the highest geometricmeanMICs of
2.86 and 3.5 �g/ml, respectively, while amphotericin B (0.24 �g/
ml), itraconazole (0.08 �g/ml), voriconazole (0.07 �g/ml), po-
saconazole (0.06 �g/ml), and isavuconazole (0.03 �g/ml) had
much lower geometric meanMIC values. Isolates withMICs out-
side the normal range were tested on two different occasions and
showed the same results. The Cryptococcus isolate with a high ﬂu-
cytosine MIC (�64 �g/ml) was cultured from blood obtained
from an HIV-positive patient. However, a second CSF isolate
from this patient from the same day had a low MIC (8 �g/ml),
while microsatellite typing revealed that both isolates were nearly
identical and should be considered microvariants of the same ge-
notype. Nine and 10 C. neoformans isolates were less susceptible
(�16 �g/ml) for ﬂucytosine and ﬂuconazole, respectively.
Patients from whommultiple C. neoformans isolates were cul-
tured, either at the same time from different body sites or at dif-
ferent time points, generally showed the same pattern of MIC
values for the seven tested antifungal compounds. However, two
HIV-positive patients were infected with serotype A isolates that
showed large differences in ﬂuconazole susceptibility (MICs of 4
FIG1 Genotypic diversity ofCryptococcus neoformans variety grubii isolates based on serotype A-speciﬁcmicrosatellite typing.Minimum spanning tree showing
259 C. neoformans var. grubii isolates based on a nine-locus microsatellite typing panel. Each circle corresponds to a unique genotype, and connected shaded
circles belong to a speciﬁc microsatellite cluster. The size of the circles corresponds to the number of isolates of the same genotype. Connecting lines correspond
to the number of differences between genotypes, with a solid thick line connecting genotypes that differ in one locus, a solid thin line connecting genotypes that
differ in up to three loci, a dashed line connecting genotypes that differ in four loci, and a dotted line connectingmicrosatellite genotypes that differ inmore than
four loci. (A)Microsatellite clusters (MCs) that are numbered according to Illnait-Zaragozi et al. (25). MC13 andMC14 are novelMCs not observed in previous
microsatellite typing studies, and yellow-colored circles represent genotypes that do not belong to a knownmicrosatellite cluster. (B) Identical to panel A, except
colors represent the AFLP genotype of the isolates: green, AFLP1; dark blue, AFLP1B; red, AFLP3. (C) Identical to panel B, except colors represent the source of
isolation: green, CSF; red, blood; dark blue, source other than blood or CSF.
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and 64 �g/ml), while the isolates were genetically nearly all iden-
tical, with a minor difference for one microsatellite locus.
Statistical analysis showed that genotype AFLP1 (serotype A)
isolates were signiﬁcantly less susceptible to amphotericin B (0.26
�g/ml) than isolates with genotypes AFLP2 (serotype D) and
AFLP3 (serotype AD) (0.18 and 0.16 �g/ml, respectively) (P �
0.0001). AFLP2 isolates were found to be signiﬁcantly (P� 0.003)
less susceptible to ﬂucytosine (5.24 �g/ml) than genotype AFLP1
and AFLP3 isolates (3.30 and 3.81 �g/ml, respectively). Genotype
AFLP2 isolates were signiﬁcantly more susceptible to ﬂuconazole,
itraconazole, voriconazole, posaconazole (P � 0.0001 for each),
and isavuconazole (P� 0.0022) than AFLP1 and AFLP3 isolates,
as shown by their geometric mean MIC values (Table 4). How-
ever, based on the geometric mean MIC values, only those of
genotype AFLP2 isolates were found to differ by more than 1 log2
dilution step for ﬂuconazole compared to AFLP1 and AFLP3 iso-
lates, whereas genotypeAFLP2 isolates also differed a log2 dilution
step for itraconazole compared to genotype AFLP1 isolates. No
signiﬁcant differences in antifungal susceptibility patterns were
observed between the four patient categories.
DISCUSSION
A cohort of Dutch HIV-positive cryptococcosis patients has been
investigated previously from a clinical epidemiological point of
view, but no data were presented on the Cryptococcus neoformans
isolates (42). To obtain detailed insights into the epidemiology of
this opportunistic pathogenic yeast in theNetherlands, a set of 300
C. neoformans isolates from 237 patients obtained during 1977 to
2007 was investigated.
Nearly half of the cryptococcosis patientswere found to beHIV
positive (n� 115; 48.5%). When patients with a known immune
status were considered, the percentage of HIV-positive patients
was 62.8%, which is similar to data from other European studies.
A French study showed that 77% (n � 177) of the patients with
cryptococcosis were HIV infected (17); in a cohort of 77 Austrian,
German, and Swiss patients this was 68% (n� 52) (40), a Spanish
study observed 87% (n � 48) (20), and a 30-month European
survey reported 77% (n� 435) of HIV-positive patients (43). In
the current study, 18 (7.6%) patients were found to have no un-
derlying disease or any other predisposing factors, such as corti-
costeroid treatment. When corrected for patients with a known
immune status, the percentage of immunocompetent patientswas
found to be 9.9%. A French study observed nine (4%) immuno-
competent patients within the studied cohort (17). Remarkably,
several recent reports from far-east Asia noted that large numbers
of cryptococcosis patients are immunocompetent, with values
ranging from13 to 92%of the investigated cohort of patients from
China, South Korea, Taiwan, and Vietnam (9–11, 14, 29, 34, 45).
Interestingly, these immunocompetent patients were found to be
infected withC. neoformans var. grubii, which was also the case for
the majority (n� 20; 83.3%) of Dutch immunocompetent cryp-
tococcosis patients. Recent studies from South Korea and Viet-
FIG 2 Genotypic diversity of Cryptococcus neoformans variety neoformans isolates based on serotype D-speciﬁc microsatellite typing. Minimum spanning tree
showing 53 C. neoformans var. neoformans isolates based on a novel seven-locus microsatellite typing panel. Each circle corresponds to a unique genotype. The
size of the circles corresponds to the number of isolates of the same genotype. Connecting lines correspond to the number of differences between genotypes, with
a solid thick line connecting genotypes that differ in one locus, a solid thin line connecting genotypes that differ in up to three loci, a dashed line connecting
genotypes that differ in four loci, and a dotted line connecting microsatellite genotypes that differ in more than four loci. (A) The microsatellite genotypes. (B)
Identical to panel A, except colors represent the AFLP genotypes of the isolates: green, AFLP2; dark blue, AFLP3; red, AFLP8. (C) Identical to panel B, except
colors represent the source of isolation: green, CSF; red, blood; dark blue, source other than blood or CSF.
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nam have observed a correlation between the immune status of
the patient and the genotype of the isolated C. neoformans var.
grubii strain (10, 14).
In contrast toC. neoformans var. grubii, the epidemiology ofC.
neoformans var. neoformanshas been poorly studied. From the few
available studies it is known that serotype D isolates are more
prevalent in Europe (27, 43). In the current study, only 12% of the
clinical isolates were serotype D (Table 3). A higher percentage of
isolates (20.5%) was found among 410 French C. neoformans iso-
lates (16). However, in Italy, 71% of the C. neoformans isolates
were found to be serotype D (41). A European survey observed
that a large proportion of the 311 C. neoformans isolates were
serotype D (30%) and serotype AD (19%) (43). A higher propor-
tion of infections caused by C. neoformans var. neoformans was
observed in several Mediterranean countries than in the north-
western European area (20, 43). Furthermore, genotyping studies
revealed that 33.9% of the isolates from Madrid, Spain, fell into
the hybrid genotype cluster AFLP3 (serotype AD) and 19.6% in
genotype AFLP2 (serotype D) (20). Other epidemiological sur-
veys from Brazil, China, South Korea, Taiwan, and Vietnam
revealed that serotype D isolates are rarely found or are absent
(2, 9–11, 29).
Until recently, it was believed that C. neoformans had a predi-
lection to cause disease in immunocompromised patients, while
C. gattiiwas found to preferentially cause disease in immunocom-
petent individuals (5). However, several studies observed that a
substantial number of cryptococcal infections in African HIV-
infected patients are caused by C. gattii, thus indicating that the
presumed preference for a certain patient category is not valid (32,
38). In the Netherlands, two patients were found to be infected by
C. gattii. One case was caused by a travel-related C. gattii AFLP6
infection in an immunocompromised Dutch patient who devel-
oped cryptococcosis after corticosteroid treatment (22). The sec-
ond case was caused by a C. gattii AFLP4 isolate that was cultured
from a 54-year-old Dutch male who became HIV infected during
his stay in Africa. MLST analysis revealed that the latter isolate fell
TABLE 4 Antifungal susceptibility per C. neoformans AFLP genotypea
Strain and antifungal agent
MIC (�g/ml)
Range MIC50 Geometric mean MIC90
C. neoformans variety grubii serotype
A, AFLP1 (n� 245)
Amphotericin B 0.125–1 0.25 0.26 0.5
Flucytosine 0.125–�64 4 3.3 8
Fluconazole 0.25–64 4 3.1 8
Itraconazole 0.016–0.5 0.125 0.09 0.25
Voriconazole 0.016–1 0.063 0.08 0.125
Posaconazole 0.016–0.5 0.063 0.06 0.125
Isavuconazole �0.016–0.5 0.031 0.04 0.125
C. neoformans variety neoformans
serotype D, AFLP2 (n� 36)
Amphotericin B 0.063–1 0.125 0.18 0.25
Flucytosine 0.5–64 4 5.24 16
Fluconazole 0.25–16 1 1.39 8
Itraconazole 0.016–0.5 0.031 0.04 0.25
Voriconazole 0.016–0.5 0.031 0.04 0.125
Posaconazole 0.016–0.25 0.031 0.04 0.125
Isavuconazole �0.016–0.25 0.031 0.02 0.125
C. neoformans variety neoformans
serotype AD, AFLP3 (n� 14)
Amphotericin B 0.063–1 0.125 0.16 0.25
Flucytosine 2–8 4 3.81 8
Fluconazole 1–32 4 4.2 8
Itraconazole 0.031–0.5 0.063 0.07 0.125
Voriconazole 0.031–0.25 0.063 0.08 0.125
Posaconazole 0.016–0.125 0.063 0.05 0.063
Isavuconazole 0.016–0.25 0.031 0.04 0.063
C. neoformans and C. gattii, all
genotypes (n� 300)
Amphotericin B 0.063–1 0.25 0.24 0.5
Flucytosine 0.125–�64 4 3.51 8
Fluconazole 0.25–64 4 2.87 8
Itraconazole 0.016–0.5 0.125 0.08 0.25
Voriconazole 0.016–1 0.063 0.07 0.125
Posaconazole 0.016–0.5 0.063 0.06 0.125
Isavuconazole �0.016–0.5 0.031 0.03 0.125
a The range, MIC50, geometric mean MIC, and MIC90 are listed for the seven tested antifungal compounds for each of the four genotypic C. neoformans groups.
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into a clade with African C. gattii AFLP4 isolates. This particular
strain (N114) was further investigated by Ferry Hagen and Teun
Boekhout (unpublished data). These cases suggest that C. gattii
can be dormant in the human host, and that it can be activated
when the immune status is attenuated due to disease or treatment
with corticosteroids. Although C. gattii AFLP4 has been isolated
from environmental sources in the Netherlands, an autochtho-
nous infection has not yet been observed in the current study (12).
Three Cryptococcus isolates from the current study were found to
be interspecies hybrids betweenC. gattiiAFLP4 andC. neoformans
AFLP2 and caused disease in an apparently healthy and an immu-
nocompromised patient, respectively (7).
Microsatellite typing has recently been applied to C. neofor-
mans var. grubii and was shown to be an excellent tool to discrim-
inate isolates as well as to study their epidemiology (24, 25). This
molecular typing tool was ﬁrst applied using a set of 122 clinical
and 68 environmental C. neoformans var. grubii isolates from
Cuba and distinguished 104 different genotypes (DCuba� 0.993)
and 11 MCs. The genetic diversity of the Dutch clinical C. neofor-
mans var. grubii population is slightly higher than that observed in
Cuba (DNetherlands� 0.994) with 196 genotypes among 259 stud-
ied isolates, including the two novel clusters MC13 and MC14
(Fig. 1). This slightly higher genetic diversity of the Dutch C. neo-
formans var. grubii isolates may be due to one or more of the
following. First, the time span of this retrospectively study is 30
years, which is longer than the 20-year time frame of the Cuban
study. Second, the composition of the Dutch population is char-
acterized by extensive immigration, which includes people from
the former overseas colonies of Surinam, Netherlands Antilles,
and Indonesia, as well as immigrants from northern Africa and
eastern Europe (CBS Statistics Netherlands; www.cbs.nl; popula-
tion data for 1899 to 2010). It is likely that a proportion of the
Dutch cryptococcosis patients are immigrants that acquired a
subclinical infection with C. neoformans prior to immigration to
the Netherlands, and this may contribute to the observed higher
genetic diversity in the studied cohort. Third, it has recently been
shown that C. neoformans can produce in vivo diploid offspring
from haploid parental isolates, via either cell fusion or endorepli-
cation (15). Thus, a further possibility is that dormant C. neofor-
mans isolates become activated upon immune suppression and
that during the course of infection and/or antifungal therapy, C.
neoformans cells fuse to formhybrids that aremore resistant to the
antifungal compounds (14). The recent observation of clinical
interspecies hybrids between C. neoformans and C. gattii from
clinical sources suggests that these hybrids can be formed in vivo
(7, 8).
Antifungal susceptibility testing has frequently been applied to
C. neoformans. The development of new antifungal drugs, such as
the novel triazoles and the reported increase in antifungal resis-
tance, highlights the importance of monitoring the susceptibility
proﬁles of clinical C. neoformans isolates. The number of resistant
and less susceptible isolates observed in the current study re-
mained low. One isolate was found to be ﬂucytosine resistant, and
nine were less susceptible for this antifungal compound. High
MICs remain exceptional; a few were found, including for the two
isolates from CSF and blood from the same patient, with at least a
4 log2 dilution difference in MIC of ﬂucytosine (8 and �64 �g/
ml). In our collection, ﬂucytosine resistancewas rare, but there are
countries where it is emerging, such as Indonesia (34). Nine iso-
lates were less susceptible for ﬂuconazole, while all other antifun-
gal compounds inhibited the growth of C. neoformans. A global
antifungal susceptibility study revealed that the observed resis-
tance against amphotericin B, ﬂucytosine, and ﬂuconazole was
less than 1%of the tested isolates (36). Interestingly, these authors
found that, during the time span of their study, C. neoformans
becamemore susceptible to ﬂucytosine andﬂuconazole. This phe-
nomenon, however, has not been observed in the current study. It
seems that the number of C. neoformans isolates resistant against
the conventional antifungal compounds remains limited. Several
recently published antifungal susceptibility studies, including the
current one, showed that posaconazole, voriconazole, and isavu-
conazole are promising candidates to replace the conventional
drugs, since the latter have potential toxic side effects (20, 21, 23,
36, 39, and this study). The present study shows that genotype
AFLP1 and AFLP3 isolates are less susceptible to ﬂuconazole than
AFLP2 isolates. This genotypic difference was only recently ob-
served in a Croatian study that found a similar result for ﬂucona-
zole, although this difference was not signiﬁcant between AFLP2
and AFLP3 isolates (31). The current study shows that there is a
trend toward lower MIC values of amphotericin B for genotype
AFLP2 isolates, similarly to that observed in the Croatian and
Spanish studies (20, 31). TheCroatian and Spanish studies did not
observe a signiﬁcant difference between any of the tested antifun-
gal compounds versus the AFLP genotypes, except for Spanish
AFLP1 isolates that were less susceptible to amphotericin B than
Spanish AFLP3 isolates (20, 31). Similarly to our study, the Span-
ish study did not observe a signiﬁcant difference between patient
categories versus antifungal susceptibility.
In conclusion, C. neoformans var. grubii is the major cause of
cryptococcosis among immunocompromised and immunocom-
petent individuals in the Netherlands. AFLP genotyping and mi-
crosatellite typing showed that the Dutch clinical C. neoformans
var. grubii population is genetically more diverse than other re-
cently studied populations. In vitro antifungal susceptibility test-
ing showed that resistance and decreased susceptibility are not
major issues in the Netherlands, and the novel triazoles are prom-
ising candidates for treatment strategies against cryptococcosis.
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Microsatellite typing and susceptibilities of serial
Cryptococcus neoformans isolates from Cuban
patients with recurrent cryptococcal meningitis
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Abstract
Background: Cryptococcus neoformans is commonly associated with meningoencephalitis in immunocompromised
patients and occasionally in apparently healthy individuals. Recurrence of infection after initial treatment is not
uncommon. We studied C. neoformans isolates from 7 Cuban patients with recurrent cryptococcal meningitis.
Antifungal susceptibility and genotyping with microsatellite molecular typing were carried out.
Methods: Isolates (n = 19) were recovered from cerebrospinal fluid, blood, urine and semen. Antifungal
susceptibilities for amphotericin B, fluconazole, flucytosine, itraconazole, voriconazole, posaconazole and
isavuconazole were tested by CLSI M27A3 broth microdilution method. Genotyping was done using a panel of 9
microsatellite (STR) markers: (CT)n, (TG)n, (TA)n, (CTA)n, (TCT)n, (CCA)n, (TTAT)n, (ATCC)n and (TATT)n.
Results: The average number of isolates/patient was 2.71. The mean time interval between the collection of any
two isolates was 52.5 days. All strains were identified as C. neoformans var. grubii (serotype Aa). Although none of
the strains were resistant to the studied drugs, in serial isolates from two patients, MICs values of triazoles
increased 4-5 log2 dilutions over time. STR patterns showed 14 distinctive profiles. In three patients the recurrent
infection was associated with genotypically identical isolates. The four other patients had relapse isolates which
were genotypically different from the initial infecting strain.
Conclusion: Recurrences of cryptococcal meningitis in our series of patients was not associated with development
of drug resistance of the original strain but by an initial infection with different strains or a reinfection with a new
strain.
Background
The incidence of cryptococcosis started to increase with
the beginning of the acquired immune deficiency syn-
drome (AIDS) epidemic in the early 1980 s. Its fre-
quency declined in the Western world since the mid
1990 s due to the use of highly active antiretroviral ther-
apy (HAART). However, cryptococcal meningitis is still
one of the most common life-threatening opportunistic
fungal infections in immunocompromised patients, par-
ticularly among those with AIDS in Sub-Saharan Africa
[1] and Asia [2]. These patients show a high tendency to
relapse despite effective antifungal therapy. Early studies
performed with karyotyping and restriction fragment
length polymorphism (RFLP) analysis of serial isolates of
AIDS patients in New York concluded that recurrent
infection was caused through persistence of the original
strain and not from infection with new strains [3,4]. A
later study using the same typing technique but with
isolates from AIDS patients from Uganda found that
among 17 patients with more than 1 cerebrospinal fluid
(CSF) isolate of Cryptococcus neoformans, sequential iso-
lates were identical or highly related in 12 patients [5].
Several treatment strategies have been used in patients
with cryptococcal meningitis but the optimum regimen
is still not clear. Amphotericin B with or without flucy-
tosine remain the agents of choice for induction therapy
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while fluconazole has proven to be superior for long-
term maintenance therapy [6,7]. High dose fluconazole
with flucytosine is an oral treatment alternative although
this regimen is not as effective as amphotericin B and
flucytosine [8]. Different molecular typing methods have
been used in the epidemiological analyses of clinical
and/or environmental isolates of C. neoformans, includ-
ing electrophoretic karyotyping, PCR fingerprinting, ran-
dom amplified polymorphic DNA analysis, RFLP
analysis, MLST and amplified fragment length poly-
morphism analysis with divergent results [9-11]. To
determine whether recurrences of cryptococcal meningi-
tis in seven Cuban patients were due to development of
drug resistance or to infection by multiple strains, we
tested the in vitro antifungal susceptibility and deter-
mined the genotypes of the sequential isolates using a
recently described microsatellite based assay [12].
Methods
Fungal isolates
From the stock collection of the mycology laboratory at
the Instituto de Medicina Tropical “Pedro Kourí” (IPK)
in Havana, Cuba, 19 clinical isolates of C. neoformans
from patients with recurrent infection were selected for
this study. The isolates were recovered at different time
intervals from cerebrospinal fluid (n = 16), blood, urine
and semen (one each) from 7 patients (6 HIV positive
and 1 HIV negative) admitted at the institute between
1995 and 2001, just before HAART was introduced in
Cuba (Table 1). All patients were admitted to the clini-
cal AIDS care division at the IPK. Initial isolates were
obtained at diagnosis and before any antifungal therapy
was used and follow up isolates were from patients dur-
ing or after treatment with antifungal drugs. Repeat
lumbar puncture was only performed in those cases
which did not react within two weeks of therapy or
those who showed a clinical deteriorisation during or
after treatment. From each culture positive sample a sin-
gle isolate from morphological similar colonies was
archived. Species identification was initially done by
growth on canavanine-glycine-bromothymol blue (CGB)
agar and strains were stored in sterile water at room
temperature until the study was carried out. From initial
isolation until the study the isolates were typically sub-
cultured between 4 and 6 times. Before use, the identifi-
cation of all isolates was repeated with a commercial
identification system (Auxacolor 2; Bio-Rad, Marnes-la-
Coquette, France).
Antifungal agents and susceptibility testing
Broth microdilution testing was performed in accordance
with Clinical and Laboratory Standards Institute docu-
ment M27-A3 guidelines [13]. Standard antifungal pow-
ders of amphotericin B (Sigma, The Netherlands),
flucytosine (Valeant Pharmaceuticals, The Netherlands),
fluconazole (Pfizer Central Research, U.K.), itraconazole
(Janssen-Cilag, The Netherlands), voriconazole (Pfizer
Central Research, U.K.), posaconazole (Schering Plough,
USA), and isavuconazole (Basilea Pharmaceutica,
Switzerland) were used. The stock solutions of the drugs
were prepared in the appropriate solvent. The final con-
centrations of the antifungal agents were 0.016 to 8 μg/
mL for amphotericin B, itraconazole, voriconazole, and
posaconazole; 0.063 to 32 μg/mL for flucytosine and flu-
conazole; and 0.004 to 4.00 μg/mL for isavuconazole.
After 72 h incubation at 35°C the minimum inhibitory
concentration (MIC) was defined as the lowest concen-
tration of drug showing absence of growth for amphoter-
icin B and a prominent reduction of growth (≥50%) for
the other antifungal agents compared to the drug-free
growth control. The MICs were read optically and spec-
trophotometrically at 420 nm after agitation. Candida
parapsilosis ATCC 22019 and C. krusei ATCC 6258 were
used as quality control [13].
Mating-, sero- and genotyping
C. neoformans isolates were grown on Sabouraud’s dex-
trose agar at 30°C for 48 h and DNA was obtained from
freshly grown cells using a MagNA lyser/MagNA Pure
protocol (Roche Diagnostics, Almere, the Netherlands).
The mating- and serotype was determined using four
different PCRs that specifically amplify the mating-type
a or a allele of the STE20 locus for either serotype A or
D isolates [14]. The reference isolates CBS9172 (aA),
CBS8710 (aA), CBS10511 (aD) and CBS10513 (aD)
were included as positive control for each of the four
PCRs.
STR analysis was performed in two steps as described
previously [12]: i) Amplification of STR loci by PCR:
three separate multiplex PCRs were used (CNA2,
CNA3, and CNA4, respectively), each amplifying three
different STRs. For every multiplex PCR, one of the
amplification primers was labelled with carboxyfluores-
cein (FAM), hexachlorofluorescein (HEX), or tetrachlor-
ofluorescein (TET) at the 5’ end, respectively. In
addition to the amplification primers (concentrations
according to reference [11]), each PCR mixture con-
tained 0.2 mM deoxynucleoside triphosphates, 1 U of
FastStart Taq DNA polymerase (Roche Diagnostics), 2
mM MgCl2 and 1 ng of genomic DNA in 1 × reaction
buffer. Thermocycling was performed in a T1 thermocy-
cler (Biometra, Göttingen, Germany) by using the fol-
lowing thermal protocol: 10 min of denaturation at 95°
C, followed by 35 cycles of 30 s of denaturation at 95°C,
30 s of annealing at 60°C, and 1 min of extension at 72°
C. Before the reaction mixtures were cooled to room
temperature, an additional incubation for 10 min at 72°
C was performed. All temperature transitions were
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performed with maximal heating and cooling settings (5°
C/s). ii) Detection and sizing of amplification products
with subsequent assignment of repeat numbers: the
fragments obtained were combined with the ET550-R
size standard (GE Healthcare, Diegem, Belgium) and
analyzed on a MegaBACE 500 automated DNA platform
(GE Healthcare), according to the instructions of the
manufacturer. Electropherograms were analyzed using
Fragment Profiler 1.2 software (GE Healthcare). Identi-
cal isolates were those that possessed alleles with the
same number of repeat units in all nine loci. Consistent
with the previous separation of genotypes into microsa-
tellites complexes (MC’s), isolates with genotypes that
differed in up to two loci were considered to be geneti-
cally related [12]. Genotypes differing in more than two
loci were considered to be unrelated. The study was
approved by the Scientific Council and Ethics Commit-
tee of the Instituto Pedro Kouri, Havana, Cuba.
Results
The majority of strains were obtained from HIV positive
patients, except those recovered from patient 7 for whom
no underlying disease could be demonstrated (Table 1).
The mean number of isolates/patient was 2.71 (range 2-4
isolates/patients). The mean time between collection of
any two isolates was 52.5 days (range 13-123 days). All
Table 1 Clinical data, origin and date of isolation of the studied strains
Patient
Nr.
Sex HIV/
Year of diagnosis
Sample Isolation
date
Interval between each
isolate in days
(number)
Total of days Antifungal
treatment
1 Male +/1991 Blood 14/04/95 0
(08-36-09-92)
0 AmB+Flu
Flu (maintenance)
CSF 14/04/95 0
(08-36-09-75)
0 AmB+Flu
Flu (maintenance)
CSF 18/07/95 96
(08-36-10-01)
96 AmB+Flu
2 Male +/1990 CSF 05/09/95 0
(08-36-09-97)
0 Flu+Itr
Urine 08/12/95 95
(08-36-09-70)
95 Flu
CSF 10/01/96 34
(08-36-09-91)
129 Flu
3 Female +/1994 CSF 18/01/96 0
(08-36-09-71)
0 AmB+Flu
Flu (maintenance)
CSF 29/02/96 34
(08-36-09-72)
34 AmB+Flu
4 Male +/1995 CSF 23/04/97 0
(08-36-09-82)
0 AmB+FC+Flu
CSF 06/05/97 14
(08-36-09-89)
14 AmB+FC+Flu
5 Male +/1998 CSF 15/04/00 0
(08-36-09-24)
0 AmB
Flu (maintenance)
CSF 26/10/00 194
(08-36-09-25)
194 AmB+FC
6 Female +/1996 CSF 12/06/00 0
(08-36-10-56)
0 AmB+FC
Flu (maintenance)
CSF 12/10/00 123
(08-36-10-52)
123 AmB
Flu (maintenance)
CSF 30/10/00 19
(08-36-10-53)
142 AmB+FC
7 Male - CSF 09/01/01 0
(08-36-09-26)
0 AmB+Itr
Flu (maintenance)
CSF 17/04/01 99
(08-36-09-30)
99 AmB+Flu
Flu (maintenance)
CSF 07/06/01 52
(08-36-09-78)
151 Flu+Itr
Semen 19/06/01 13
(08-36-09-42)
164 Liposomal AmB
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patients received antifungal treatment but only the
HIV negative patient (nr. 7) survived. All clinical
strains were identified as C. neoformans var. grubii ser-
otype A and mating-type a.
For the antifungal susceptibility testing, no differences
between visual and spectrophotometric readings were
observed, and the MICs for the quality control strains
were all within the suggested reference ranges (data not
shown). Table 2 summarizes the in vitro susceptibilities
of the isolates according to the origin of the strains.
When all data were considered together, the widest
ranges and highest MICs were for fluconazole (0.25 to 8
μg/mL) and flucytosine (0.5 to 8 μg/mL) and the lowest
were for isavuconazole, voriconazole, and posaconazole.
Amphotericin B, posaconazole and isavuconazole exhib-
ited similar MICs patterns among all the studied iso-
lates. Isolates from patients 6 and 7 exhibited a stepwise
increase among serial isolates for some of the drugs.
Increased MICs values of at least 4 log2 dilutions over
the time for fluconazole, itraconazole, voriconazole and
isavuconazole were observed in patient 6. In patient 7
higher MICs were found between initial and last isolate
for fluconazole (4 log2), itraconazole (6 log2) and vorico-
nazole (5 log2). Amphotericin B, flucytosine and posaco-
nazole demonstrated maximally only a 1-3 log2 difference
among serial isolates.
STR patterns of the 19 isolates showed 14 distinct
profiles. Three patients (patients 2, 3 and 6) had genoty-
pically identical isolates over the course of time. The
serial isolates from patient 6 were genotypically identical
but also showed the largest difference in MIC for the
triazoles including drugs which have not been used
(itraconazole, voriconazole, isavuconazole). The other
four patients were probably infected by more than one
genotype (Figure 1) although this might be biased
because from each positive CSF culture only one colony
was archived for future study.
Discussion
No previous studies of the antifungal susceptibility and
genetic diversity of sequential isolates of C. neoformans
obtained from individual patients have been done in
Cuba. Here we studied 19 serial clinical strains of C.
neoformans from 7 patients with recurrent cryptococcal
meningitis during the pre-HAART period by analyzing
their antifungal susceptibility and molecular profiles.
Our results on the in vitro activities of the main anti-
fungal drugs are similar to those published previously
[15-17]. Amphotericin B has long successfully been used
to treat various yeasts and mould infections. In this ser-
ies there was only one log2 dilution difference between
the sequential isolates with a highest observed MIC of
Table 2 Minimum inhibitory concentration of all C. neoformans var. grubii isolates for seven antifungal drugs
Patient Nr. Strain
Nr.
Minimum Inhibitory Concentration (μg/mL) reading at 72 h
AmB FC Flu Itr Vor Pos Isa
1 08-36-09-92 0.125 8 4 0.125 0.016 0.125 0.016
08-36-09-75 0.25 2 4 0.063 < 0.016 0.063 < 0.004
08-36-10-01 0.25 4 4 0.25 0.125 0.125 < 0.004
2 08-36-09-97 0.125 2 1 0.031 0.063 0.125 < 0.004
08-36-09-70 0.25 2 2 0.063 0.063 0.125 0.016
08-36-09-91 0.125 1 1 0.031 < 0.016 0.063 0.008
3 08-36-09-71 0.25 2 2 0.063 0.063 0.016 0.016
08-36-09-72 0.125 8 2 0.125 0.125 0.031 < 0.004
4 08-36-09-82 0.25 2 2 0.031 0.031 0.031 0.008
08-36-09-89 0.25 1 4 0.031 0.125 0.063 0.008
5 08-36-09-24 0.25 2 1 < 0.016 < 0.016 0.016 0.004
08-36-09-25 0.25 1 0.25 0.031 < 0.016 0.016 < 0.004
6 08-36-10-56 0.125 0.5 0.25 < 0.016 < 0.016 0.063 < 0.004
08-36-10-52 0.125 0.5 4 0.125 0.125 0.016 0.031
08-36-10-53 0.25 1 8 0.125 0.25 0.016 0.063
7 08-36-09-26 0.25 0.5 0.5 < 0.016 < 0.016 0.031 0.016
08-36-09-30 0.25 0.5 0.5 0.031 0.031 0.016 0.004
08-36-09-78 0.125 1 1 0.031 0.063 0.016 < 0.004
08-36-09-42 0.25 4 8 0.5 0.25 0.031 < 0.004
Abreviations: AmB: amphotericin B, FC; flucytosine, Flu; fluconazole, Itr; itraconazole, Vor; voriconazole, Pos; posaconazole, Isa; isavuconazole.
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0.25 μg/mL way below the suggested breakpoint for
resistance of MIC ≥2 μg/mL, which was found to be
associated with therapeutic failure [18]. All flucytosine
MICs were < 16 μg/mL which are regarded as suscepti-
ble [7,14]. Among the azoles, fluconazole showed the
lowest in vitro activity. In fact, previous reports have
already demonstrated the low activity of this drug
against C. neoformans isolates, even though it has pro-
ven to be more active in vivo [19]. According to these
authors, the good therapeutic results obtained are lar-
gely attributable to its high concentrations in cerebrosp-
inal fluid. Although no resistance has been found in the
present collection of isolates (MIC < 16 μg/mL) [20], a
stepwise increase of 4 and 5 dilutions was found in 2
patients suggesting development of reduced levels of
antifungal susceptibility [7]. In one patient (nr. 6) the
sequential isolates were genotypically identical. Of inter-
est is the finding that the increase of fluconazole MICs
over time in patients 6 and 7 parallels data with itraco-
nazole, voriconazole and isavuconazole but not with
posaconazole. These observations support previous work
that suggests the development of cross-resistance of flu-
conazole with other triazoles [20]. Isavuconazole is an
experimental broad-spectrum antifungal triazole active
against clinically relevant yeasts and moulds [21]. Our
results are in agreement with previously published stu-
dies which demonstrated a high in vitro activity of this
drug for C. neoformans [17,22]. It has been demon-
strated that there are no trends towards higher MICs
for strains isolated from patients who failed to respond
to a given therapy compared to isolates from patients
who did not [23]. On the other hand, patient 4 was
infected with two different genotypes with similar
susceptibility profiles. Because the short time in between
each isolation it is suggestive that this was not a recur-
rent infection, it is possible that the patient was infected
simultaneously with both strains. Patients 2 and 5 had
three and two isolates respectively with similar suscept-
ibility patterns. In the first case only the CSF isolates
were genotypically similar. This might imply that this
patient was also infected simultaneously with more than
one strain however there might be a bias because mixed
infections in one sample of morphologically similar
cryptococci might have been missed. In the second case,
isolates differed in one marker and were thus considered
to be genetically related. These observations suggest
microevolution of C. neoformans during human infec-
tion. This process may allow the fungal population to
change and escape eradication by the immune system,
and thus cause chronic infections as suggested by Jain et
al. [24]. Patient 1 had two baseline isolates, from blood
and CSF, that had similar susceptibility but were genoty-
pically different. Since both genotypes were isolated
simultaneously this could mean that the patient was
infected with both strains at time of first sampling. As
has been stated before we might have missed mixed
infection at baseline because not all (morphologically)
similar colonies were studied. After more than three
months of fluconazole maintenance therapy, the patient
was re-admitted because signs and symptoms of relapse.
The CSF isolate obtained at that time had higher MIC
values for voriconazole and a different genotype com-
pared with the previous isolates. These findings suggest
two possibilities: i) the patient was re-infected with a
new strain during the maintenance therapy or ii) the
initial strains underwent genetic microevolution.
Figure 1 Details of the 19 C. neoformans isolates from 7 patients and relationship between the obtained genotypes. The numbers
below the genotype correspond to the number of repetitions observed in markers CNA2a, CNA2b, CNA2c, CNA3a, CNA3b, CNA3c, CNA4a,
CNA4b and CNA4c, respectively. A hyphen indicates that no result was obtained. The dendrogram is based on a categorical analysis using
UPGMA clustering. The scale bar indicates the percentage similarity.
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Cerebrospinal fluid from patient 7 remained microscopi-
cally (Indian ink) and culture positive during more than
5 months, despite antifungal therapy. Only the second
and third isolate showed the same genotype which was
different from the first and the fourth isolate. This could
be explained by simultaneous infection with more than
one strain or by re-infection with a new strain during
treatment which developed genetic changes over time.
This is corroborated by the increased MICs values for
fluconazole, itraconazole and voriconazole of the last
isolate.
Other authors have studied the molecular relationship
of C. neoformans isolates obtained from the same epi-
sode of infection or during a recurrent infection with
several different techniques [10,11,24-26]. Although the
obtained results are variable, most authors suggest that
persistence or recurrence of the infection is caused by
relapse rather than re-infection and/or microevolution
of the original isolate [20,25-28]. Multiple strain infec-
tion was rarely considered until a recent study reported
a high frequency of mixed infections in 20% of patients
with cryptococcal disease and speculated that multiple
strains could be exogenously acquired from the environ-
ment, either simultaneous or sequentially [29]. A bias
was entered in our study because only one colony was
selected for archiving from each sampling point
(because all growing colonies were morphologically
similar). Morphological similar colonies might have dif-
ferent genotypic backgrounds as has been shown
recently [29].
Conclusions
STR typing as presented in this study has not been lar-
gely used for Cryptococcus molecular characterization.
This new typing technique allowed the observation of
high genetic variability among the studied clinical iso-
lates keeping in mind the previous mentioned limitation
of this study and we confirm the observation of within-
host strain diversity [29]. Recurrence of infection in the
majority of these patients were not associated with drug
resistance but probably by co-infection with different
strains or strains genetically modified during the long
maintenance therapy.
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Cuban Cryptococcus isolates (n � 165) were tested in vitro against amphotericin B, flucytosine, fluconazole,
itraconazole, voriconazole, posaconazole, and isavuconazole, giving MIC90 values of 0.25, 8, 4, 0.25, 0.125,
0.016, and 0.016 �g/ml, respectively. Isavuconazole and posaconazole seem to be potentially active drugs for
treating cryptococcal infections.
Antifungals available for therapy of cryptococcosis are lim-
ited to amphotericin B, ﬂucytosine, and ﬂuconazole; however,
the side effects associated with administration of amphotericin
B and ﬂucytosine may restrict their use (17, 25). A new gen-
eration of triazoles, including posaconazole, voriconazole,
ravuconazole, and isavuconazole, has been developed. These
agents possess potent broad-spectrum activity and favorable
pharmacokinetic proﬁles (14, 18, 23). Isavuconazole is a water-
soluble triazole that is suitable for oral and intravenous admin-
istration; its active moiety, BAL4815, is a potent inhibitor of
ergosterol biosynthesis. In vitro, the active drug shows activity
against all major opportunistic and pathogenic fungi (14, 20,
21, 23).
Previous studies have been done regarding the activity of the
new azoles against a wide variety of fungi. This report summa-
rizes the in vitro activities of isavuconazole and six other anti-
fungal drugs on a large number of Cuban Cryptococcus isolates
from clinical and environmental origins by a broth microdilu-
tion method in accordance with the CLSI (formerly NCCLS)
M27-A2 guidelines (12). To our knowledge, this is the ﬁrst
report evaluating the susceptibility of this yeast to this new
triazole and the largest study ever done with Cuban Cryptococ-
cus strains.
(Part of this work was presented at the 46th Interscience
Conference on Antimicrobial Agents and Chemotherapy, San
Francisco, CA, 27 to 30 September 2006 [10a].)
A total of 165 Cryptococcus strains were included: 117 were
obtained from clinical samples, including one isolated from a
cheetah imported from South Africa. Forty-ﬁve strains were
isolated from pigeon guano in three different geographical
locations of Cuba: Havana City (n � 8), Cienfuegos (n � 6),
and Pinar del Rı´o (n � 31). Species identiﬁcation was initially
performed by standard mycological methods (9), and samples
were stored on sterile water at room temperature until the
study was carried out. Before use, the identities of all isolates
were conﬁrmed with a commercial identiﬁcation system
(Auxacolor 2; Bio-Rad, Marnes-la-Coquette, France). Can-
dida krusei ATCC 6258 and Candida parapsilosis ATCC 22019
strains were used for quality control.
Standard antifungal powders of amphotericin B, ﬂucytosine,
ﬂuconazole, itraconazole, voriconazole, posaconazole, and isa-
vuconazole were used and were obtained from Sigma (The
Netherlands), Valeant Pharmaceuticals (The Netherlands),
Pﬁzer Central Research (United Kingdom), Janssen-Cilag
(The Netherlands), Pﬁzer Central Research (United States),
Schering Plough (United States), and Basilea Pharmaceutica
(Switzerland), respectively. The stock solutions of the drugs
were prepared in the appropriate solvent (12).
Broth microdilution testing was performed in accordance
with the guidelines in CLSI document M27-A2 (12). The ﬁnal
concentrations of the antifungal agents were 0.016 to 8 �g/ml
for amphotericin B, itraconazole, voriconazole, and posacon-
azole; 0.063 to 32 �g/ml for ﬂucytosine and ﬂuconazole; and
0.004 to 4.00 �g/ml for isavuconazole. Drug-free and yeast-free
controls were included. The MICs at 48 and 72 h were read
optically and spectrophotometrically at 420 nm after agitation.
The MIC was deﬁned as the lowest concentration of drug
showing no growth for amphotericin B and a prominent re-
duction of growth (�50%) for the other antifungals compared
to the drug-free growth control.
All strains were identiﬁed as Cryptococcus neoformans var.
grubii, except one obtained from an animal (Cryptococcus gat-
tii) and two obtained from environmental samples from Pinar
del Rio (Cryptococcus albidus and Cryptococcus albidisimilus).
No differences between visual and spectrophotometric read-
ings were observed, and the MICs for the quality control
strains were all within the reference ranges (data not shown).
Table 1 summarizes the in vitro susceptibilities of all the iso-
lates according to the origin of the strain. In this study, most of
the C. neoformans isolates showed quite uniform patterns of
susceptibility to the antifungal agents tested. All of the strains
* Corresponding author. Mailing address: Department of Medical
Microbiology and Infectious Diseases, Canisius Wilhelmina Hospital,
P.O. Box 9015, 6500 GS Nijmegen, The Netherlands. Phone:
31243657514. Fax: 31243657516. E-mail: j.meis@cwz.nl.
� Published ahead of print on 22 January 2008.
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were susceptible to amphotericin B, voriconazole, posacon-
azole, and isavuconazole.
When all of the strains were considered together, the widest
ranges and highest MICs were for ﬂucytosine (0.063 to 64
�g/ml) and ﬂuconazole (0.25 to 64 �g/ml). The lowest MICs
were for isavuconazole, voriconazole, and posaconazole.
The environmental isolates seem to be less susceptible to
ﬂuconazole than the clinical ones.
Strains obtained from human immunodeﬁciency virus-neg-
ative patients showed lower MIC90s, especially for amphoter-
icin B and ﬂuconazole, compared with those from AIDS pa-
tients.
Our results on the in vitro activities of the main antifungal
drugs against C. neoformans are similar to those published
previously (3, 7, 8, 16, 19, 24). Amphotericin B has long suc-
cessfully been used to treat various yeast and mold infections.
Unfortunately, its clinical use is hindered by intrinsic nephro-
toxicity (5). There are no deﬁned amphotericin B breakpoints
by CLSI for C. neoformans. For this reason, breakpoints were
used according to Nguyen and Yu (13) and Lozano et al. (11).
They deﬁne an isolate as resistant with a MIC of �2 �g/ml,
which was found to be associated with therapeutic failure.
Although isolates from non-HIV patients showed higher am-
photericin B MICs, the studied strains appear to be susceptible
to this drug.
Flucytosine is a drug with a limited spectrum of action that
includes Candida spp. and C. neoformans (5). The CLSI
M27-A2 document recommends that isolates for which MICs
are 32 �g/ml be regarded as resistant to this drug (12). By this
deﬁnition, none of the studied clinical isolates was resistant;
nevertheless, a justiﬁed fear of the emergence of resistance has
led to its use in combination with amphotericin B in vitro and
in patients with cryptococcosis (4, 7, 22, 25).
Among the azoles, ﬂuconazole showed the lowest activity. In
fact, previous reports have already demonstrated the low ac-
tivity of this drug against C. neoformans isolates, even though
it has proven to be more active in vivo (1). According to these
authors, the good therapeutic results obtained are largely at-
tributable to its high concentrations in cerebrospinal ﬂuid.
Although no resistance has been found in the present collec-
tion of isolates, we continue paying attention to the emerging
resistance to this antifungal agent due to its widespread use as
primary prophylaxis in AIDS patients.
Fortunately, the antifungal armamentarium has increased
during the past two decades with the addition of several agents
and, although the echinocandins seem to be inactive, other
new triazoles are expected to be licensed shortly (5, 14). Vori-
conazole has in vitro activity against cryptococcal yeasts (15)
including those that are resistant in vitro to ﬂuconazole (13).
Our results show that voriconazole was more potent than itra-
conazole against Cuban Cryptococcus isolates. However, these
promising in vitro results should be complemented by clinical
conﬁrmation.
Posaconazole and isavuconazole belong to the latest gener-
ation of azole antifungal agents that are being investigated for
their role in treating serious infections due to yeasts and molds.
In addition to potent activity, they are well tolerated and offer
a diminished toxicity proﬁle compared with other currently
marketed systemic antimycotics and their pharmacokinetics
are characterized by slow elimination, low plasma clearance,
and extensive tissue distribution (14, 26, 27).
Posaconazole is the broadest-spectrum azole licensed to
date. It exhibits linear pharmacokinetics in volunteers (6) and
has demonstrated safety and efﬁcacy comparable to those of
ﬂuconazole in human and animal studies, although there is no
intravenous formulation available (26). In agreement with our
results with Cryptococcus, other in vitro studies have docu-
mented a potency and spectrum of activity against clinically
important yeasts and Aspergillus spp. similar to those of itra-
conazole and superior to those of ﬂuconazole. Consistent with
these results, in vivo studies have demonstrated efﬁcacy in
treating infections due to Candida spp. and C. neoformans with
this antifungal agent (2, 10).
The prodrug isavuconazole is a water-soluble triazole pre-
cursor that is suitable for oral and intravenous administration.
Its active moiety, BAL4815, is a potent inhibitor of ergosterol
biosynthesis (14, 20, 21). In vitro, the drug shows broad-spec-
trum activity against all major opportunistic and true patho-
TABLE 1. In vitro susceptibilities of Cryptococcus isolates to
amphotericin B, ﬂucytosine, ﬂuconazole, itraconazole,
voriconazole, posaconazole, and isavuconazole according
to origin and underlying disease of patients
Origin (no. of strains) Antifungal agent
MIC (�g/ml)
Range 50% 90%
Environmental (45) Amphotericin B 0.016–0.5 0.25 0.5
Flucytosine 0.5–64 4 8
Fluconazole 0.25–64 4 8
Itraconazole 0.016–0.5 0.063 0.25
Voriconazole 0.016–0.25 0.063 0.25
Posaconazole 0.016–0.125 0.31 0.63
Isavuconazole 0.002–0.031 0.004 0.016
Clinical (117) Amphotericin B 0.031–1 0.25 0.25
Flucytosine 0.063–8 4 8
Fluconazole 0.25–8 2 4
Itraconazole 0.016–1 0.031 0.25
Voriconazole 0.016–0.25 0.031 0.125
Posaconazole 0.016–0.5 0.004 0.016
Isavuconazole 0.002–0.063 0.004 0.016
AIDS patients (85) Amphotericin B 0.031–1 0.25 0.25
Flucytosine 0.125–8 4 8
Fluconazole 0.25–8 2 2
Itraconazole 0.016–0.5 0.031 0.125
Voriconazole 0.016–0.25 0.031 0.125
Posaconazole 0.016–0.125 0.031 0.125
Isavuconazole 0.002–0.063 0.008 0.016
Non-AIDS patients Amphotericin B 0.125–1 0.25 1
(32) Flucytosine 0.063–8 2 4
Fluconazole 0.25–8 2 8
Itraconazole 0.016–1 0.031 0.063
Voriconazole 0.016–0.25 0.063 0.063
Posaconazole 0.016–0.5 0.063 0.125
Isavuconazole 0.004–0.063 0.008 0.031
Total Amphotericin B 0.016–1 0.25 0.25
Flucytosine 0.063–64 4 8
Fluconazole 0.25–64 2 4
Itraconazole 0.016–1 0.031 0.25
Voriconazole 0.016–0.25 0.031 0.125
Posaconazole 0.002–0.125 0.004 0.016
Isavuconazole 0.002–0.063 0.004 0.016
a 50% and 90%, MIC50 and MIC90, respectively.
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genic fungi (14, 23). In animals as well as in humans, the
pharmacokinetics of this drug are characterized by slow elim-
ination, low plasma clearance (approximately 10% of liver
blood ﬂow), and extensive tissue distribution (20, 21). To our
knowledge, this is the ﬁrst report evaluating the action against
Cryptococcus spp. of isavuconazole, which seems to be the most
effective antifungal drug in terms of in vitro activity. In con-
clusion, our results indicate that there has been no signiﬁcant
shift in the MICs of amphotericin B and ﬂuconazole for Cuban
C. neoformans (8), despite the widespread use of these agents
in persons with AIDS. Given the high oral bioavailability and
the well-tolerated nature of the new azoles, they might become
an important addition to the armamentarium of antifungal
agents: both voriconazole and posaconazole show strong anti-
fungal activity against Cuban Cryptococcus strains in vitro,
while isavuconazole showed even lower MICs. These promis-
ing results still need to be correlated with clinical outcome.
This study was made possible by an unrestricted research grant from
the International Society of Human and Animal Mycology (ISHAM)
to M.T.I.-Z.
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The in vitro susceptibilities of a worldwide collection of 350 Cryptococcus gattii isolates to seven antifungal
drugs, including the new triazole isavuconazole, were tested. With ampliﬁed fragment length polymorphism
(AFLP) ﬁngerprinting, human, veterinary, and environmental C. gattii isolates were subdivided into seven
AFLP genotypes, including the interspecies hybrids AFLP8 and AFLP9. The majority of clinical isolates (n �
215) comprised genotypes AFLP4 (n� 76) and AFLP6 (n� 103). The clinical AFLP6 isolates had signiﬁcantly
higher geometric mean MICs for ﬂucytosine and ﬂuconazole than the clinical AFLP4 isolates. Of the seven
antifungal compounds examined in this study, isavuconazole had the lowest MIC90 (0.125 �g/ml) for all C.
gattii isolates, followed by a 1 log2 dilution step increase (MIC90, 0.25 �g/ml) for itraconazole, voriconazole, and
posaconazole. Amphotericin B had an acceptable MIC90 of 0.5 �g/ml, but ﬂuconazole and ﬂucytosine had
relatively high MIC90s of 8 �g/ml.
The basidiomycetous yeast Cryptococcus gattii is responsible
for life-threatening invasive disease in apparently healthy hu-
mans and animals (7, 19). A typical C. gattii infection is ac-
quired through the respiratory tract, from which it can further
disseminate to the central nervous system, resulting in fatal
meningitis (7, 19, 32). Cryptococcosis caused by the primary
pathogenic yeast C. gattii was, until a decade ago, a rarely
encountered infection outside tropical and subtropical regions
(17, 26, 27). However, this changed due to an unprecedented
outbreak that emerged in the temperate climate of Vancouver
Island (British Columbia, Canada) that subsequently expanded
farther into the Paciﬁc Northwest (1, 8, 10, 16). Its sibling
species, Cryptococcus neoformans, differs ecologically and epi-
demiologically from C. gattii since it occurs on a global scale
and is linked with disease occurring in immunocompromised
individuals, such as HIV-positive patients and transplant pa-
tients who receive immune-suppressive medicines (7, 10, 18,
19, 31).
Cryptococcus gattii can be discerned from C. neoformans
using a wide range of microbiological and molecular tech-
niques (7, 20). A convenient method is the use of canavanine-
glycine-bromothymol blue (CGB) medium, which allows C.
gattii but not C. neoformans to grow and which changes the pH
indicator in the medium from green-yellowish to blue (18).
With the increasing use of molecular techniques, such as PCR
ﬁngerprinting, restriction fragment length polymorphism
(RFLP) analysis of the PLB1 and URA5 loci, and ampliﬁed
fragment length polymorphism (AFLP) ﬁngerprint analysis, as
well as several multilocus sequence typing (MLST) ap-
proaches, it became clear that C. gattii could be divided into
ﬁve distinct genotypes, named AFLP4/VGI, AFLP5/VGIII,
AFLP6/VGII, AFLP7/VGIV, and AFLP10 (the last one of
which is a recently observed novel genotype) (2, 6, 7, 13, 16, 20,
21, 23). Until recently, a serotype agglutination assay was
widely used to distinguish C. neoformans (serotypes A and D)
from C. gattii (serotypes B and C) (7, 27). In general, serotype
B strains are found in each of the ﬁve C. gattiiAFLP genotypes,
but it seems that C. gattii serotype C strains are restricted to
genotypes AFLP5/VGIII and AFLP7/VGIV (2, 6, 16, 21, 27).
In addition, it was found that C. gattii and C. neoformans can
form interspecies hybrids, named genotype AFLP8 (C. neofor-
mans var. neoformans AFLP2/VNIII serotype D � C. gattii
AFLP4/VGI serotype B) and AFLP9 (C. neoformans var. grubii
AFLP1/VNI serotype A � C. gattii AFLP4/VGI serotype B).
These interspecies hybrids have, until now, been isolated only
from clinical samples, and they might have a higher virulence
potential than regular C. gattii or C. neoformans isolates (4, 5;
F. Hagen, K. Tintelnot, and T. Boekhout, unpublished data).
Treatment of cryptococcosis depends on, besides the im-
mune status of the patient, the severity and localization of the
infection (11). Severe cases of cryptococcosis in immunocom-
petent and -compromised patients are treated according to the
guidelines of the Infectious Diseases Society of America, ac-
cording to which treatment consists of an induction therapy for
* Corresponding author. Mailing address: Canisius Wilhelmina
Hospital, Department of Medical Microbiology and Infectious Dis-
eases, Weg door Jonkerbos 100, Nijmegen, 6532 SZ Netherlands.
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2 weeks with a combination of amphotericin B and ﬂucytosine,
followed by a 10-week consolidation therapy with ﬂuconazole
(11, 24).
Cryptococcus neoformans has been extensively studied for its
in vitro susceptibility to a wide variety of antifungal com-
pounds, including the new triazoles posaconazole, voricon-
azole, ravuconazole, and isavuconazole (12, 14, 28, 29, 33).
Despite the ongoing C. gattii outbreak, only a few studies using
relatively small sets of C. gattii isolates have been performed to
investigate their in vitro susceptibilities to amphotericin B,
ﬂucytosine, ﬂuconazole, and the new triazole antifungals (12,
15, 28–30). A few studies divided the C. gattii isolates into
groups according to their serotype or genotype (15, 29).
Therefore, we studied the in vitro susceptibilities of each of
the C. gattii genotypes from a large worldwide collection, sub-
divided by AFLP genotyping, to amphotericin B, ﬂucytosine,
ﬂuconazole, itraconazole, voriconazole, posaconazole, and the
new experimental broad-spectrum antifungal triazole isavu-
conazole.
MATERIALS AND METHODS
Strains and media. A worldwide collection of 350 C. gattii strains, represented
by 215 clinical isolates (61.4%), 57 veterinary isolates (16.3%), 73 environmental
isolates (20.9%), and 5 isolates from an unknown source (1.4%), were included
in this study. Strains were obtained from the public culture collections of the
CBS-KNAW Fungal Biodiversity Centre (Utrecht, Netherlands), BCCM-IHEM
Scientiﬁc Institute of Public Health (Brussels, Belgium), as well as the working
group collections of the authors. According to their geographical origins, the C.
gattii strains were grouped as being of African (n � 28; 8.0%), Asian (n � 22;
6.3%), Australian (n � 20; 5.7%), European (n � 101; 28.9%), North American
(n � 95; 27.1%), South American (n � 81; 23.1%), and unknown (n � 3; 0.9%)
origin. The group of North American strains contained a set of 75 (24.1%) C.
gattii strains related to the ongoing Vancouver Island outbreak. The distributions
of the C. gattii strains, according to their geographical origins and sources of
isolation, are listed in Table 1. The strains were checked for purity and were
cultivated on malt extract agar medium (MEA; Oxoid, Basingstoke, United
Kingdom). After inoculation, the cultures were incubated for 2 days at 30°C. A
working collection was made by growing the C. gattii strains on MEA slants for
2 days at 30°C, after which the strains were stored at 4°C.
Genomic DNA extraction. An extraction procedure previously described by
Bolano et al. (3) was further optimized to obtain high-quality genomic DNA. C.
gattii strains were subcultured for 2 days at 30°C on yeast extract (1%)–peptone
(1%)–D-glucose (2%) agar supplemented with 0.5 M NaCl to prevent the for-
mation of a polysaccharide capsule. Approximately 150 �l of C. gattii cells was
incubated for 3 h in 1.6 ml urea solution (10.7 M) at room temperature. After
centrifugation at 4,000� g for 2 min, the pellet was resuspended in 750 �l of lysis
buffer (10% [wt/vol] sodium dodecyl sulfate, 10% [wt/vol] sodium Sarkosyl in TE
[Tris-EDTA] buffer, pH 8.0) and 750 �l phenol-chloroform-isoamyl alcohol
(25:24:1, pH 8.0). The cells were disrupted by bead beating at full speed
(TissueLyser; Qiagen, Venlo, Netherlands) for 5 min. After centrifugation at
17,000 � g for 15 min at 4°C, approximately 750 �l supernatant was added to an
equal volume of ice-cold 96.2% ethanol and 100 �l ice-cold 3.0 M sodium
acetate. Precipitation of genomic DNA was accelerated by incubating the solu-
tion at �20°C for 1 h. Genomic DNA was precipitated by centrifugation at
17,000 � g for 15 min at 4°C, the pellet obtained was dissolved in 100 �l
Tris-EDTA buffer (pH 8.0), and 1 �l RNase (Invitrogen, Breda, Netherlands)
was added, followed by an incubation step at 37°C to degrade any remaining
RNA. The quality and quantity of genomic DNA were measured using an
ND-1000 spectrophotometer (Nanodrop, Wilmington, DE), and ﬁnal working
solutions, each with a concentration of 100 ng/�l, were prepared.
Mating typing, serotyping, and genotyping. The mating types of all isolates
were determined by partial ampliﬁcation of the STE12 locus and either the
MATa or theMAT� allele using two different primer sets, as described by Bovers
et al. (5). Brieﬂy, 1 �l genomic DNA (100 ng/�l) was added to 24 �l PCR mixture
consisting of 17.8 �l double-distilled H2O, 0.75 �l MgCl2 (50 mM; Bioline,
London, United Kingdom), 2.5 �l 10� PCR buffer (Bioline), 1.9 �l deoxynucleo-
side triphosphates (1 mM; Bioline), 0.1 �l Taq DNA polymerase (5 U/�l; Bio-
line), and 0.5 �l of the forward and reverse primers (Biolegio, Nijmegen, Neth-
erlands) for either the STE12� allele (forward primer STE12�-F809 [5�-TTGA
CCTTTTRTTCCGCAATG-3�] and reverse primer STE12�-R1607 [5�-TTTCT
TCTCCCCTGTTTATAGGC-3�]) or the STE12a allele (forward primer
STE12a-F537 [5�-GTTCTTTGGAATGGCTTATTTCATAT-3�] and reverse
primer STE12a-R1299 [5�-GMCTTGCGTGGATCATATCTA-3�]). PCRs were
carried out with an initial denaturation step at 94°C for 5 min, followed by 35
cycles of denaturation at 94°C for 30 s, annealing at 58°C for 30 s, and extension
at 72°C for 1 min and then 72°C for 5 min. The reaction mixture was ﬁnally
cooled to 21°C. As a control, C. gattiimating type � strains CBS6956 and WM276
(CBS10510) and mating-type a strains CBS1930 and E566 (CBS11233) were
included.
A Cryptocheck agglutination test kit (Iatron Laboratories, Tokyo, Japan) was
used to determine the serotypes of those C. gattii isolates with contradictory
serotype data.
The genotype of each C. gattii isolate was determined using AFLP ﬁngerprint
analysis, as described previously by Boekhout et al. (2). C. gattii isolates WM178
(CBS10082; AFLP6/VGII), A1M-R265 (CBS10514; AFLP6A/VGIIa), A1M-
R272 (CBS10865; AFLP6B/VGIIb), A6M-R38 (CBS11545; AFLP6C/VGIIc),
WM161 (CBS10081; AFLP5/VGIII), WM179 (CBS10078; AFLP4/VGI),
WM779 (CBS10101; AFLP7/VGIV), CBS10488 (AFLP8), CBS10496 (AFLP9),
and IHEM14941S (CBS11687; AFLP10) were used as controls to assign the
AFLP genotypes to all C. gattii isolates (2, 8, 13, 20, 21).
TABLE 1. Distribution of Cryptococcus gattii strains on the basis of AFLP genotype proﬁles, geographical origin,
and clinical, veterinary, or environmental source
AFLP
genotype
proﬁle
No. (%) of strainsa
Geographical origin Source of isolation
Total
Africa Asia Australia Europe NorthAmerica
South
America Unknown Clinical Veterinary Environmental Unknown
AFLP4 16 (11.7) 14 (10.2) 8 (5.8) 74 (54.0) 9 (6.6) 15 (10.9) 1 (0.7) 76 (55.5) 29 (21.2) 30 (21.9) 2 (1.5) 137 (39.1)
AFLP5 1 (4.5) 2 (9.1) 10 (45.5) 7 (31.8) 2 (9.1) 15 (68.2) 5 (22.7) 2 (9.1) 22 (6.3)
AFLP6 3 (1.8) 6 (3.6) 11 (6.5) 19 (11.2) 75 (44.4) 55 (32.5) 103 (60.9) 27 (16.0) 38 (22.5) 1 (0.6) 169 (48.3)
AFLP6A 4 (5.5)* 1 (1.4)* 5 (6.8)* 56 (76.7)* 7 (9.6)* 36 (49.3)* 18 (24.7)* 18 (24.7)* 1 (1.4)* 73 (43.2)*
AFLP6B 3 (3.4)* 2 (2.3)* 10 (11.4)* 14 (15.9)* 11 (12.5)* 48 (54.5)* 61 (69.3)* 7 (8.0)* 20 (22.7)* 88 (52.1)*
AFLP6C 8 (100)* 6 (75.0)* 2 (25.0)* 8 (4.7)*
AFLP7 7 (63.6) 2 (18.2) 2 (18.2) 10 (90.9) 1 (9.1) 11 (3.1)
AFLP8 2 (33.3) 2 (33.3) 2 (33.3) 6 (100) 6 (1.7)
AFLP9 2 (66.7) 1 (33.3) 3 (100) 3 (0.9)
AFLP10 2 (100) 2 (100) 2 (0.6)
Total 28 (8.0) 22 (6.3) 20 (5.7) 101 (28.9) 95 (27.1) 81 (23.1) 3 (0.9) 215 (61.4) 73 (20.9) 57 (16.3) 5 (1.4) 350 (100)
a An asterisk indicates strains that belong to one of the subgenotypes within AFLP6, namely, AFLP6A, AFLP6B, or AFLP6C; these strains are the cumulative
number of strains in the main genotype AFLP6 group.
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In vitro susceptibility testing. The MICs of amphotericin B (Bristol Myers
Squibb, Woerden, Netherlands), ﬂucytosine (Valeant Pharmaceuticals, Zoeter-
meer, Netherlands), ﬂuconazole and voriconazole (Pﬁzer Central Research,
Sandwich, Kent, United Kingdom), itraconazole (Janssen Cilag, Tilburg, Neth-
erlands), posaconazole (Schering-Plough Corp., Kenilworth, NJ), and isavucon-
azole (Basilea Pharmaceutica, Basel, Switzerland) were determined using the
broth microdilution method, in accordance with the guidelines in CLSI docu-
ment M27-A3 (9). Drug-free and sterile controls were included. Paecilomyces
variotii (ATCC 22319) and Candida krusei (ATCC 6258, CBS573) were used for
quality control. The microtiter plates were incubated for 72 h at 35°C under
aerobic conditions.
Data analysis. Values for the MIC50 and MIC90 were obtained by ordering the
MIC data for each antifungal in ascending arrays and selecting the median and
90th quantile, respectively, of the MIC distribution. Geometric mean MICs were
computed using Microsoft Ofﬁce Excel 2007 software, for which purpose values
of �x were set equal to 0.5x and values more than �y were set equal to 2y (x and
y are the lowest and highest MICs, respectively, in the range). A two-tailed
Mann-Whitney-Wilcoxon test was applied to compare the MIC values between
different C. gattii genotypes; and a multivariate analysis of variance (MANOVA)
test was applied to compare geographical origins, AFLP genotype proﬁles, and
MIC values (StatistiXL software, version 1.8, StatistiXL, Nedland, WA, Austra-
lia). A P value of �0.05 was considered statistically signiﬁcant.
RESULTS
Mating typing, serotyping, and genotyping. On the basis of
the AFLP genotypes, the 350 C. gattii isolates were divided
into ﬁve haploid AFLP genotypes (n � 341; 97.4%) and two
hybrid AFLP genotypes (n � 9; 2.6%), namely, AFLP4 (n �
137; 39.1%), AFLP5 (n � 22; 6.3%), AFLP6 (n � 169;
48.3%), AFLP7 (n � 11; 3.1%), AFLP8 (n � 6; 1.7%),
AFLP9 (n � 3; 0.9%), and AFLP10 (n � 2; 0.6%). The
majority of the 215 clinical C. gattii isolates belonged to
either genotype AFLP4 (n � 76; 35.4%) or genotype AFLP6
(n � 103; 47.9%). Strains that clustered within genotype
AFLP6 could be further divided into the three subgenotypes
AFLP6A (n � 73; 43.2%), AFLP6B (n � 88; 52.1%),
and AFLP6C (n � 8; 4.7%) (Table 1).
The serotypes of the genotype AFLP7 strains were investi-
gated in more detail, since several of these isolates were, ac-
cording to the literature, known to be serotypes B and C (6, 21,
23). However, we determined that all C. gattii AFLP7 isolates
were serotype C. The two genotype AFLP10 strains were de-
termined to be serotype B. Within the other AFLP genotypes,
no contradictions from the literature were found, and serotyp-
ing was omitted for these groups.
The mating types for all C. gattii isolates were determined by
ampliﬁcation of either the STE12a or the STE12� allele. This
revealed that within the group of 341 haploid C. gattii strains
(genotypes AFLP4 to AFLP7 and AFLP10), the mating type �
strains (n � 296; 86.8%) were dominant over the mating type
a strains (n � 45; 13.2%).
In vitro susceptibility testing. MIC ranges, MIC50s, geomet-
ric mean MICs, and MIC90s related to AFLP genotype are
presented in Table 2. For each antifungal for each AFLP
genotype examined, the MIC50 and geometric mean MIC val-
ues differed by�1 log2 dilution step, indicating that in all cases
the MIC50s obtained by inspection reasonably reﬂect the cen-
tral tendency of antifungal susceptibility of the population.
Isavuconazole had the lowest MIC90s for all C. gattii iso-
lates surveyed by at least 1 log2 dilution step. The overall
ranges of MICs for each of the seven drugs were �0.016 to
1 �g/ml for amphotericin B, 0.125 to �64 �g/ml for ﬂucy-
tosine, 0.25 to �64 �g/ml for ﬂuconazole, �0.016 to 1 �g/ml
for itraconazole and voriconazole, and � 0.016 to 0.5 �g/ml
for posaconazole and isavuconazole. The geometric mean
MIC values varied widely when they were calculated for all
350 C. gattii strains (Table 2). The highest geometric mean
MIC was 3.573 �g/ml for ﬂuconazole, followed by geometric
mean MICs of 2.896 �g/ml for ﬂucytosine and 0.272 �g/ml
for amphotericin B and much lower geometric mean MICs
for itraconazole and the new triazoles voriconazole,
posaconazole, and isavuconazole (0.124, 0.108, 0.113, and
0.051 �g/ml, respectively).
Comparison of geometric mean MIC values of the C. gattii
strains obtained from clinical, environmental, and veteri-
nary sources revealed that the last category of strains had
decreased susceptibility to all seven antifungal drugs investigated
except ﬂucytosine in comparison to the susceptibilities of the
clinical and environmental strains. When the susceptibilities of
the clinical versus veterinary C. gattii strains and the environmen-
tal versus veterinary C. gattii strains were compared, these differ-
ences were signiﬁcant for itraconazole (P � 0.026 and P � 0.02,
respectively) and the novel triazoles posaconazole (P� 0.008 and
P � 0.02, respectively), voriconazole (P � 0.013 and P � 0.008,
respectively), and isavuconazole (P � 0.004 and P � 0.002, re-
spectively).
A MANOVA showed that there was a signiﬁcant difference
(P � 0.001) between the susceptibility values obtained for the
seven antifungal compounds and the geographical origins of
the C. gattii strains (Table 3). It was observed that the MIC
values of amphotericin B and ﬂucytosine contributed to this
signiﬁcant difference (P � 0.003 and P � 0.02, respectively).
This difference was caused by C. gattii strains from Europe,
which differed signiﬁcantly in their susceptibility to amphoter-
icin B compared to the susceptibilities of strains from Africa
(P � 0.002), Asia (P � 0.014), Australia (P � 0.041), North
America (P � 0.001), and South America (P � 0.019), which
were found to be less susceptible. For ﬂucytosine, North Amer-
ican C. gattii strains had a signiﬁcantly higher geometric mean
MIC than African (P � 0.001), Asian, (P � 0.001), European
(P� 0.001), and South American (P� 0.001) strains (Table 3).
When all C. gattii genotype AFLP4 and AFLP6 strains (Table
2) were analyzed by MANOVA, it was observed that it was not
the geographical origin but the genotype that contributed to
the signiﬁcant differences in antifungal susceptibility patterns
(P � 0.001). The antifungal drugs amphotericin B (P � 0.001),
ﬂuconazole (P � 0.001), itraconazole (P � 0.038), voricon-
azole (P � 0.001), and isavuconazole (P � 0.001) were found
to be highly signiﬁcant contributors to this phenotypic differ-
ence between AFLP4 and AFLP6 C. gattii strains.
Clinical strains that belonged to the genotype AFLP6 cluster
had a signiﬁcantly (P� 0.05) higher geometric mean MIC than
strains of genotype AFLP4 for six of the seven antifungal
compounds tested. However, both genotypes had almost iden-
tical geometric mean MICs for posaconazole (0.112 and 0.124
�g/ml, respectively; P � 0.391). Strikingly, clinical AFLP6 iso-
lates had high geometric mean MICs of 4.961 and 5.638 �g/ml
for ﬂucytosine and ﬂuconazole, respectively, compared to
those for clinical isolates within genotype AFLP4 (1.401 and
2.467 �g/ml, respectively).
C. gattii strains within the Vancouver outbreak-related ge-
notype, genotype AFLP6, were divided into the three deﬁned
subgenotypes AFLP6A (n � 73; 43.2%), AFLP6B (n � 88;
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TABLE 2. MIC ranges, MIC50s, MIC90s, and geometric mean MICs for all 350 C. gattii strains and AFLP genotypes
Strain Drug
MIC (�g/ml)
Range 50% Geometric mean 90%
All C. gattii strains (n � 350) Amphotericin B �0.016–1 0.25 0.272 0.5
Flucytosine 0.125–�64 2 2.896 8
Fluconazole 0.25–64 4 3.573 8
Itraconazole �0.016–1 0.125 0.124 0.25
Voriconazole �0.016–1 0.125 0.108 0.25
Posaconazole �0.016–0.5 0.125 0.113 0.25
Isavuconazole �0.016–0.5 0.063 0.051 0.125
C. gattii AFLP4 (n � 137) Amphotericin B �0.016–0.5 0.25 0.238 0.5
Flucytosine 0.125–16 1 1.667 4
Fluconazole 0.25–16 2 2.550 8
Itraconazole �0.016–0.5 0.125 0.119 0.25
Voriconazole �0.016–0.25 0.063 0.090 0.25
Posaconazole �0.016–0.5 0.125 0.123 0.25
Isavuconazole �0.016–0.5 0.031 0.044 0.125
C. gattii AFLP5 (n � 22) Amphotericin B 0.125–0.5 0.25 0.214 0.5
Flucytosine 0.5–4 2 1.938 4
Fluconazole 0.25–8 2 2.064 4
Itraconazole �0.016–0.25 0.063 0.078 0.125
Voriconazole �0.016–0.125 0.063 0.059 0.125
Posaconazole 0.031–0.25 0.063 0.076 0.125
Isavuconazole �0.016–0.063 0.031 0.023 0.063
C. gattii AFLP6 (n � 169) Amphotericin B 0.125–1 0.25 0.312 0.5
Flucytosine 0.5–�64 4 5.033 8
Fluconazole 0.5–64 4 5.137 16
Itraconazole �0.016–1 0.125 0.148 0.5
Voriconazole �0.016–1 0.125 0.142 0.25
Posaconazole �0.016–0.5 0.125 0.119 0.25
Isavuconazole �0.016–0.5 0.063 0.067 0.25
C. gattii AFLP6A (n � 73) Amphotericin B 0.125–0.5 0.25 0.299 0.5
Flucytosine 1–16 4 5.268 8
Fluconazole 0.5–32 4 4.235 8
Itraconazole �0.016–1 0.125 0.123 0.5
Voriconazole �0.016–1 0.125 0.117 0.25
Posaconazole �0.016–0.5 0.125 0.105 0.25
Isavuconazole �0.016–0.5 0.063 0.050 0.25
C. gattii AFLP6B (n � 88) Amphotericin B 0.125–1 0.25 0.319 0.5
Flucytosine 0.5–�64 4 4.609 8
Fluconazole 1–16 8 5.438 16
Itraconazole �0.016–0.5 0.25 0.162 0.25
Voriconazole �0.016–0.5 0.125 0.152 0.25
Posaconazole �0.016–0.25 0.125 0.124 0.25
Isavuconazole �0.016–0.25 0.063 0.078 0.25
C. gattii AFLP6C (n � 8) Amphotericin B 0.25–0.5 0.25 0.354 0.5
Flucytosine 4–16 8 8.724 16
Fluconazole 8–64 16 16.000 64
Itraconazole 0.25–0.5 0.25 0.297 0.5
Voriconazole 0.25–1 0.25 0.354 1
Posaconazole 0.125–0.5 0.25 0.229 0.5
Isavuconazole 0.063–0.5 0.25 0.193 0.5
C. gattii AFLP7 (n � 11) Amphotericin B 0.125–0.5 0.5 0.343 0.5
Flucytosine 1–8 2 2.269 8
Fluconazole 0.5–32 4 4.537 16
Itraconazole �0.016–0.25 0.125 0.104 0.25
Voriconazole 0.031–0.25 0.125 0.117 0.25
Posaconazole 0.031–0.25 0.125 0.110 0.25
Isavuconazole �0.016–0.25 0.063 0.052 0.125
C. gattii AFLP8–10 (n � 11) Amphotericin B 0.125–0.5 0.25 0.220 0.25
Flucytosine 1–8 1 1.656 8
Fluconazole 0.5–8 2 2.130 8
Itraconazole �0.016–0.125 0.063 0.043 0.125
Voriconazole �0.016–0.25 0.031 0.059 0.125
Posaconazole �0.016–0.125 0.063 0.043 0.125
Isavuconazole �0.016–0.063 0.016 0.020 0.063
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52.1%), and AFLP6C (n � 8; 4.7%). Signiﬁcant differences in
the geometric mean MICs between C. gattii AFLP6A and
AFLP6B strains were found for all antifungal drugs except
amphotericin B (P � 0.398) and ﬂucytosine (P � 0.091); how-
ever, the geometric mean MICs were within 1 log2 dilution
step. There was also no signiﬁcant difference in amphotericin B
MICs when AFLP6A and AFLP6C strains (P � 0.353) and
AFLP6B and AFLP6C strains (P � 0.607) were compared,
while all other antifungal compounds tested showed signiﬁcant
differences between these subgenotypes (Table 2). However,
the number of strains within subgenotype AFLP6C is too small
to compare its antifungal susceptibility characteristics with
those of the larger group of strains within genotypes AFLP6A
and AFLP6B.
DISCUSSION
Despite the fact that C. gattii has become an important
primary pathogen due to the expanding outbreak in British
Columbia (Canada) and the Paciﬁc Northwest (United States),
there is a lack of in-depth studies on the susceptibilities of large
sets of C. gattii strains to conventional and new antifungal
compounds (10). In particular, the relation between suscepti-
bility proﬁles and the different genotypes within the C. gattii
complex has rarely been studied and has been studied with only
low numbers of isolates (15). In this study, we have compared
the susceptibilities of 350 C. gattii isolates collected from dif-
ferent geographical regions and sources (e.g., clinical, veteri-
nary, and environmental) to four clinically used antifungal
TABLE 3. In vitro susceptibilities of the C. gattii strains according to geographical origin
C. gattii strain origin Drug
MIC (�g/ml)
Range 50% Geometric mean 90%
Africa (n � 28) Amphotericin B 0.125–0.5 0.25 0.320 0.5
Flucytosine 1–16 2 2.378 8
Fluconazole 0.25–32 4 4.308 8
Itraconazole �0.016–0.25 0.125 0.111 0.25
Voriconazole �0.016–0.25 0.125 0.114 0.25
Posaconazole �0.016–0.25 0.125 0.122 0.25
Isavuconazole �0.016–0.5 0.063 0.058 0.125
Asia (n � 22) Amphotericin B 0.125–0.5 0.25 0.312 0.5
Flucytosine 0.5–16 2 2 8
Fluconazole 0.5–16 2 2.741 8
Itraconazole 0.031–0.5 0.125 0.1 0.250
Voriconazole 0.031–0.25 0.063 0.08 0.250
Posaconazole 0.063–0.5 0.125 0.107 0.250
Isavuconazole 0.016–0.25 0.031 0.044 0.125
Australia (n � 20) Amphotericin B 0.125–0.5 0.25 0.297 0.5
Flucytosine 1–32 2 3.138 16
Fluconazole 0.5–16 2 2.639 8
Itraconazole 0.063–0.5 0.125 0.134 0.25
Voriconazole 0.031–0.25 0.125 0.091 0.25
Posaconazole 0.031–0.5 0.125 0.121 0.25
Isavuconazole 0.016–0.125 0.063 0.049 0.125
Europe (n � 101) Amphotericin B �0.016–1 0.25 0.223 0.5
Flucytosine 0.125–�64 2 2.263 8
Fluconazole 0.5–32 4 3.301 8
Itraconazole �0.016–0.5 0.125 0.137 0.25
Voriconazole �0.016–1 0.125 0.112 0.25
Posaconazole �0.016–0.5 0.125 0.131 0.25
Isavuconazole �0.016–0.5 0.063 0.055 0.125
North America (n � 95) Amphotericin B 0.125–0.5 0.25 0.300 0.5
Flucytosine 1–16 4 4.334 8
Fluconazole 0.5–64 4 4.240 8
Itraconazole �0.016–1 0.125 0.121 0.25
Voriconazole �0.016–1 0.125 0.114 0.25
Posaconazole �0.016–0.5 0.125 0.103 0.25
Isavuconazole �0.016–0.5 0.063 0.047 0.25
South America (n � 81) Amphotericin B 0.125–1 0.25 0.277 0.5
Flucytosine 0.5–16 4 2.865 8
Fluconazole 0.25–16 4 3.548 16
Itraconazole �0.016–1 0.125 0.126 0.25
Voriconazole �0.016–0.5 0.125 0.111 0.25
Posaconazole �0.016–0.5 0.125 0.104 0.25
Isavuconazole �0.016–0.5 0.063 0.051 0.25
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compounds, i.e., amphotericin B, ﬂucytosine, ﬂuconazole, and
itraconazole, and the three novel triazoles voriconazole,
posaconazole, and isavuconazole. The older antifungal drugs,
amphotericin B, ﬂucytosine, and ﬂuconazole, had lower levels
of activity against all C. gattii isolates than itraconazole and the
novel triazoles, as visualized by their geometric mean MIC
values (Table 2). The observation that ﬂucytosine and ﬂucon-
azole had poorer antifungal activity against C. gattii, as well as
against its sibling, C. neoformans, was a consistent ﬁnding in
previous studies (12, 14, 15, 25, 29, 30). For testing of C.
neoformans susceptibility to amphotericin B, ﬂucytosine, and
ﬂuconazole, so-called surrogate breakpoints were introduced
by Pfaller et al. (25). C. neoformans was regarded to be highly
susceptible to amphotericin B when the MIC in vitro was �1
�g/ml. In this study, none of the 350 C. gattii strains showed
higher in vitro MICs, and thus, all isolates remained highly
susceptible. Similar ﬁndings were reported in three other stud-
ies, which tested lower numbers of isolates (15, 29, 30). On the
contrary, decreased in vitro susceptibility (�16 �g/ml) to ﬂu-
conazole was observed for 26 strains (7.4%), and only one
clinical isolate within the AFLP6C cluster appeared to have
high-level resistance (MICs,�64 �g/ml) to ﬂuconazole in vitro.
With respect to ﬂucytosine, the number of strains within the
group of isolates with decreased susceptibility (MICs, �8 �g/
ml) was 84 (24.3%), of which 9 (2.57%) belong to the category
of high-level-resistant isolates (MICs, �32 �g/ml).
The majority of C. gattii isolates in the present study belong
to either genotype AFLP4 (n � 137; 39.1%) or AFLP6 (n �
169; 48.3%), while the remaining 44 (12.6%) C. gattii isolates
belong to one of the minor genotypes (AFLP5 or AFLP7 to
AFLP10) that are more restricted to certain geographical re-
gions and which less frequently cause infections (7, 27). The
preponderance toward C. gattii strains with an AFLP4 or
AFLP6 genotype can be interpreted as being the result of the
analysis of a nonrepresentative selection of strains. This ap-
parent overrepresentation might be due to the inclusion of
preserved culture collection strains from well-studied geo-
graphical localities, such as Australia and the C. gattii outbreak
region in North America (27). These localities were repeatedly
found to harbor more genotype AFLP4 or AFLP6 strains
rather than strains of genotype AFLP5 or AFLP7 (15, 16, 27).
The South American continent has been shown to be a melting
pot of known haploid AFLP genotypes compared to the diver-
sity of genotypes in other localities (21, 23, 27). However,
preserved C. gattii strains from the less well studied regions,
Africa, Asia, and Europe, were found to follow the trend that
strains with an AFLP4 genotype proﬁle were more frequently
isolated than others (13, 27). Hence, it appears that C. gattii
AFLP4 and AFLP6 strains are collected and preserved more
frequently and that the availability and exchangeability of
strains can inﬂuence studies toward a speciﬁc genotype (13,
27). It might inﬂuence the outcome of susceptibility values
when only the geographical origin is taken into consideration,
while a combined analysis of the geographical origin with a
genotyping method (e.g., RFLP, AFLP, or MLST) will reveal
more subtle differences, as has been shown in the current
study.
When only the clinical C. gattii strains from the two major
genotypes, genotypes AFLP4 and AFLP6, were compared, it
appeared that strains belonging to AFLP6 (n � 103) had
signiﬁcantly (P � 0.05) higher geometric mean MICs for six of
the antifungal compounds tested than strains belonging to ge-
notype AFLP4 (n � 76). However, both genotypes had almost
identical geometric mean MICs for posaconazole (0.112 and
0.124 �g/ml, respectively). Strikingly, clinical AFLP6 isolates
had higher geometric mean MICs of 4.961 and 5.638 �g/ml for
ﬂucytosine and ﬂuconazole, respectively, than clinical isolates
within genotype AFLP4 (1.401 and 2.467 �g/ml, respectively).
Similar results were recently reported for a collection of 43
North American C. gattii isolates (15). In the current study,
ﬂuconazole and ﬂucytosine had the lowest levels of activity
against the C. gattii strains. Itraconazole, which has been used
clinically to treat cryptococcosis, had a MIC90 of only 0.25
�g/ml, which is 1 or 2 log2 dilutions lower than the MIC90s
previously found by others (15, 30). Isavuconazole, posacon-
azole, and voriconazole demonstrated excellent potency
against each isolate and all AFLP genotypes, including isolates
with reduced ﬂuconazole susceptibilities.
The results for voriconazole (MIC90, 0.25 �g/ml) were com-
parable to those of other studies (15, 29, 30) and 1 log2 dilution
higher than that found in one study (22). Posaconazole MICs
differed by a maximum of 2 log2 dilution steps between this and
previous studies. Isavuconazole had the lowest MIC90 (0.125
�g/ml) in this large study, and the MIC90 was within 1 log2
dilution of that recently reported (MIC90, 0.063 �g/ml) by
Thompson et al. (29). When isolates were tested by Etest,
these authors also found a MIC90 of 0.125 �g/ml (28). Isavu-
conazole has even better in vitro activity against C. neoformans,
a ﬁnding which also holds true for the other antifungal com-
pounds (14).
All antifungal compounds tested were active against all C.
gattii genotypes; however, some strains showed high MICs, as
was the case for amphotericin B (up to 1 �g/ml), ﬂucytosine
(�64 �g/ml), ﬂuconazole (64 �g/ml), and itraconazole and
voriconazole (1 �g/ml). The two novel triazoles isavuconazole
and posaconazole had relatively low MIC values compared to
those of the other antifungal compounds tested. We conclude
that amphotericin B, itraconazole, voriconazole, posaconazole,
and isavuconazole were the drugs that were the most active
against C. gattii isolates in vitro. Isavuconazole, with its attrac-
tive pharmacological and toxicological properties and avail-
ability in oral and parenteral formulations, may be a welcome
addition to the clinician’s antifungal armamentarium to ﬁght
this pathogen.
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Epidemiological cutoff values (ECVs) for the Cryptococcus neoformans-Cryptococcus gattii species complex versus fluconazole,
itraconazole, posaconazole, and voriconazole are not available. We established ECVs for these species and agents based on wild-
type (WT)MIC distributions. A total of 2,985 to 5,733 CLSI MICs for C. neoformans (including isolates of molecular type VNI
[MICs for 759 to 1,137 isolates] and VNII, VNIII, and VNIV [MICs for 24 to 57 isolates]) and 705 to 975 MICs for C. gattii (in-
cluding 42 to 260 for VGI, VGII, VGIII, and VGIV isolates) were gathered in 15 to 24 laboratories (Europe, United States, Argen-
tina, Australia, Brazil, Canada, Cuba, India, Mexico, and South Africa) and were aggregated for analysis. Additionally, 220 to 359
MICs measured using CLSI yeast nitrogen base (YNB) medium instead of CLSI RPMImedium for C. neoformanswere evaluated.
CLSI RPMImedium ECVs for distributions originating from at least three laboratories, which included>95% of the modeled
WT population, were as follows: fluconazole, 8 �g/ml (VNI, C. gattii nontyped, VGI, VGIIa, and VGIII), 16 �g/ml (C. neofor-
mans nontyped, VNIII, and VGIV), and 32 �g/ml (VGII); itraconazole, 0.25�g/ml (VNI), 0.5�g/ml (C. neoformans and C. gat-
tii nontyped and VGI to VGIII), and 1�g/ml (VGIV); posaconazole, 0.25�g/ml (C. neoformans nontyped and VNI) and 0.5
�g/ml (C. gattii nontyped and VGI); and voriconazole, 0.12 �g/ml (VNIV), 0.25 �g/ml (C. neoformans and C. gattii nontyped,
VNI, VNIII, VGII, and VGIIa,), and 0.5�g/ml (VGI). The number of laboratories contributing data for other molecular types
was too low to ascertain that the differences were due to factors other than assay variation. In the absence of clinical breakpoints,
our ECVsmay aid in the detection of isolates with acquired resistance mechanisms and should be listed in the revised CLSI
M27-A3 and CLSI M27-S3 documents.
The Cryptococcus neoformans-Cryptococcus gattii complex is themost common species of non-Candida yeasts recovered from
clinical specimens (32.9% of 8,717 isolates) (41). In addition,
cryptococcal disease has been reported as the second most com-
mon severe fungal infection in certain regions (41). Infections
caused by C. neoformans var. grubii (serotype A) and, to a lesser
degree, by C. neoformans var. neoformans (serotype D) are seen
worldwide among immunocompromised hosts (4). The more
geographically restricted C. gattii (serotypes B and C) causes in-
fections among immunocompromised as well as nonimmuno-
compromised patients, and the infections are more difﬁcult to
treat (27, 38). Irrespective of the species, cryptococcal disease is
associated with high mortality rates (�12.7%) (15, 17, 38). Using
molecular methodologies, eight major molecular types have been
identiﬁed among the four serotypes and their hybrids (4, 6, 8, 25,
31, 51). C. neoformans comprises molecular types VNI and VNII
(both serotype A), VNIII (serotype A/D hybrid), and VNIV (se-
rotype D), while C. gattii comprises VGI, VGII, and VGIV (all
serotype B), VGII, and VGIV (both serotype C) (25). Molecular
type VGII has been of particular interest in recent years due to the
emergence of the novel subtypes VGIIa, VGIIb, and VGIIc; mo-
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lecular types VNI to VNIV and VGI to VGIV also have been des-
ignated AFLP1 to AFLP3 and AFLP4 to AFLP7, respectively (4, 6,
7). Identiﬁcation of these different molecular types has been asso-
ciated with differences in antifungal susceptibility and virulence
(4, 6–11, 22, 25, 33, 51).
In addition to the different amphotericin B formulations, ﬂu-
conazole and itraconazole are recommended as primary alterna-
tive induction treatments for infections caused by C. neoformans
and C. gattii and voriconazole and posaconazole as salvage con-
solidation therapies (35, 38); ﬂuconazole is also the drug of choice
for lifelong suppressive (maintenance) therapy or primary ther-
apy in some areas (24). The azoles block the pathway of ergosterol
biosynthesis by inhibiting the 14-�-lanosterol demethylase en-
zyme, which is coded by the CYP51 gene in C. neoformans
(CnCYP51; also called ERG11) (46). The wide use of ﬂuconazole
and other triazoles has led to in vitro resistance among Candida
and Cryptococcus isolates, especially to ﬂuconazole more than to
the newer triazoles, voriconazole, and posaconazole (38). Two
azole resistance mechanisms have been identiﬁed in C. neofor-
mans (18, 32, 46, 54).
The use of standard testing methods has allowed the recog-
nition of antifungal resistance, as well as the proposal of clinical
breakpoints (CBPs) for Candida spp. and epidemiological cut-
off values (ECVs) for Aspergillus spp. by the Clinical and Lab-
oratory Standards Institute (CLSI) and the European Commit-
tee for Antimicrobial Susceptibility Testing (AFST-EUCAST)
(19–21, 40, 42, 44, 47). More recently, CLSI amphotericin B
and ﬂucytosine ECVs were deﬁned for the Cryptococcus neofor-
mans-Cryptococcus gattii species complex (22). CBPs are based
on MIC distributions, pharmacokinetic and pharmacody-
namic (PK/PD) parameters, animal studies, and clinical out-
comes to therapy, while the ECV is based mostly on MIC dis-
tributions. Numerous surveys indicate that CLSIMICs are�16
�g/ml (ﬂuconazole) and�0.5�g/ml (the other three triazoles)
for most C. neoformans and C. gattii isolates (5, 9, 10, 16, 24, 43,
50). In the last few years, azole (mostly ﬂuconazole) antifungal
susceptibility differences have been reported for these two spe-
cies and for their molecular types and serotypes (10, 11, 25, 33,
50, 51). However, CBPs or ECVs based on data from multiple
laboratories are not available for either C. neoformans or C.
gattii versus the triazoles. ECVs deﬁned in the present study
could help to characterize the susceptibility of these species and
to monitor the emergence of strains with mutations that could
lead to reduced antifungal susceptibility to ﬂuconazole, itra-
conazole, posaconazole, and voriconazole.
The purpose of the studywas dual: (i) to deﬁnewild-type (WT;
population of isolates in a species-drug combination with no de-
tectable acquired resistance mechanisms) (14, 52) susceptibility
endpoint distributions of each species/molecular type and triazole
combination originating from at least 3 laboratories and (ii) to
propose ECVs (highest WT susceptibility endpoint) of four tria-
zoles.We aggregated theCLSI RPMI brothmicrodilutionMICs of
ﬂuconazole, itraconazole, posaconazole, and voriconazole ob-
tained in 15 to 24 laboratories (2,985 to 5,733 MICs for C. neofor-
mans and 705 to 975 MICs for C. gattii [species/molecular type
and agent/combination dependent]) in Europe, theUnited States,
Argentina, Australia, Canada, Cuba, Brazil, India, Mexico, and
South Africa. The 220 to 359 MICs that were obtained using the
alternative CLSI yeast nitrogen base (YNB) broth (12, 13) for C.
neoformans were analyzed separately.
MATERIALS AND METHODS
Isolates. Each isolate originated from a unique clinical specimen. The
MICs of the four triazoles used in the present study for ECV deﬁnition
were obtained at one of the followingmedical centers: VCUMedical Cen-
ter, Richmond, VA; Unidad de Microbiologia Experimental, Hospital
Universitario La Fe, Valencia, Spain; Universidad Nacional Autónoma de
México, Mexico; Vallabhbhai Patel Chest Institute, University of Delhi,
Delhi, India; Departamento de Micología, INEI, ANLIS “Dr. Carlos G.
Malbrán,” Buenos Aires, Argentina; Servicio deMicología, CentroNacio-
nal de Microbiología, Instituto de Salud Carlos III, Madrid, Spain;
University of Texas Health Science Center, San Antonio, TX; The Univer-
sity of Alberta, Edmonton, Alberta, Canada; National Institute for Com-
municable Diseases, National Health Laboratory Service, Johannesburg,
South Africa; Department of Medical Microbiology and Infectious
Diseases, Canisius-Wilhelmina Hospital, Nijmegen, the Netherlands; In-
stitute of Tropical Medicine Pedro Kouri, Havana, Cuba; The HPA My-
cology Reference Laboratory, Kingsdown, Bristol, United Kingdom;
Women’s and Children’s Hospital, Adelaide, South Australia, Australia;
The Innsbruck Medical University, Innsbruck, Austria; Centers for Dis-
ease Control and Prevention, Atlanta, GA; The Adolfo Lutz Institute Pub-
lic Health Reference Center, São Paulo and Rio Claro, Brazil; Hospital
Universitario de Valme, Sevilla, Spain; University of Texas Health Science
Center, Houston, TX; Hospital General Universitario GregorioMarañón,
Faculty of Medicine-Universidad Complutense, Madrid, Spain; Univer-
sity of Iowa, Iowa City, IA; Duke University Medical Center, Durham,
NC; Institut national de santé publique du Québec, Laboratoire de santé
publique du Québec, Canada; and Instituto de Pesquisa Clinica Evandro
Chagas-FIOCRUZ, Rio de Janeiro, Brazil. Species and molecular type
identiﬁcation were performed at each medical center using standard
methodologies (8, 11, 25, 28, 33, 36, 51). We have aggregated the maxi-
mum available CLSI data from each laboratory and agent as follows: 2,985
posaconazole, 4,019 itraconazole, 4,693 voriconazole, and 5,733 ﬂucona-
zole MICs for C. neoformans (including MICs for the VNI to VNIV iso-
lates) and 705 posaconazole, 828 itraconazole, 923 voriconazole, and 975
ﬂuconazole MICs for C. gattii (including those for the VGI to VGIV iso-
lates) (8, 11, 24, 25, 26, 33, 36, 51). Sets of 220 (itraconazole) to 359
(ﬂuconazole) MICs obtained using CLSI YNB broth instead of the CLSI
RPMI medium (12) for C. neoformans were also available and analyzed
separately. One or both quality control (QC) isolates (Candida parapsilo-
sis ATCC 22019 and Candida krusei ATCC 6258) were used by the partic-
ipant laboratories (Table 1) (12, 13).
Antifungal susceptibility testing. In order to include MIC results in
the total set of available aggregated CLSI data from the participant labo-
ratories (Tables 2 to 5), triazole MICs were obtained at each center by
following theCLSIM27-A3 brothmicrodilutionmethod (standardRPMI
1640 broth [0.2% dextrose], ﬁnal inoculum concentrations that ranged
from 0.4� 103 to 5� 103 CFU/ml, and 72 h of incubation); MICs were
the lowest drug concentrations that produced �50% growth inhibition
compared to the growth control (12). Testing conditions and interpre-
tation of MICs were otherwise identical for those isolates grown in
CLSI YNB broth. MIC data for the two QC reference strains, utilized
during the years of testing in each center, were obtained each time that
a set of isolates was tested following the CLSI M27-A3 broth microdi-
lution method (12, 13).
Definitions.The ECV, a termpreviously used in similar fungal reports
and also known as the COWT, is the highest wild-type (WT) cutoff sus-
ceptible value (19–22, 44). ECVs are based on MIC distributions where
there are two distinct populations: (i) theWTpopulation of isolates/MICs
with no detectable acquired or mutational resistance to the drug being
evaluated and (ii) the non-WT population or isolates that harbor one or
more resistance markers (14, 52). A non-WT organism shows reduced
susceptibility to the agent being evaluated compared to the WT popula-
tion, but it may or may not respond to treatment to the drug being eval-
uated. When data pertaining to the establishment of clinical breakpoints
(CBPs) are not available, ECVs serve as an early indication of emerging
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changes in the patterns of susceptibility of organisms to the agent being
evaluated.
Data analysis. MIC distributions from each laboratory (laboratories
were coded) for each available combination of triazole and species or
molecular type were listed in Excel spreadsheets before they were aggre-
gated for the analysis. The MIC distributions of each of the four triazoles
for C. neoformans (Tables 2 to 5) were as follows: (i) CLSI RPMI medium
aggregated data from 11 to 18 laboratories for nonmolecular typed iso-
lates (here referred to as nontyped isolates), (ii) CLSI RPMI medium
aggregated data from 2 to 6 laboratories for VNI to VNIVmolecular types
(here referred to as typed isolates), and (iii) single-laboratory CLSI YNB
data. The ﬁnal WT distributions for C. gattii (Tables 2 to 5) were as fol-
lows: (i) CLSI RPMImedium aggregated data of each of the four triazoles
from4 to 6 laboratories for nontyped isolates and (ii) CLSI RPMImedium
aggregated data from 1 to 7 laboratories for VGI to VGIV (also referred to
as typed isolates). The aggregated MIC distributions obtained in at least
TABLE 1MICs for QC strains used in 11 to 15 laboratories according to the CLSI broth microdilution method at 48 ha
QC isolate
Antifungal
agent
QC MIC range (mode)
in �g/ml (CLSI
document)
% MICs within
range (CLSI
document)
MIC range in
�g/ml
(present study) Modes in �g/ml (present study)b
Candida parapsilosis
ATCC 22019
Fluconazole 1–4 (2) 98.1 1–4 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 4, 4, ND
Itraconazole 0.06–0.5 (0.25)b 97.5 0.03–0.5c 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12,
0.12, 0.25, 0.25, ND, ND, ND, ND
Posaconazole 0.03–0.25 (0.12) 98.8 0.03–0.25 0.06, 0.06, 0.06, 0.06, 0.12, 0.12, 0.12, 0.12, 0.12, 0.12, 0.25,
ND, ND, ND, ND, ND, ND, ND
Voriconazole 0.03–0.25 (0.06) 100 0.01–0.25c 0.03, 0.03, 0.03, 0.03, 0.03, 0.03, 0.06, 0.06, 0.06, 0.06, 0.06,
0.06, 0.12, 0.12, 0.12, ND, ND, ND, ND
Candida krusei
ATCC 6258
Fluconazole 16–128 (32) 100 2–64d 16, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 64, ND, ND, ND
Itraconazole 0.25–1 (0.5) 100 0.03–1d 0.12, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.5, 0.5, 0.5, 0.5, ND,
ND, ND, ND, ND, ND
Posaconazole 0.12–1 (0.5) 99.6 0.12–2d 0.12, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, ND, ND,
ND, ND, ND, ND, ND
Voriconazole 0.12–1 (0.5) 100 0.12–0.5 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.25, 0.5, 0.5, 0.5, 0.5,
ND, ND, ND, ND
a MICs were determined as described by the CLSI M27-A3 document using RPMI 1640 broth (12).
b Modes were not listed for 9 of the 25 laboratories because only 24-h (from 4 to 5 laboratories) or a single (from two to four laboratories) MIC(s) for QC isolates (C. parapsilosis
and C. krusei) were reported for small subsets of isolates (8 to 84 isolates). However, MICs were in range (95 to 100%) and available 24-h modes were within 1 to 2 dilutions. ND,
not determined or obtained using the CLSI YNB broth.
c MICs were outside the range in one (itraconazole [4.5%]) and two (voriconazole [2 to 3%]) laboratories for QC isolate C. parapsilosis ATCC 22019.
d MICs were outside the range in two (ﬂuconazole [0.3 to 5%] and posaconazole [1.5 to 2%]) to four (itraconazole [0.8 to 5%]) laboratories for QC isolate C. krusei ATCC 6258.
TABLE 2WT ﬂuconazole MIC distributions for the Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or
molecular type Mediumb Genotypedc
No. of
labsd
Total no.
of isolates
No. of isolates for which the MIC (�g/ml) was:e
�0.12 0.25 0.5 1 2 4 8 16 32 �64
C. neoformans RPMI N 18 4,446 92 133 258 543 1,225 1,372 569 180 52 22
VNI Y 6 1,137 4 12 40 127 376 456 89 20 10 3
VNII Y 4 42 1 1 1 7 13 12 5 2
VNIII Y 4 54 1 3 9 9 22 8 1 1
VNIV Y 4 54 2 17 19 6 6 2 2
All isolates Both 24 5,733 97 149 319 705 1,629 1,868 668 206 67 25
C. neoformans YNB N 1 359 1 5 13 23 73 84 126 26 8
C. gattii RPMI N 6 137 1 8 19 71 25 6 4 3
VGI Y 7 260 1 18 39 69 101 29 3
VGIIf Y 4 101 3 3 26 32 17 13 7
VGIIa Y 3 200 2 1 16 93 80 6 2
VGIIb Y 2 106 3 9 31 54 9
VGIIc Y 2 42 1 2 21 17 1
All VGII isolates Y 6 449 2 7 28 151 168 53 32 8
VGIII Y 3 43 1 1 6 12 18 4 1
VGIV Y 3 86 2 3 21 19 32 5 4
All isolates Both 10 975 2 24 63 149 360 258 68 40 11
a Fluconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identiﬁed as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
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three laboratories were used to calculate ECVs by the statistical method
(52), where the modeled population is based on ﬁtting a normal distribu-
tion at the lower end of the MIC range, working out the mean and stan-
dard deviation of that normal distribution, and using those parameters to
calculate the MIC that captures at least 95%, 97.5%, and 99% of the
modeledWTpopulation (19–22). A search for outlier laboratories in each
distribution was also performed, and only one outlier set of voriconazole
MICs was excluded from the analysis. In addition, ECVs were not esti-
Table 3WT itraconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or
molecular type Mediumb Genotypedc
No. of
labsd
Total no.
of isolates
No. of isolates for which the MIC (�g/ml) was:e
�0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 �4
C. neoformans RPMI N 11 2,731 106 174 377 949 865 222 32 4 2
VNI Y 6 1,145 25 54 147 315 447 144 13
VNII Y 4 32 1 3 3 15 7 2 1
VNIII Y 4 54 1 8 20 14 4 7
VNIV Y 4 57 17 15 9 6 6 4
All isolates Both 20 4,019 26 181 347 736 1,423 1,021 247 32 4 2
C. neoformans YNB N 1 220 1 5 22 38 91 61 1 1
C. gattii RPMI N 5 70 4 9 16 25 12 4
VGI Y 6 257 3 11 42 77 103 20 1
VGIIf Y 3 47 2 13 15 10 6 1
VGIIa Y 2 176 7 15 44 63 41 6
VGIIb Y 2 106 4 5 34 44 14 4 1
VGIIc Y 2 42 1 9 24 7 1
All VGII isolates Y 4 371 4 9 33 94 126 85 18 2
VGIII Y 3 44 1 1 3 14 17 6 2
VGIV Y 3 86 1 1 4 22 24 29 3 2
All isolates Both 9 828 8 5 31 98 232 282 144 24 4
a Itraconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identiﬁed as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
Table 4WT posaconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or
molecular type Mediumb Genotypedc
Total no.
of labsd
No. of
isolates
No. of isolates for which the MIC (�g/ml) was:e
�0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 �4
C. neoformans RPMI N 13 2,120 52 152 418 938 440 92 23 5
VNI Y 3 759 21 49 108 334 203 42 2
VNII Y 2 24 1 15 5 2 1
VNIII Y 2 35 2 19 12 2
VNIV Y 2 47 18 11 11 4 3
All isolates Both 15 2,985 21 122 305 780 1,149 486 94 23 5
C. neoformans YNB ND ND
C. gattii RPMI N 4 68 1 8 8 17 20 12 1 1
VGI Y 3 182 3 6 37 64 58 13 1
VGIIf Y 1 5 1 1 1 1 1
VGIIa Y 2 176 7 18 51 62 35 3
VGIIb Y 2 106 5 6 60 31 4
VGIIc Y 2 42 1 3 6 21 11
All VGII isolates Y 2 329 5 1 8 25 115 100 61 14
VGIII Y 2 42 2 14 7 8 10 1
VGIV Y 2 84 2 17 25 28 12
All isolates Both 6 705 9 9 26 93 223 203 113 29
a Posaconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 document (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identiﬁed as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
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mated when (i) the distribution was grossly skewed, which precluded
statistical ﬁtting, or (ii) there were data from less than 3 laboratories or the
total number of isolates in a molecular type was less than 50.
RESULTS AND DISCUSSION
The ultimate goal of susceptibility testing is to predict with some
reliability the clinical outcome when an infected patient is treated
with the speciﬁc agent evaluated and is referred to as the CBP (14,
30). CBPs are based on the correlation of in vitro data, or theMIC
for the infecting pathogen, with clinical and microbiological out-
comes in order to differentiate an organism as treatable or non-
treatable (14, 30). On the other hand, and as previously deﬁned,
ECVs are based on MIC distributions that comprise the WT and
non-WT populations; the ECV is the highest MIC that belongs to
theWT population. While CBPs predict clinical outcome of ther-
apy, the role of the ECV is to detect emerging resistance or those
non-WT strains with reduced susceptibility (due tomutations) to
the agent being evaluated. Attempts to correlate in vitro ﬂucona-
zole results with clinical outcomehave not been successful (15, 55)
and, to our knowledge, have not been reported for the other three
triazoles. Therefore, CBPs for either C. neoformans or C. gatti in-
fections versus any antifungal agent are not available due to the
paucity of data on PK/PD and clinical outcomes compared to
MICs. However, the ECVs of the four triazoles established in the
present study for C. neoformans and C. gattii may identify the
non-WT clinical isolates and serve as an early indication of emerg-
ing changes in the susceptibility patterns of these organisms. Even
though cryptococcal meningitis and other infections decreased
with the use of antiretroviral therapies in developed countries,
these infections are still a major problem among immunosup-
pressed patients and in certain geographical areas. The triazoles,
especially ﬂuconazole, are primary or salvage therapeutic agents
for cryptococcal infections (2, 38).
Despite standardization efforts, variability is common during
interlaboratory comparisons of MIC results (12, 13). Table 1 de-
picts the MIC data obtained in participant laboratories for one or
both QC isolates (overall range and individual modes), C. parap-
silosis ATCC 22019 and C. krusei ATCC 6258, when clinical iso-
lates were tested. As in previous CLSI ECV studies (19–22), the
majority ofMIC rangeswerewithin theCLSI established limits for
the two QC strains (�98%), with a certain degree of interlabora-
tory modal variability (mostly �2-fold dilution); inconsistencies
were more frequent when testing itraconazole, where MICs were
outside the range of 0.8 to 5% for C. parapsilosis ATCC 22019 (1
laboratory) and C. krusei ATCC 6258 (4 laboratories). Intralabo-
ratory reproducibility was excellent in the laboratory using the
CLSI YNB medium (data not shown). Similar modal variability
was also observed among the laboratories for the clinical Crypto-
coccus spp. isolates in this and previous multicenter studies estab-
lishing ECVs of several antifungal agents for Aspergillus spp. and
Cryptococcus spp. (19–22). The most probable reason is the indi-
vidual interpretations of MIC endpoints, and/or it may be due to
the use of different lots of antifungal powders.
The aggregated MIC distributions of the four triazoles for C.
neoformans and C. gattii (for nontyped and typed isolates) are
depicted in Tables 2 to 5, which also list single-laboratory distri-
butions for C. neoformans (CLSI YNB data). Fluconazole modal
MICs measured in RPMI medium were 1 to 4 �g/ml for C. neo-
formans typed and nontyped isolates, with the lowest mode for
VNIV.Modes were consistently higher among theC. gattii groups
(4 to 16�g/ml), with the highest for VGIIc (Table 2). Fluconazole
modes from individual contributing laboratories were either 2 or
Table 5WT voriconazole MIC distributions for Cryptococcus neoformans-Cryptococcus gattii species complexa
Species or
molecular type Mediumb Genotypedc
Total no.
of labsd
No. of
isolates
No. of isolates for which the MIC (�g/ml) was:e
�0.008 0.016 0.03 0.06 0.12 0.25 0.5 1 2 �4
C. neoformans RPMI N 12 3,473 34 412 814 1,090 748 252 92 20 6 5
VNI Y 5 1,089 35 48 100 385 376 119 19 5 1 1
VNII Y 3 27 5 6 9 3 4
VNIII Y 3 51 9 7 19 12 3 1
VNIV Y 3 53 13 19 12 6 2 1
All isolates Both 22 4,693 69 487 946 1,515 1,145 380 113 25 7 6
C. neoformans YNB N 1 281 35 78 105 53 10
C. gattii RPMI N 5 98 2 7 13 37 23 11 5
VGI Y 6 258 3 13 38 69 90 45
VGIIf Y 3 96 1 1 29 38 23 4
VGIIa Y 3 197 6 3 47 113 23 3 2
VGIIb Y 2 106 3 2 6 46 47 2
VGIIc Y 2 42 1 2 7 19 11 2
All VGII isolates Y 5 441 3 7 7 84 204 112 20 4
VGIII Y 2 42 1 3 12 21 5
VGIV Y 2 84 8 28 29 16 3
All isolates Both 9 923 8 28 69 230 367 189 28 4
a Voriconazole MICs were determined by the CLSI broth microdilution method (12).
b RPMI and YNB, RPMI 1640 and yeast nitrogen base, respectively, as described by the CLSI M27-A3 (12).
c Y, yes; N, no.
d Number of laboratories contributing data to each MIC distribution.
e The modal MIC for each distribution is underlined.
f Isolates identiﬁed as belonging to the VGII molecular type and not being one of the VGIIa, VGIIb, or VGIIc subtypes examined as a separate group.
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4 �g/ml for C. neoformans nontyped and most typed isolates; the
exception was the mode (1 �g/ml) from two of the four laborato-
ries that contributed data for VNIV, but the number of isolates
was small. Overall, our values reﬂect previous ﬂuconazoleMIC90s
andmodes for similar sets of typed or nontypedC. neoformans and
C. gattii isolates and the fact that MICs are usually higher (MIC90s
and modes, 2 to 8 �g/ml versus 8 to 32 �g/ml) for C. gattii inde-
pendent of testing conditions (10, 16, 23, 50).However, theMIC90
has also been higher (16�g/ml) forC. neoformans nontyped isolates
(5, 39), but some of those results were obtained by the EUCAST
method (39). The modal MIC for C. neoformans measured in CLSI
YNB medium was higher (mode, 8 �g/ml) than those measured in
CLSI RPMI medium; this discrepancy has been reported previously
(10, 55). These results further underline the variability of susceptibil-
ity test results using different methodologies.
Modes for the other three triazoles were more species-, molec-
ular type- and medium-dependent (Tables 3 to 5). In agreement
with previous data (10, 16, 23, 50), the MICs of itraconazole, po-
saconazole, and voriconazole for C. gattii also tended to be higher
(modes, 0.06 to 0.5 �g/ml, typed and nontyped isolates) than
those for C. neoformans (modes, 0.016 to 0.12 �g/ml, typed and
nontyped isolates), with the highest modes for VGIIb and VGIIc
(voriconazolemode, 0.25�g/ml) and VGIIc and VGIV (itracona-
zole and posaconazole mode, 0.5 �g/ml) (Tables 3 to 5). Reﬂect-
ing ﬂuconazole distributions, modes from individual participant
laboratories were within one dilution of each other (modes, 0.12
to 0.25 �g/ml and 0.06 to 0.12 �g/ml for itraconazole and both
posaconazole and voriconazole, respectively). Based on these data
and the wide geographical range over which the MICs have been
collected in the present study, we surmise that we are presenting
valid data.
Table 6 depicts the proposed ﬂuconazole, itraconazole, po-
saconazole, and voriconazole ECVs for the aggregated distribu-
tions of C. neoformans and C. gattii (typed or nontyped isolates).
ECVs were proposed when the data originated from at least three
laboratories using the statistical methodology that comprised
�95% of the modeled population instead of the observed popu-
lation; the values that comprised �97.5 and �99% of the popu-
lation were also obtained. Some of the proposed ECVs were based
on small numbers of isolates (Tables 2 to 5, n �100), and those
could be considered tentative values. Although three other distri-
butions (ﬂuconazole versus VNIV and itraconazole versus VNIII
and VNIV) originated in at least three laboratories, statistical ﬁt-
ting was not possible and ECVs were not proposed. The CLSI
TABLE 6 ECVs and percentages of isolates of the Cryptococcus neoformans-Cryptococcus gattii species complex above each triazole WT distribution
obtained in 3 to 18 laboratories by the CLSI M27-A3 broth microdilution method
Species Genotypea
Antifungal
Agent
Mode
(�g/ml)b
ECV (�g/ml) (% of observations above
each statistical ECV or non-WT)c
Statistical ECV
�95%
Statistical ECV
�97.5%
Statistical ECV
�99%
C. neoformans Nontyped isolates Fluconazole 4 16 (1.7) 16 (1.7) 32 (0.5)
Itraconazole 0.12 0.5 (1.1) 1 (0.2) 1 (0.2)
Posaconazole 0.12 0.25 (5.7) 0.5 (1.3) 0.5 (1.3)
Voriconazole 0.06 0.25 (3.5) 0.25 (3.5) 0.5 (0.9)
VNI Fluconazole 4 8 (2.9) 8 (2.9) 16 (1.1)
Itraconazole 0.12 0.25 (1.1) 0.5 (0) 0.5 (0)
Posaconazole 0.06 0.25 (0.3) 0.25 (0.3) 0.25 (0.3)
Voriconazole 0.06 0.25 (2.4) 0.25 (2.4) 0.5 (0.6)
VNIII Fluconazole 4 16 (1.9) 16 (1.9) 32 (0)
Voriconazole 0.06 0.25 (2) 0.25 (2) 0.5 (0)
VNIV Voriconazole 0.03 0.12 (5.7) 0.12 (5.7) 0.12 (5.7)
C. gattii Nontyped isolates Fluconazole 4 8 (9.5) 8 (9.5) 16 (5.1)
Itraconazole 0.12 0.5 (0) 0.5 (0) 1 (0)
Posaconazole 0.12 0.5 (1.5) 0.5 (1.5) 1 (0)
Voriconazole 0.06 0.25 (5.1) 0.5 (0) 0.5 (0)
VGI Fluconazole 4 8 (1.2) 16 (0) 16 (0)
Itraconazole 0.25 0.5 (0.4) 0.5 (0.4) 1 (0)
Posaconazole 0.12 0.5 (0.5) 0.5 (0.5) 1 (0)
Voriconazole 0.12 0.5 (0) 0.5 (0) 1 (0)
VGII Fluconazole 8 32 (6.9) 32 (6.9) 64 (1)
Itraconazole 0.12 0.5 (2.1) 0.5 (2.1) 1 (0)
Voriconazole 0.12 0.25 (4.1) 0.5 (0) 0.5 (0)
VGIIa Fluconazole 4 8 (4) 16 (1) 16 (1)
Voriconazole 0.12 0.25 (2.5) 0.25 (2.5) 0.25 (2.5)
VGIII Fluconazole 4 8 (2.3) 8 (2.3) 16 (0)
Itraconazole 0.25 0.5 (4.5) 1 (0) 1 (0)
VGIV Fluconazole 8 16 (4.7) 32 (0) 32 (0)
Itraconazole 0.5 1 (2.3) 1 (2.3) 2 (0)
a Data from laboratories using the CLSI RPMI broth (12).
b Mode, MIC most frequently obtained for each distribution.
c Calculated ECVs comprising�95%,�97.5%, or�99% of the statistically modeled population for which MIC distributions originated in at least three laboratories.
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ﬂuconazole ECVs for the different subsets of C. neoformans iso-
lates were either 8�g/ml (VNI) or 16�g/ml (nontyped andVNIII
isolates). Fluconazole ECVs for C. gattii ranged from 8 �g/ml
(nontyped, VGI, VGIIa, andVGIII isolates) to 32�g/ml (VGII). It
is interesting that a ﬂuconazole MIC of�16 �g/ml is anecdotally
believed to be the resistance cutoff, but this value can be perceived
here as a non-WT value for some of the subsets of the two species.
So far mutations have not been observed when the ﬂuconazole
MIC is�16�g/ml (49). ECVs of the three other triazoleswere also
species-, agent-, andmolecular type-dependent as follows: (i) itra-
conazole ECVs of 0.25�g/ml (VNI), 0.5�g/ml (nontyped isolates
of both species and VGI to VGIII), and 1 �g/ml (VGIV); (ii)
posaconazole ECVs of 0.25 �g/ml (C. neoformans nontyped and
VNI) and 0.5 �g/ml (C. gattii nontyped and VGI); and (iii) vori-
conazole ECVs of 0.12 �g/ml (VNIV), 0.25 �g/ml (nontyped iso-
lates of both species, VNI, VNIII, VGII, andVGIIa), and 0.5�g/ml
(VGI). The overall trend was that ECVs for C. neoformansmolec-
ular types were lower than those forC. gattii. PreviousMIC90s and
modes of these three triazoles have been similar (9, 10, 23, 44, 50).
Because the distributions in CLSI YNB originated from a single
laboratory, ECVs were not proposed for these distributions (Ta-
bles 2, 3, and 5). Tentative values of 16 �g/ml for ﬂuconazole
(encompassing 97.8% of the isolates), 2 �g/ml for itraconazole
(encompassing 99.5%of the isolates), and 0.5�g/ml for voricona-
zole (encompassing 100% of the isolates) can be suggested for
CLSI YNB MICs (data not shown). Additional data from other
laboratories using either CLSI YNB or CLSI RPMI medium (at
least three laboratory subsets), or for subsets comprising at least
100 isolates, should corroborate/extend our tentative values.
ECVs encompassing both �97.5% and �99% of the modeled
populationweremostly the same or one dilution higher (Table 6);
the same applied when all isolates of each species were pooled
together, e.g., all VGIIs (data not shown). Although the proposed
ECVs in the present study are not predictors of clinical outcome,
these critical drug concentrations may aid in identifying those
cryptococcal strains with decreased susceptibility to the triazole
being evaluated.
The frequency of MICs above the ECV (non-WT) varied ac-
cording to the distribution analyzed (Table 6). The rate of ﬂu-
conazole non-WTMICswas higher (1.7 to 9.5%) than those of the
other three triazoles (0 to 5.7%). Between the two species, the
ﬂuconazole and itraconazole rates of non-WTMICs were usually
lower for all C. neoformans isolates (1.1 to 2.9%) than for all C.
gatti isolates (0 to 9.5%) and almost the same for voriconazole. In
contrast, the rate was lower for posaconazole (0.3 to 5.7% versus
0.5 to 1.5%). However, C. gattii MIC distributions were small
(Tables 2 to 5). Although cryptococcal infections caused by both
species are clinically similar, there is more of a delayed treatment
response and other complications in infections caused by C. gattii
than those due to C. neoformans (38). In vitro resistance to ﬂu-
conazole (3.1% to 46%) and itraconazole (0.5% to 17.4%) has
been reported for C. neoformans isolates; although the itracona-
zole cutoff was �1 �g/ml, it was variable for ﬂuconazole (�16
�g/ml and �64 �g/ml) (5, 16, 39). Based on arbitrary voricona-
zole cutoffs of�2 �g/ml for both Cryptococcus spp., in vitro resis-
tance to this agent has been low or absent (0% to 0.9%) (23, 24, 43,
50); the same applies to posaconazole (23, 24, 43). Species identi-
ﬁcation and antifungal susceptibility testing emphasize the utility
ofWTcutoffs as a practical tool to detect triazole resistance among
Cryptococcus isolates. Our results also point out that ECVs should
be species-speciﬁc and, for this fungal group, molecular type-spe-
ciﬁc. This information is important; it has been reported that 20%
of cryptococcal infections are caused by multiple strains or mo-
lecular types, but generally only one isolate per infection is tested
(17).
During the 1990s, the early years of ﬂuconazole therapy, re-
lapses were not associatedwith in vitro resistance due to the higher
initial ﬂuconazole doses (38). Since then, relapses have been at-
tributed to the excessive use of this agent as primary and prophy-
lactic therapies, as well as the use of suboptimal doses for long
periods of time, especially amongAIDSpatients. As relapses began
to be associated with high ﬂuconazole MICs and/or a 4-fold MIC
increase (1, 24, 37, 38), several aspects of sterol metabolism in
these isolates were investigated to determine azole resistance
mechanisms in C. neoformans. A point mutation in the ERG11
(CnCYP51) gene resulting in a G484S substitution in the target
enzyme has been observed in C. neoformans strains with high ﬂu-
conazole MICs (�32 �g/ml); this mutation alters the afﬁnity of
the drug for the target enzyme (32, 48, 54). The overexpression of
the gene CnAFR1 that encodes the membrane efﬂux pumps has
been found to reduce cell drug (ﬂuconazole) content inC. neofor-
mans (29, 45). Azole cross-resistance among cryptococcal strains
is rare; the lack of cross-resistance between itraconazole and ﬂu-
conazole has been attributed to the dual itraconazole target in C.
neoformans, which appears to block both the lanosterol 14-�-de-
methylase and the NADH-dependent 3-ketosteroid reductase
(37). Thiswas recently conﬁrmed in aC. neoformans isolate, where
cross-resistance was evident between ﬂuconazole (MICs� 64�g/
ml) and voriconazole (MICs � 2 �g/ml) but not with itracona-
zole. In contrast, increased itraconazole susceptibility (lower
MIC) andno change in the posaconazoleMICwere observed (49).
A missense mutation (Y145F substitution) in the ERG11 gene
(P450Dm, ERG11) led to ﬂuconazole-voriconazole cross-resistance.
In addition, a high level of heteroresistance to ﬂuconazole, more
commonly observed inC. gattii than inC. neoformans isolates, was
observed in the same isolate (49, 53). Some of these ﬁndings ex-
plain the different rates of non-WT isolates found in the present
study.
Based on small numbers of patients/isolates and the use of
different methodologies, correlations between a variety of ﬂu-
conazole MICs and clinical outcomes (1, 3, 34) have been re-
ported: more rapid CSF sterilization and infection eradication has
been associated with MICs of 4 to 8 �g/ml and clinical failure or
recurrence with MICs of�16 �g/ml. In addition, either a lack of
correlation (15) or a relationship that was dependent on the com-
bination of high MICs with other factors have been documented
(55). A more useful MIC cutoff that would predict azole failure in
treatment of cryptococcal infections has also been hampered by
other factors that inﬂuence outcome to therapy in addition to
microbiological clearance (17, 37). Conversely, our ECVs could
aid in the separation of WT strains from those with reduced azole
susceptibility or non-WT isolates. However, more information is
needed regarding azole resistance in C. neoformans and C. gattii,
especially for posaconazole and voriconazole, as well as the rela-
tionship between non-WT strains and resistance mechanisms.
In conclusion, the ECVs of ﬂuconazole (8 to 32 �g/ml), itra-
conazole (0.25 to 1�g/ml), posaconazole (0.25 to 0.5�g/ml), and
voriconazole (0.12 to 0.25�g/ml) proposed in this study for theC.
neoformans-C. gattii species complex are species- and molecular
type-speciﬁc, but these differences were mostly within one dilu-
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tion. Further investigation should determine the relationship be-
tween molecular mechanisms of triazole resistance and our pro-
posed non-WT values. Some of the distributions were small
(especially for various C. neoformans molecular types), and con-
tinuing surveillance should either corroborate or expand the in-
formation provided in the present study. In the absence of CBPs,
these ECVs may be clinically useful in detecting non-WT isolates
that have reduced susceptibility to itraconazole, posaconazole,
and voriconazole or that harbor ﬂuconazole resistance mecha-
nisms. ECVs should be included in the revised version of the CLSI
M27-A3 document.
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Summary Cryptococcus isolates from Cuban patients were identified as C. neoformans var. grubii.
Although this species has since long been associated with bird droppings, a recent
genotyping study provided strong evidence for additional origins of exposure. We
sampled different species of trees in Havana, Cuba to identify other potential sources of
exposure to this fungus. A total of 662 samples were collected from 331 trees and cacti
from Havana, Cuba. Initial selection of the isolates was carried out by conventional
techniques. Isolates were further characterised using a combination of AFLP analysis
and DNA sequence analysis. Identification by conventional methods yielded 121
C. neoformans and 61 C. gattii isolates. Molecular analyses showed that none of these
isolates was C. gattii and only one isolate proved to be C. neoformans var. grubii. A total
of 27 different other species were identified. The most prevalent species was
C. heveanensis (33%). Sixty-five unidentifiable isolates segregated into ten potentially
novel species. Conventional cultivation methods have a low specificity for
C. neoformans complex and molecular analyses need to be applied to confirm
identification of isolates from environmental sources. Environmental niches
responsible for most of human cryptococcal infections in Cuba remain to be identified.
Key words: Cryptococcus, identification, environment, AFLP.
Introduction
Since the mid 1980s, cryptococcosis emerged as a life-
threatening infection in patients with AIDS, where
dissemination is commonly fatal even when treated
with the most effective antifungal drugs.1,2 The limited
empirical evidence for direct person to person transmis-
sion of this infection have led to the belief that infections
in humans are predominantly caused by inhalation of
basidiospores from environmental sources.3
The genus Cryptococcus encompasses over hundred
species,4 but the C. neoformans ⁄ C. gattii species complex
is the most common associated with human and animal
diseases.4,5 At present, mycosis due to this fungus ranks
as one of the three most common life-threatening
opportunistic infections in persons with impaired T-cell
function, particularly in patients with AIDS.5
This saprophytic yeast was first cultivated by Sanfelice
from fermenting peach juice in 1894 and during the
following years, the fungus was isolated from lesions or
secretions of humans and animals. More than 50 years
later, Emmons reported its isolation from the environ-
ment and until now it has been recognised in many
areas of the world.1,5–7 On the basis of differences in
ecology, physiology, capsular polysaccharide, clinical
manifestation and genetics, two species with two vari-
eties and five serotypes have been recognised. C. neofor-
mans var. grubii (serotype A), that are responsible of
more than 90% of all human cryptococcal infections;
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C. neoformans var. neoformans (serotype D) causes fewer
cases of disease and is being considered less pathogenic;
hybrid serotype AD strains have been isolated from the
environment and from patients in North America and
Europe and C. gattii, (serotypes B and C) which tend to
infect immunocompetent individuals.1,5–7
Previous epidemiological studies on clinical and
environmental isolates from pigeon droppings, carried
out in different regions along the Cuban island, showed
that all studied isolates represented C. neoformans var.
grubii and that only few microsatellite genotypes from
environmental isolates could be linked to genotypes
from human isolates, suggesting that certain clinical
isolates may originate from additional ecological
niche(s).8 At present, it has become clear that Crypto-
coccus isolates, in addition to bird excreta,9 are present
on trees and cacti.1,7,10,11 Here, we report the results of
a study on the environmental occurrence of this yeast in
relation to different species of trees and cacti.
Materials and methods
Tree sampling
Plants were sampled along the northern coast of Havana,
Cuba between April and June, which corresponds to the
flowering season. Urban areas with large numbers and
variety of plants species were chosen. Three hundred and
twenty-nine adult plants were sampled: 65 Indian
almond trees (Terminalia cattapa), 65 flamboyant trees
(Delonix regia), 65 Ficus spp. (mainly Indian laurel trees),
60 cacti of different species, 60 casuarins (Casuarina
equisetifolia), five blue mahoe trees (Talipariti elatum),
three ceiba (Ceiba pentandra), two seagrape (Coccoloba
uvifera), one copey (Clusia resea), one yellow Oleander
(Thevetia peruviana), one yellow flamboyant (Peltophorum
adratum), one ballnut (Calophyllum inophyllum), one
caribbean pine (Pinus caribaea) and one roble (Tabebuia
pentaphylle). From each tree and cactus, two samples
were obtained. Sampling was done by rubbing the inner
surface of hollows or fissures with a sterile cotton-tipped
swab wetted in sterile saline.12 After sampling, each
swab was placed in a sterile glass tube with 2 ml of saline
and transported to the mycology laboratory where they
were processed within 4 h. Swabs were directly inocu-
lated onto caffeic acid agar plates (CAA),13 incubated at
28 �C and inspected daily for 7–10 days.
Conventional identification
All pigmented colonies suspicious of representing Cryp-
tococcus were isolated separately on Sabouraud dextrose
agar (SDA) and yeast growth was confirmed by micro-
scopic examination. Initial identification was based on
colony- and cellular morphology, phenoloxidase activity
(characteristic brown appearance on CAA), urease
production, growth at 37 �C, and growth on canava-
nine-glycine-bromothymol blue medium (CGB).14
DNA isolation
A full loop of freshly grown cells was resuspended in a
vial containing lysis buffer (350 ll) and ceramic beads
(Roche Diagnostics, Almere, The Netherlands) and
subjected to mechanical lysis in a Magnalyzer instru-
ment (Roche Diagnostics) for 30 s at 6500 rpm.
Following centrifugation for 2 min at 12 000 · g,
200 ll of supernatant was combined with proteinase
K (30 ll) (Roche Diagnostics) and incubated 10 min at
65 �C and for 10 min at 95 �C. Finally, the DNA was
purified using a MagNA Pure LC instrument (Roche
Diagnostics) in combination with MagNA Pure DNA
Isolation Kit III, according to the manufacturer�s
instructions. DNA yield and purity were estimated by
UV absorbance measurements using standard proce-
dures.
AFLP analysis
Approximately 50 ng of genomic DNA was subjected to
a combined restriction–ligation procedure containing
5 pmol of EcoRI adapter, 50 pmol MseI adapter, 2 U of
EcoRI (New England Biolabs, Beverly, MA, USA), 2 U of
MseI (New England Biolabs) and 1 U of T4 DNA ligase
(Promega, Leiden, The Netherlands) in a total volume of
20 ll of 1· reaction buffer for 1 h at 20 �C. Next, the
mixture was diluted five times with 10 mmol l)1
Tris ⁄HCl pH 8.3 buffer. Adapters were made by mixing
equimolar amounts of complementary oligonucleotides
(5¢-CTCGTAGACTGCGTACC-3¢ and 5¢-AATTGGTACG-
CAGTC-3¢ for EcoRI; 5¢-GACGATGAGTCCTGAC-3¢ and
5¢-TAGTCAGGACTCAT-3¢ for MseI) and heating to
95 �C, subsequently cooling slowly to ambient temper-
ature. One microlitre of the diluted restriction–ligation
mixture was used for amplification in a volume of 25 ll
under the following conditions: 1 lmol l)1 EcoRI primer
with two selective residues (5¢-Flu-GACTGCGTACCA-
ATTCAC-3¢), 1 lmol l)1 MseI primer with one selective
residues (5¢-GATGAGTCCTGACTAAG-3¢), 0.2 mmol l)1
each dNTP and 1 U of Taq DNA polymerase (Roche
Diagnostics) in 1· reaction buffer containing
1.5 mmol l)1 MgCl2. After an initial denaturation step
for 4 min at 94 �C in the first 20 cycles, a touch-down
procedure was applied: 15 s denaturation at 94 �C; 15 s
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annealing at 66 �C with the temperature for each
successive cycle lowered by 0.5 �C and 1 min of
extension at 72 �C. Cycling was then continued for 30
cycles with an annealing temperature of 56 �C. After
completion of the cycles, incubation at 72 �C for 10 min
was performed before the reactions were cooled to room
temperature. The amplicons were then combined with
the ET550-R size standard (GE Healthcare, Diegem,
Belgium) and analysed on a MegaBACE 500 automated
DNA analysis platform equipped with a 48 capillary
array (GE Healthcare), according to the manufacturer�s
instructions.
DNA sequence analysis
Part of the ribosomal gene cassette containing the
ITS1 ⁄ 5.8S ⁄ ITS2 and D1–D2 regions was amplified by
PCR. The 50 ll amplification reaction contained 1 ll of
DNA (approx. 20–100 ng), 0.5 lmol l)1 of amplifica-
tion primers V9 (5¢-TGCGTTGATTACGTCCCTGC-3¢ and
RLR3R 5¢-GGTCCGTGTTTCAAGAC-3¢), 0.2 mmol l)1
dNTP�s, 2 mmol l)1 MgCl2 and 1 U of FastStart Taq
DNA polymerase (Roche Diagnostics) in 1· reaction
buffer. After an initial denaturation for 10 min at 94 �C,
35 cycles of 30 s 94 �C, 30 s 52 �C and 2 min 72 �C
were applied. After an additional incubation for 10 min
at 72 �C, the reactions were cooled to room tempera-
ture. Amplified products were purified by SPRI chemis-
try (AMPure; Beckman Coulter, Mijdrecht, The
Netherlands) and subjected to bidirectional sequence
analysis using primers 5¢-ITS1 (TCCGTAGGTGAACCT-
GCGG-3¢) and ITS4 (5¢-TCCTCCGCTTATTGATATGC-3¢)
for the ITS1 ⁄ 5.8S ⁄ ITS2 region and primers NL1 (5¢-
GCATATCAATAAGCGGAGGAAAAG-3¢) and RLR3R
for the D1–D2 regions respectively. Sequence reactions
were performed using the DYEnamic ET Dye Terminator
Kit (GE Healthcare) according to the recommendations
of the manufacturer. Sequence reaction products were
purified using SPRI chemistry (CleanSeq; Beckman
Coulter) and analysed using a MegaBACE 500 platform
as recommended. Obtained DNA sequences were com-
pared with the public DNA databases using BLAST
analysis15 and with the in-house yeast database of the
CBS-KNAW Fungal Biodiversity Centre.
Data analysis
AFLP data were analysed using BioNumerics version
5.1 (Applied Maths, Sint-Martens-Latem, Belgium)
using the Pearson correlation coefficient and UPGMA
clustering for DNA fragments in the range of 60 bp and
to 500 bp.
Results
According to the conventional methods, 34% of the
sampled trees (111 ⁄ 331) yielded one or more smooth
and variably mucoid yeast-like colonies exhibiting some
chocolate brown shades after 2–4 days of incubation on
CAA medium. Multiple colonies on one plate were
analysed separately. A total of 198 isolates suspected to
represent Cryptococcus spp. were analysed. Initial iden-
tification results of all samples are shown in Table 1.
More than one-third of all CAA positive isolates (73 out
of 198) were also CGB positive. All Cryptococcus-like
isolates from trees were subjected to AFLP analysis. The
resulting dendrogram showed 28 clusters of AFLP
fingerprints (Fig. 1). From each ten isolates in a cluster,
one random isolate was identified by sequencing the
ITS1 ⁄ 5.8S ⁄ ITS2 and D1–D2 regions. Molecular identi-
fication showed that the most prevalent species was
C. heveanensis (36%). Eighteen isolates had sequences
Table 1 Number of isolates obtained from tree samples inoculated
on CAA and distribution according to their behaviour on CGB
medium.
Plant species (nr. positive
samples ⁄ total nr. of samples) CGB (+) CGB ()) Total
Almond (41 ⁄ 65) 31 48 79
Casuarins (35 ⁄ 60) 42 11 53
Flamboyants (25 ⁄ 65) 36 9 45
Cacti (10 ⁄ 60) 14 5 19
Others* (0 ⁄ 81) 0 0 0
Total 123 73 196
CAA, caffeic acid agar plates; CGB, canavanine-glycine-
bromothymol blue medium.
*Ficus spp. (n = 65), blue mahoe trees (n = 5), ceiba (n = 3), sea
grape (n = 2), copey, yellow oleander, yellow flamboyant, ballnut,
caribbean pine and roble (one each).
Figure 1 Dendrogram of AFLP fingerprints restricted to DNA fragments in the range of 60–500 bp based on UPGMA cluster analysis and
the Pearson correlation coefficient. The scale bar represents the percentage of similarity. Coloured squares under A indicate the species of
tree from which the isolates were obtained (yellow: casuarina; red: almond; blue: flamboyant). Coloured squares under B indicate the
growth on CGB medium (cyan: negative; purple: positive).
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matching C. flavescens, but these segregated into four
different AFLP clusters, suggesting that these isolates
represent four different closely related yeast species. Ten
isolates were identified as C. liquefaciens or C. albidosim-
ilis. The distinction between these two species is difficult
to make based on the ITS and D1 ⁄ D2 species, but these
isolates clearly segregated into two AFLP clusters with
four and six isolates respectively. Seventeen isolates
(three AFLP clusters) had sequences matching Genbank
entries, but corresponded to yet unnamed species.
Additional identified species represented Kwoniella mang-
roviensis, Bullera dendrophila, B. pseudoalba, C. flavus,
Sterigmatomyces elviae, C. albidus and one Candida sp.
Approximately one-third of all isolates (n = 65) distrib-
uted over ten AFLP clusters could not be identified based
on ITS and D1–D2 sequences and may represent novel
fungal taxa. Only one strain isolated from an almond
tree was identified as C. neoformans var. grubii. The
genotype of this isolate was determined using microsat-
ellite analysis and corresponded to those of isolates
previously recovered from pigeon droppings (results not
shown). An overview of molecular identification results
is shown in Table 2. In Cuba, Cryptococcus species seem
to be more associated with almond trees and this is the
first time that they are found in relation with casuarina
and flamboyant trees. Although many Indian laurel
trees were sampled, C. neoformans species complex-like
organisms were not found on this tree. Most non-
C. neoformans species identified in this study were
predominantly associated with one species of tree.
Within multiple species, both CGB positive and negative
isolates were found, indicating CGB positivity to be a
poor parameter for fungal identification of environmen-
tal Cryptococcus isolates.
Discussion
A recent study has shown that all clinical cryptococcal
isolates from Cuban patients represented C. neoformans
var. grubii. Molecular characterisation by genotyping
suggests that isolates obtained from bird droppings play
only a minor role in the exposure to this pathogen and
that many clinical isolates may originate from addi-
tional ecological niche(s).8 In our search for cryptococ-
cal isolates from the environment, we used two
screening media (CAA and CGB) to facilitate presump-
tive recognition of either C. neoformans or C. gattii.
Pigmentation on media with phenolic substrates is
widely used for isolation and identification of these
yeasts due to its high sensitivity when compared with
other mycological media.16–20 Our primary isolations
were initially selected by the presence of pigmented
colonies on CAA. This medium generally performs well
with C. neoformans ⁄ C. gattii species complex isolated
from clinical samples, but we19 and others21–24 expe-
rienced that isolates from the environment and some
clinical isolates may display variability in pigmentation
intensity. In addition, it has been shown that UV
radiation may induce mutations affecting melanogene-
sis.25 This might also occur in the environment due to
sunlight exposure. Therefore, we selected colonies that
exhibited any degree of pigmentation (even beige or tiny
brown) for further identification by conventional and
molecular methods.
The CGB medium was proposed in 1982 by Kwon-
Chung et al. [14] to distinguish C. neoformans from
C. gattii. In the present study, although 33% of primar-
ily selected colonies on CAA yielded a positive reaction
on CGB medium, molecular analyses showed that none
of these isolates was actually C. gattii. Due to the
growing number of environmental studies and the
development of more reliable identification methods,
many new Cryptococcus species have been described in
recent years.4 However, C. neoformans ⁄ C. gattii species
complex remains the major responsible agent causing
human and animal cryptococcosis. Typical colour
change on CGB medium is widely used in mycology
laboratories for the differentiation of both species of the
complex,26,27 suggesting that it can be used as a
presumptive identification test. However, there are
several other microorganisms beside C. gattii, which
Table 2 Identification results of environmental Cryptococcus iso-
lates (n = 198) collected from Cuban trees and cacti based on
AFLP analysis and ITS - D1 ⁄ D2 sequences. Cluster IDs correspond
to those in Fig. 1.
# Isolates # AFLP clusters (ID)
Cryptococcus heveanensis 71 1 (22)
Unknown sequences1 65 10 (1,2,3,4,10,
14,15,17,24,28)
Cryptococcus flavescens 18 4 (7,8,12,13)
Unidentified sequence2 17 3 (5,6,9)
Cryptococcus
albidosimilis ⁄ liquefaciens
10 2 (26,27)
Kwoniella mangroviensis 6 1 (16)
Bullera dendrophila 2 1 (18)
Bullera pseudoalba 2 1 (23)
Cryptococcus flavus 2 1 (11)
Sterigmatomyces elviae 2 1 (20)
Candida sp. 1 1 (21)
Cryptococcus albidus 1 1 (25)
Cryptococcus neoformans
var. grubii
1 1 (19)
1Sequence not matching to any Genbank entry.
2Sequence matching to a Genbank entry, but with no organism
name provided.
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show a positive reaction on CGB medium24,28–31 and
other species different from the C. neoformans ⁄ C. gattii
species complex are rarely involved in human infection.
This is in marked contrast with the high diversity of
species found in the environment, which are more likely
to increase the chance of misidentification when using
conventional techniques such as pigmentation on CAA
and growth on CGB media. These results highlight the
need for molecular confirmation for reliable identifica-
tion of cryptococcal isolates from the environment.
AFLP has been reported before as a powerful method
for inter- and ⁄ or intraspecific discrimination between
closely related fungal species from various genera of
filamentous fungi such as Aspergillus,32 Scedospori-
um ⁄ Pseudallescheria33 and Apophysomyces34 but also
from yeasts such as Candida.35 Our results show that
AFLP is a highly efficient and powerful method as a first
line screening tool to distinguish between different
fungal species in large collections of isolates from
environmental sources such as Cryptococcus spp.
It has been suggested that the primary habitat of
C. neoformans could be vegetations and decaying wood,
not being associated with a particular tree, but rather
with a specialised niche resulting from the natural
biodegradation of wood.11,27,28 Because of previous
reports of isolation of Cryptococcus from almond, laurel
trees and cactus,7,10,36 these species were selected while
the criterion for inclusion of the other tree species was
their narrow geographical relation with the first ones.
Our results are in agreement with those reported by Tay
et al. [29] who found non-neoformans ⁄ gattii cryptococ-
cal isolates during an environmental sampling study,
while looking for C. gattii in Klang Valley, Malaysia.
Interestingly, a total of 29 (76.3%) C. laurentii isolates
from their collection produced blue colours on CGB
agar.
Although many authors prefer gathering debris from
decayed wood in tree trunk hollows, we selected
swabbing as sampling method, which lately has been
regarded as more useful compared with conventional
approaches. This method not only consistently yielded
more frequent isolations of fungi, less false-negative
results and much higher mean colony counts, but it was
also a more simple, less time-consuming and less
hazardous technique.7,12 For the C. neoformans ⁄ C. gattii
species complex, the scavenging capacity of chemical
compounds made by other microbes suggests that this
organism gains the benefit of melanisation by having
the machinery for melanin synthesis and remodelling
without having to invest in biosynthetic pathways. This
fact establishes a precedence for a new substrate for
melanisation in this yeast that could provide a new
source for melanin substrates from the environment.37
We propose the hypothesis that other non-neoformans
species also could use similar ways as survival mech-
anism in the environment, which must be verified.
Due to the increase in yeast infections in different
human diseases, renewed attention is focused on the
question of the epidemiology and origin of these fungi.
In this context, the question of the importance of the
different environmental sources as reservoir of Crypto-
coccus species less virulent than C. neoformans complex
has been neglected so far.4 Analysing the structure of
the environmental population of C. neoformans and
C. gattii can significantly increase our knowledge of its
ecology, evolution and epidemiology. However, the low
number of reports of the prevalence of this yeast in the
environment does not allow a generally valid epidemi-
ological evaluation, and more epidemiological studies
should be performed to determine the exact distribution
of C. neoformans and C. gattii in Cuba.
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Introduction
Cryptococcosis is a major cause of mycosis with a
worldwide distribution found in the human and warm-
blooded animal population. Its causative agents are
Cryptococcus neoformans and C. gattii, which are the
most important pathogens among the basidiomycetous
fungi (Caban˜es FJ, Rev Iberoam Micol 2008; 25: S1–S3).
The genus includes over 80 species; however, only
C. neoformans and C. gattii are considered pathogenic
[Fonseca A et al., Cryptococcus Vuilemin. In: The Yeasts:
A Taxonomic Study, 5th edn. Kurtzman CP et al. (eds),
1661–737. Elsevier, Amsterdam, 2011]. The C. neofor-
mans ⁄ C. gattii species complex formerly included the
two varieties C. neoformans var. neoformans (serotypes A
and D) and C. neoformans var. gattii (serotypes B and C).
Currently, C. neoformans var. gattii has been raised to
the species level as C. gattii whereas C. neoformans was
separated into the two different varieties C. neoformans
var. grubii (serotype A) and C. neoformans var. neofor-
mans (serotype D) (Kwon-Chung KJ et al., Taxon 2002;
51: 804–6).
Until recently an agglutination assay was widely used
to determine the serotypes of C. neoformans ⁄ C. gattii
species complex (Bovers M et al., FEMS Yeast Res 2006;
6: 599–607). With the emergence of molecular tech-
niques, such as PCR fingerprinting, restriction fragment
length polymorphism (RFLP) analysis of the PLB1 and
URA5 locus, amplified fragment length polymorphism
(AFLP) fingerprint analysis as well as several multi-
locus sequence typing (MLST) approaches, it became
clear that C. neoformans and C. gattii could be divided
into distinct genotypes named AFLP1 ⁄ VN1, AFLP2 ⁄
VNIV and AFLP3 ⁄VNIII for C. neoformans and genotype
AFLP4 ⁄VGI, AFLP5 ⁄VGIII,AFLP 6 ⁄ VGII, AFLP7 ⁄VGIV
and AFLP10 ⁄ VGIV for C. gattii (Franzot SP et al., J Clin
Microbiol 1999; 37: 838–40; Boekhout T et al., Micro-
biology 2001; 147: 891–907; Hagen F et al., Antimicrob
Agents Chemother 2010; 54: 5139–45).
Cryptococcus neoformans has a global distribution and
infects predominantly immunocompromised animal and
human hosts, whereas C. gattii was thought to be
restricted to tropical and subtropical regions and has
not been associated with an impaired immune system
(Bovers M et al., FEMS Yeast Res 2006; 6: 599–607;
Bovers M et al., Rev Iberoam Micol 2008; 25: S4–S12.).
Up to now, only C. neoformans var. grubii has been
routinely isolated from environmental and clinical
samples in Cuba (Illnait-Zaragozi MT et al., PloS One
2010; 5: e9124). Herein, we characterise a yeast strain
isolated from a captivated cheetah (Acinonyx jubatus)
that was imported from South Africa and kept at the
National Zoo in Havana, Cuba.
Methods
A yeast-like fungus was isolated from nasal discharge of
a cheetah and was subsequently identified using mac-
romorphological and micromorphological characteris-
tics including growth at 37 �C, absence of germ tube
formation, morphology on cornmeal agar with Tween
80, pigmentation on caffeic acid agar, urea hydrolysis,
myo-inositol assimilation, growth on canavanine-
glycine-bromothymol blue medium and serological
agglutination using the Crypto Check system (Iatron
Laboratories, Tokyo, Japan). The strain was deposited in
the public culture collection of the CBS-KNAW Fungal
Biodiversity Centre (Utrecht, The Netherlands) under
accession number CBS11421.
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Genomic DNA was extracted as described previously
(Hagen F et al., Antimicrob Agents Chemother 2010; 54:
5139–45). The mating-type was determined using two
PCRs that specifically amplify the mating-type a and a
allele of the STE12 locus (Bovers M et al., FEMS Yeast
Res 2006; 6: 599–607). Reference strains WM779
(mating-type a, genotype AFLP7 ⁄VGIV) and CBS1930
(mating-type a, genotype AFLP6 ⁄VGII) were included
in the analysis. AFLP analysis was carried out as
previously described (Boekhout T et al., Microbiology
2001; 147: 891–907). Strains WM179 (AFLP4 ⁄VGI),
WM161 (AFLP5 ⁄VGIII), WM178 (AFLP 6 ⁄VGII) and
WM779 (AFLP7 ⁄ VGIV) served as reference isolates and
a phenetic tree was calculated using the single linkage
clustering algorithm in combination with Pearson
correlation using the software package Bionumerics
version 4.6.1 algorithm (Applied Maths, Sint-Martens-
Latem, Belgium).
Multi-locus sequence typing was performed using the
seven standard loci: CAP59, GPD1, IGS1, LAC1, PLB1,
SOD1 and URA5 according to Meyer W et al. (Med
Mycol 2009; 47: 561–70). In addition, the CAP10,
MPD1 and TEF1a loci were sequenced to compare the
strain with a recently published large C. gattii MLST
dataset (Fraser JA et al., Nature 2005; 437: 1360–4).
Sequences have been deposited in GenBank under
accession numbers HQ733955–HQ734184.
Susceptibility testing using a broth microdilution
method was performed in accordance with Clinical
and Laboratory Standards Institute document M27-A3
guidelines (Reference Method for Broth Dilution Antifungal
Susceptibility Testing of Yeasts. Approved Standard, 3rd
edn, M27-A3. Wayne, PA, 2008). Standard antifungal
powders of amphotericin B (Sigma, Zwijndrecht, The
Netherlands), flucytosine (Valeant Pharmaceuticals,
Zoetermeer, The Netherlands), itraconazole (Janssen ⁄
Cilag, Tilburg, The Netherlands), fluconazole (Pfizer
Central Research, Sandwich, Kent, UK), voriconazole
(Pfizer Central Research), posaconazole (Schering
Plough, Kenilworth, NJ, USA) and isavuconazole
(Basilea Pharmaceuticals, Basel, Switzerland) were
used. The stock solutions of the drugs were prepared
in the appropriate solvent. The final concentrations of
the antifungal agents were 0.016–8 lg ml)1 for
amphotericin B, itraconazole, voriconazole, and posa-
conazole; 0.063–32 lg ml)1 for flucytosine and fluco-
nazole; and 0.004–4.00 lg ml)1 for isavuconazole.
After 72 h incubation at 35 �C the MIC was defined
as the lowest concentration of drug showing absence of
growth for amphotericin B and a prominent reduction
of growth (‡50%) for the other antifungal compounds
compared with the drug-free growth control. The MICs
at 72 h were read optically at 420 nm after agitation.
Candida parapsilosis ATCC 22019 and Candida krusei
ATCC 6258 were used as quality control.
Results and discussion
Cryptococcus has the potential to infect a wide range of
animals throughout the world, including wild animals,
farm animals, domestic animals, aquatic animals and
several varieties of birds (Duncan C et al., Can Vet J
2006; 47: 993–8). Even though this is the most
frequent systemic fungal disease described in felines,
subclinical infection with spontaneous elimination of
cryptococci is much more common. Factors mediating
progression to infection have been linked to the pres-
ence of concurrent disease or other immunosuppressive
conditions. (Duncan C et al.,Med Mycol 2005; 43: 663–
6; Duncan C et al., Med Mycol 2005; 43; 511–6;
Duncan C et al., Can Vet J 2006; 47: 993–8; MacDou-
gall L et al., Emerg Infect Dis 2007; 13: 42–50).
The cheetah has been considered a paradigm of
vulnerability to infectious diseases because the species
lacks heterogeneity at MHC loci that encodes peptides
mediating immune responsiveness to pathogens (Mill-
ward IR and Williams MC, J S Afr Vet Assoc 1999; 70:
35–9; Miller-Edge MA and Worley MB, Vet Immunol
lmmunopathol 1992; 30: 261–74). Cryptococcosis in
these felines has been described in captive animals from
South Africa, especially due to C. gattii (Beehler WA, J
Am Vet Med Assoc 1982; 181: 1400–1; Berry WL et al.,
J Zoo Wildl Med 1997; 28: 485–90; Bolton LA et al., J S
Afr Vet Assoc 1999; 70: 35–9; Millward IR and Williams
MC, J S Afr Vet Assoc 1999; 70: 35–9).
In the present case, the cheetah was imported from
South Africa to Cuba at the age of approximately
1 year, where it was subsequently displayed at the
carnivores� area of the National Zoo. After 16 months in
captivity, the cheetah showed signs of sudden loss of
weight, fatigue, anorexia, shortness of breath and nasal
discharge. The animal was taken to the veterinary clinic
for sampling and died before any diagnosis could be
made (Polo-Leal JL et al., Rev Cub Med Trop 2010; 62:
257–60).
Using AFLP and MLST analysis the strain was
classified as genotype AFLP4 ⁄ VGI. Additional mating-
type analysis revealed that the STE12a allele was
present and previous identification of the yeast as a C.
gattii strain serotype B based on conventional tech-
niques and serology was confirmed.
There are several arguments that support the
hypothesis that the animal had a dormant infection at
the time of entry at the zoo. First, so far all Cryptococcus
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isolates obtained from clinical and environmental sam-
ples in Cuba have been identified as C. neoformans var.
grubii and despite an extensive search, no C. gattii has
been found (Martı´nez-Machı´n G et al., Rev Cub Med Trop
2004; 56: 77–9; Illnait-Zaragozi MT et al., PloS One
2010; 5: e9124). Secondly, it has been shown before
that the interval between exposure and development of
clinical disease is highly variable. At one extreme, acute
infections have been reported while reactivations of long
silent subclinical infections are evident (Lindberg J et al.,
Emerg Infect Dis 2007; 13: 178–9; Hagen F et al., Med
Mycol 2010; 48: 528–31). We hypothesise that cap-
tivity could be a very stressful factor for these animals
that have normally a solitary life style and are adapted
to running. This might have contributed to the poor
health of the cheetah and reactivation of the dormant
infection after being held in captivity during 1 year at
the zoo.
And finally, other studies have shown that there is a
regional correlation among environmental and clinical
isolates from Africa, France, Japan and the USA where
this aspect has been studied (Sorrell T et al., J Clin
Microbiol 1996; 34: 1253–60). In the current case,
molecular biological characterisation showed that the
strain belonged to C. gattii genotype AFLP4 ⁄VGI, a
lineage that can be found in the tropical and subtropical
regions of Africa, Asia, Australia, Central America and
South America (Hagen F et al., Antimicrob Agents
Chemother 2010; 54: 5139–45; Springer DJ and Cha-
turvedi V, Emerg Infect Dis 2010; 16: 14–20). The usage
of large MLST datasets has recently been proven to be
an excellent approach to trace a clinical C. gattii strain
to its geographic origin (Lindberg J et al., Emerg Infect Dis
2007; 13: 178–9; Hagen F et al., Med Mycol 2010; 48:
528–31). MLST data of the cheetah C. gattii strain was
compared with a large C. gattiiMLST dataset and a subset
of these strains was finally used to show the relationship
between the cheetah C. gattii strain and environmental,
veterinary and clinical C. gattii AFLP4 ⁄VGI strains that
are most closely related (Fig. 1). This revealed that the C.
gattii strain from the cheetah was nearly identical to a
strain isolated from an unknown source in Kenya,
whereas the cheetah strain was far more distantly related
to strains from Central and South America (Fig. 1). This
strongly suggests that the cheetah had a dormant or
subclinical C. gattii infection, acquired in Africa, which
was activated during its captivity in the National Zoo in
Havana, Cuba.
Although some veterinarians prefer surgery when
possible or euthanasia, a review of the literature showed
Figure 1 Cryptococcus gattii isolated from
the cheetah is presented in bold; underlined
strain numbers representing the four
strains WM179 (AFLP4 ⁄ VGI), WM161
(AFLP5 ⁄ VGIII), WM178 (AFLP6 ⁄ VGII)
and WM779 (AFLP7 ⁄ VGIV) were used as
references. A set of 18 C. gattii AFLP4 ⁄ VGI
strains is included to represent genetic lin-
eages from other continents. The evolu-
tionary history was inferred using the
Maximum Parsimony method in MEGA
version 4.1 (http://www.megasoftware.
net). Values shownnext to the branches are
percentages (>75%) of replicated trees in
which the associated taxa clustered to-
gether in the bootstrap test (1000 repli-
cates).
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that antifungal compounds in the group of azoles,
especially ketoconazole and itraconazole, have been
widely used in the treatment of animals affected with
cryptococcosis, although the optimum treatment strat-
egy is still not clear (Beehler BA, J Am Vet Med Assoc
1982; 181: 1400–1; Medleau L et al., Am J Vet Res
1990; 51: 1454–8).
The CLSI M27-A3 document recommends that yeast
strains with flucytosine MICs ‡32 lg ml)1 can be
regarded as resistant to this drug (CLSI, Reference
Method for Broth Dilution Antifungal Susceptibility Testing
of Yeasts. Approved Standard, 3rd edn, M27-A3. Wayne,
PA, 2008). At present there has been no amphotericin B
breakpoint established for the C. neoformans ⁄ C.gattii
complex; therefore, we defined a strain being resistant
with a MIC ‡2 lg ml)1, which was found to be
associated with therapeutic failure (Lozano-Chiu M et
al., J Clin Microbiol 1998; 36; 2817–22). By these
definitions the studied isolate was susceptible to flucy-
tosine and amphotericin B (8 and 0.125 lg ml)1,
respectively). The MIC of 2 lg ml)1 for fluconazole
was the highest in vitro activity among the azoles.
Previous reports have also demonstrated a low activity
of fluconazole against C. neoformans strains and suggest
that good therapeutic results obtained with this agent
are due to its high concentrations in cerebrospinal fluid
(Aller AI et al., Antimicrob Agents Chemother 2000; 44:
1544–8). In agreement with previously published
studies, which have shown high in vitro activity of the
new azole isavuconazole for Cryptococcus species (Illnait-
Zaragozı´ MT et al., Antimicrob Agents Chemother 2008;
52: 1580–2; Hagen F et al., Antimicrob Agents Chemo-
ther 2010; 54: 5139–45), we found that isavuconazole
was more potent (0.016 lg ml)1) than voriconazole
and itraconazole (0.031 lg ml)1 each one) for this C.
gattii strain. Unfortunately, the cheetah died before the
diagnosis was made and no treatment was attempted.
This is the first documented case of C. gattii in Cuba,
although genotypic analysis suggests that the animal
had a dormant or subclinical infection at the moment of
entrance into the zoo. Investigation of cryptococcal
cases using molecular tools may improve our under-
standing of the risk factors for this disease, and we
suggest performing active search for cryptococcal col-
onisation ⁄ infection in these captive animals which
could lead to the formulation of preventive strategies.
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a b s t r a c t
We describe the first clinical case of cryptococcosis due C. gattii in a Cuban immunocompetent patient
who had a traveling history two years before to Central America. Molecular characterization of the
isolate showed it to be genotype AFLP5 of which MLST sequences clustered with clinical and
environmental strains from Colombia. The patient died one year after the diagnosis despite a prolonged
treatment with (liposomal) amphotericin B, fluconazole, voriconazole and gamma interferon.
& 2013 International Society for Human and Animal Mycology. Published by Elsevier B.V All rights
reserved.
1. Introduction
Cryptococcosis is a life-threatening mycosis that develops
following the inhalation and dissemination of fungal conidia
and/or desiccated yeast forms. The Cryptococcus neoformans/
Cryptococcus gattii species complex are free-living saprophytic
yeasts which can survive in diverse niches [1]. The complex
includes two species with their varieties and serotypes: C. neofor-
mans var. grubii (serotype A; genotype AFLP1), C. neoformans var.
neoformans (serotype D; genotype AFLP2) and the intervarietal
state C. neoformans serotype AD (genotype AFLP3), which mostly
affect immunocompromised patients worldwide; the other
species, C. gattii (serotypes B and C; genotypes AFLP4-7 and
AFLP10) mainly affects individuals without apparent alterations
of the immune system and used to have a more restricted
distribution to tropical and subtropical climates, although recent
findings indicates a drastic change in the adaptation of this
organism to other environments [2–4]. Up to now, only C. neoformans
var. grubii has been routinely isolated from environmental and
human clinical samples in Cuba [5,6]. Here we report a fatal case of
C. gattii meningitis in Cuba in an immunocompetent patient.
2. Case
A 56-year-old white Cuban male from Villa Clara, a city in the
central part of the island, who had no significant medical history,
was admitted on July 5th 2011 because of mild fever, myalgia,
malaise and diffuse headache. He was a moderate smoker and
used only sporadically alcohol. His most recent travel history was
to Honduras (2003–2005) and Guatemala (2007–2009) where he
worked as a general practitioner. Physical examination revealed a
mild fever of 38 1C, signs of lung consolidation on the lower right
side, and fine crackles with chest auscultation. A chest radiograph
showed an inflammatory lesion on the lower right side consistent
with pneumonia. No cultures or clinical chemical investigations
were performed. The patient was treated empirically with peni-
cillin but after seven days (July 12th, 2011) he was admitted to
the local hospital because of worsening of his general condition
and development of a severe headache. Hematologic and serolo-
gic tests, including HIV antibody screening, were negative. A
lumbar puncture showed a high opening pressure (40 cm H2O)
and cerebrospinal fluid (CSF) analysis revealed pleocytosis (215
cells/mm3 predominantly lymphocytes), reduced glucose level
(2.6 mg/dL) and elevated protein level (480 mg/dL) (Table 1).
2211-7539/$ - see front matter & 2013 International Society for Human and Animal Mycology. Published by Elsevier B.V All rights reserved.
http://dx.doi.org/10.1016/j.mmcr.2013.02.001
n Corresponding author at: Department of Medical Microbiology and Infectious
Diseases, Canisius Wilhelmina Hospital, PO Box 9015, Nijmegen 6500 GS,
The Netherlands. Tel.: þ31 243657514.
E-mail address: jacques.meis@gmail.com (J.F. Meis).
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Sputum and CSF was cultured and treatment was started with
ceftriaxone (4 g/d). After isolation of Klebsiella pneumoniae from
sputum cultures, amikacin (15 mg/kg/d during seven days) was
added to the treatment. The patient did not improve satisfactorily
and therefore a computerized tomography (CT) scan and mag-
netic resonance imaging (MRI) were performed which were
unremarkable. To reduce suspected intracranial hypertension,
the lumbar puncture was repeated a week later (July 20th,
2011). Opening pressure was still increased with signs of inflam-
mation (Table 1). Direct microscopic examination of CSF with
India ink showed the presence of a large number of rounded and
encapsulated yeasts compatible with Cryptococcus. The treatment
was changed to amphotericin B deoxycholate (0.7 mg/kg) intrave-
nously and 400 mg (b.i.d.) of fluconazole orally. Flucytosine was
not available in Cuba. After an initial improvement with antifungal
treatment the patient experienced worsening pulmonary functions,
intense headache, neurological impairment, decreased visual acuity
and hearing loss on the right side. Therefore on August 23th, 2011,
the patient was transferred to an infectious diseases reference center
in Havana where the isolate was identified as Cryptococcus gattii. In
vitro susceptibility testing showed low MICs of amphotericin B
(0.125 mg/L), fluconazole (2 mg/L), flucytosine (0.5 mg/L), itracona-
zole (0.125 mg/L), posaconazole (0.125 mg/L), voriconazole
(0.063 mg/L) and isavuconazole (0.016 mg/L).
So far the patient had received a cumulative dose of 1.500 mg
amphotericin B deoxycholate and his kidney functions had
become slightly disturbed (creatinine 130 mmol/L, ureum
10.6 mmol/L). Mayor findings at physical examination revealed
a right VI cranial nerve palsy, blurred vision and diplopia in
addition to a non-resolving pneumonia. Repeat CT scan with and
without contrast did not show signs of cerebral edema or other
abnormalities. Because of the poor clinical response and worsen-
ing kidney function amphotericin B deoxycholate was changed to
liposomal amphotericin B (3 mg/kg) and fluconazole 800 mg/d
was continued from August 29th to October 6th, 2011, but again
without clinical improvement. Several lumbar punctures were
necessary to control high intracranial pressure. All samples
remained microscopically positive for cryptococci (Table 1). In
this period the patient became blind and lost his hearing. After a
total dose of 8 g liposomal amphotericin B, fluconazole was
replaced by voriconazole (800 mg/d orally) and the patient was
discharged on December 5th, 2011. During the last 2-month
period the patient also received recombinant IFNg (200 mg)
subcutaneously thrice weekly. Because voriconazole was no
longer available he was treated with fluconazole 400 mg from
March 21st until July 1st 2012. The patient’s blindness and loss of
hearing remained permanent. He was re-admitted to hospital on July
1st, 2012, due to progressive deterioration, clinical signs of intracra-
nial hypertension, seizures and papilledema. This improved slightly
after CSF puncture but after seven days receiving amphotericin B
deoxycholate (1 mg/kg/day) and fluconazole 800mg/d he died on
July 8th, 2012, one year after the start of the clinical presentation of
the disease. An autopsy was not performed.
Identification of the isolated yeasts as C. gattii was performed
by urease, inositol fermentation test and growth on canavanine-
glycine bromothymol blue (CGB) agar to differentiate C. neofor-
mans from C. gattii. Molecular identification as C. gattii genotype
AFLP5 was done by using amplified fragment length polymorphism
(AFLP) fingerprinting, as described previously [7,8]. The mating-
type was determined using a conventional PCR using STE12a- and
STE12a-specific primers [8] that revealed the presence of the
mating-type a allele for both isolates. The two Cuban C. gattii
AFLP5 isolates were sequenced for the seven nuclear loci CAP10,
GPD1, IGS1, LAC1, MPD1, PLB1 and TEF1 to compare them to the
data of other isolates with the genotype AFLP5, as published by
Hagen et al. (2012) and Byrnes et al. (2011) [3,9]. Sequences were
deposited in Genbank and can be accessed via the accession
numbers KC424622–KC424635. Isolates were deposited in the
CBS Fungal Biodiversity collection in Utrecht, the Netherlands as
CBS 12755 (CUBA 250) and CBS 12754 (CUBA 350). A bootstrap
Maximum Likelihood phylogenetic analysis was performed using
the settings as being used for a previously published C. gattii MLST
study [3] (Fig. 1).
3. Discussion
C. gattii differs from the more commonly isolated C. neofor-
mans in clinical aspects, ecological niche and genetic makeup.
Unlike C. neoformans, it most often affects immunocompetent
patients exposed to an environmental source causing pulmonary
and cerebral infections. Furthermore C. gattii is known to be more
resistant to antifungal agents. In the Caribbean, cryptococcosis
appears to be a relatively rare disease with an estimated 7800
new patients each year [10]. In Cuba, the disease was first
reported in the early 1950s [11]. Since then sporadic cases were
associated with alcoholism, organ transplantations and immuno-
logical disorders. In 1986, with the beginning of the AIDS
epidemic in Cuba, the amount of individuals suffering from
cryptococcosis had increased over the years with an average of
eight new cases each year [12]. This might still be an under-
representation since a retrospective autopsy study of HIV/AIDS
patients performed during a 10-year period showed that disse-
minated or central nervous system cryptococcosis was a serious
and common disorder in 29% of the cases [13]. The clinical
presentation of cryptococcal infection varies from asymptomatic
pulmonary colonization to severe pneumonia with respiratory
failure and life-threatening meningitis [14,15]. Mostly infections
due to C. gattii genotypes AFLP4 and AFLP6 usually occurs in
patients without detectable predisposing factors while genotypes
AFLP5, AFLP7 and AFLP10 appear to be associated with an
impaired immune system (mainly AIDS, but also any other
immunosuppressive condition including solid organ transplanta-
tion) which is similar to C. neoformans [3,16]. Interestingly none
of these underlying diseases, previously associated with C. gattii
AFLP5 infection, could be demonstrated in our patient.
About 65%–77% of cases with C. gattii infections presents
more often with lung involvement [1]. Initial symptoms of our
patient fitted with a community-acquired pneumonia and sputum
cultures only demonstrated Klebsiella. It might be hypothesized
that the development of a community-acquired pneumonia could
generate appropriated conditions favoring rapid multiplication and
dissemination of C. gattii from its dormant state. Cryptococcal
Table 1
CSF findings during one year of C. gattii meningoencephalitis
Date Results
OP (cm
H2O)
Clinical chemistry Microbiology
Protein
(mg/dL)
Glucose
(mg/dL)
Cells
(mm3)
India
ink
Culture
12/7/2011 40 480 2.6 70 (þ) C. gattii
20/7/2011 35 171 2.4 215 (þ) C. gattii
25/8/2011 32 40.2 3.4 17.5 (þ) (�)
5/9/2011 28 20 3.8 12 (þ) (�)
19/9/2011 25 30 3.8 10 (þ) (�)
3/10/2011 26 35 4 11 (þ) (�)
13/10/2011 38 28 4.18 13 (þ) (�)
23/10/2011 25 17.8 3.49 10 (þ) (�)
9/11/2011 35 17.8 3.49 10 (þ) (�)
5/12/2011 22 38 4.1 13.5 (þ) (�)
1/7/2012 50 45 2.5 15 (þ) (�)
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infection involves any part of the central nervous system and leads
to a wide spectrum of neurological symptoms such as headache,
altered consciousness, seizures, and cranial nerve palsies. Seaton
et al. [17] reviewed the ophthalmic findings in 82 immunocompe-
tent patients in whom C. gattii was involved. A high rate of visual
loss was observed in 52.6% of survivors similar what had occurred
in our patient.
Environmental exposure is known to be the dominant risk
factor for C. gattii infection, but so far all pathogenic clinical and
environmental Cryptococcus isolates from Cuba have been identi-
fied as C. neoformans var. grubii [5]. However a single case of a
fatal veterinary C. gattii genotype AFLP4 infection was described
recently in a cheetah imported from South Africa. Molecular
epidemiologic studies strongly suggested that the animal was
not infected in Cuba, but most likely in Africa [18]. It has been
demonstrated before that C. gattii infections can be imported
subclinically and reactivate after being dormant for many
years [3]. There are three main arguments that support the
hypothesis that our patient had a dormant infection when he
returned to Cuba from Central America. First, there is no evidence
suggesting environmental presence of this species despite multi-
ple attempts to recover C. gattii from plants, trees and cacti in
Cuba [6], which is in strong contrast to for example India where
C. gattii can be isolated from up to 50% of investigated trees [16].
Secondly, it has been ample demonstrated that the time interval
between exposure to C. gattii and the development of the disease
is highly variable; at one extreme, acute infection have been
reported while reactivation of long silent subclinical infections is
also possible depending of the immunological status of the
patient [3,19]. We have no indication that a hereditary immune
disorder might have been involved but there is in vitro evidence
that clinical C. gattii isolates induced a more pronounced inflam-
matory response compared to other Cryptococcus species and
environmental C. gattii [20]. This might explain the severe
immunopathology seen in human (and animal) C. gattii infections.
And finally, molecular biological characterization showed that the
strain belonged to C. gattii genotype AFLP5. Although this geno-
type was originally reported from India and the USA, current
literature show that it has spread throughout Latin-American
countries (Argentina, Brazil, Colombia, Guatemala Mexico, and
Venezuela), the west coast of the USA., as well as over Asia and
Australia [3,16]. Comparison with a large C. gattii genotype AFLP5
MLST dataset [3,9] yielded a high similarity degree to strains from
clinical and environmental sources in Colombia. The patient’s
travel history to Central America suggests acquisition during this
time period.
The neurological picture in conjunction with the presence of
yeasts in the CSF let to suspect cryptococcal infection in our
patient initiating treatment according to management guidelines
[21] and availability of drugs. For meningoencephalitis and
disseminated disease due to C. gattii, recommended induction,
consolidation, and suppressive treatment are basically the same
as for C. neoformans. Because C. gattii infection is associated with
more neurological complications and delayed response to ther-
apy, as demonstrated in this case, a longer course of therapy,
increasing dose and/or recombinant IFNg as salvage therapy for
patients unresponsive to multiple antifungal drugs has been
suggested [21]. The latter salvage therapy was successful in
patients with C. neoformans infections [22]. For persistent and
relapse isolates it is highly recommended to look for changes in
the MIC from the original isolate (Z3-dilution difference suggests
development of direct drug resistance) [13,21]. Unfortunately,
although the direct examination of CSF stayed positive during the
whole disease course, cultures remained negative. Our case is a
quick alert to suspect C. gattii AFLP5 infection also in HIV negative
patients, to consider the growing possibility of imported
Fig. 1. A 1000� bootstrap Maximum Likelihood phylogenetic analysis of the two
Cuban strains (CBS 12755 and CBS 12754), compared to C. gattii AFLP5 strains
from previously published MLST studies [3,9]. Both Cuban strains (marked in red)
clustered together with clinical and environmental strains from Colombia.
Numbers next to branches represent bootstrap valuesZ75. (For interpretation
of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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infections from endemic regions and the need for more effective
alternatives for treating this mycosis.
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Cryptococcus gattii Induces a Cytokine Pattern That Is
Distinct from Other Cryptococcal Species
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Abstract
Understanding more about the host’s immune response to different Cryptococcus spp. will provide additional insight into
the pathogenesis of cryptocococcis. We hypothesized that the ability of C. gattii to cause disease in immunocompetent
humans depends on a distinct innate cytokine response of the host to this emerging pathogen. In the current study we
assessed the cytokine profile of human peripheral blood mononuclear cells (PBMCs) of healthy individuals, after in vitro
stimulation with 40 different well-defined heat-killed isolates of C. gattii, C. neoformans and several hybrid strains. In
addition, we investigated the involvement of TLR2, TLR4 and TLR9 in the pro-inflammatory cytokine response to C. gattii.
Isolates of C. gattii induced higher concentrations of the pro-inflammatory cytokines IL-1b, TNF-a and IL-6 and the Th17/22
cytokine IL-17 and IL-22 compared to C. neoformans var neoformans and C. neoformans var grubii. In addition, clinical C.
gattii isolates induced higher amounts of cytokines than environmental isolates. This difference was not observed in C.
neoformans var. grubii isolates. Furthermore, we demonstrated a likely contribution of TLR4 and TLR9, but no role for TLR2,
in the host’s cytokine response to C. gattii. In conclusion, clinical heat-killed C. gattii isolates induced a more pronounced
inflammatory response compared to other Cryptococcus species and non-clinical C. gattii. This is dependent on TLR4 and
TLR9 as cellular receptors.
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Introduction
The incidence of cryptococcosis has increased dramatically over
the past decades, due in a large part to the global HIV pandemic.
More than 600,000 deaths are estimated to occur each year as a
result of cryptococcal meningoencephalitis [1]. The species C.
neoformans is an opportunistic pathogen mainly affecting immuno-
compromised hosts. In contrast, C. gattii mainly causes disease in
apparently immunocompetent hosts at lower incidence [2,3]. C.
gattii is emerging over the past decade as a pathogen in the Pacific
North-West of North America and has caused a large outbreak on
Vancouver Island [4,5]. This outbreak was mainly caused by a
single, hypervirulent genotype of C. gattii, namely AFLP6A/VGIIa
[6].
Cells of the innate immune system are important for initial
defense against pathogens. Upon contact with pathogens, they
produce pro-inflammatory cytokines such as tumor necrosis factor
(TNF)-a, Interleukin (IL)-1b and IL-6, thereby initiating a specific
adaptive cellular immune response. Anti-inflammatory cytokines
such as IL-1RA are also produced and act as downregulators of
this immune response. Of particular interest for fungal infections,
the cytokines IL-1b and IL-6 in the presence of IL-23 induce the
development of T-helper (Th)17 cells. IL-17 and IL-22, the major
cytokines excreted by Th17 cells, have several pro-inflammatory
functions, one of which is eliciting defensin production by
epithelial cells [7]. Previous studies have shown a crucial role of
Th17 cells in human antifungal defense against mucosal Candida
albicans infections [8–10]; but the role of this particular Th-
lymphocyte subset in anti-cryptococcal defense is not clear.
Which cytokines are released depends on recognition of
microbial components by pattern recognition receptors (PRRs)
on the cells of the innate immune system. Toll-like receptors
(TLRs), a well-defined set of PRRs, are expressed on a variety of
cells and are important mediators of pro-inflammatory cytokine
release. However, their role in mediating cytokine response to
Cryptococcus spp. is being debated [11–15].
Understanding more about the host’s immune response to
different Cryptococcus spp, will provide additional insight into the
pathogenesis of cryptocococcis. We hypothesized that the ability of
C. gattii to cause disease in immunocompetent humans depends on
a distinct innate cytokine response of the host to this emerging
pathogen. Therefore, in the current study we assessed the cytokine
profile of human peripheral blood mononuclear cells (PBMCs) of
healthy individuals, after in vitro stimulation with well-defined heat-
killed isolates of C. gattii, C. neoformans and several hybrids. In
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addition, we investigated the involvement of TLR2, TLR4 and
TLR9 in the pro-inflammatory cytokine response to C. gattii.
Results
Quantitative comparison of cytokine induction between
different Cryptococcus spp.
We determined the concentration of several cytokines produced
by PBMCs upon stimulation with 40 different heat-killed
Cryptococcus species complex isolates in order to elucidate the
cytokine milieu in cryptococcal infection and to explore differences
between the species. In preliminary experiments, we determined
that the minimal concentration of yeasts necessary to induce
cytokine production is 107 microorganisms/mL (data not shown).
There was substantial inter-strain variation in the production of
the pro-inflammatory cytokines IL-1b, TNF-a, IL-6 and the anti-
inflammatory cytokine IL-1Ra. TNF-a and IL-1b were induced in
low amounts (up to 300 pg/mL). Interestingly, production of these
cytokines using a 100-fold lower concentration of Candida albicans
was much higher (data not shown). Results for the induction of T-
cell derived cytokines IL-17 and IL-22 after 7 days of incubation
are shown in Figure 1. It appeared that the studied Cryptococcus
strains induce low amounts of IL-17 but substantial quantities of
IL-22, again with significant inter-strain variation in the produc-
tion of these cytokines.
Figure 2 shows a quantitative comparison of cytokine induction
between two varieties of C. neoformans, C. gattii and various hybrid
isolates. C. gattii was a more potent inducer of the pro-
inflammatory cytokines TNF-a, IL-1b, IL-6 and the T-cell
cytokines IL-17 and IL-22, compared to both C. neoformans
varieties. The different species did not differ with regard to IL-
1Ra induction. Interestingly, the interspecies hybrids containing C.
gattii as a partner of the mating pair induced significantly higher
cytokine production than hybrids which were the result of mating
between the two varieties of C. neoformans. This suggests that an
Figure 1. All forty Cryptococcus strains induce low amounts of IL-17, but high amounts of IL-22. IL-17 and IL-22 production after 7 d by
PBMCs stimulated with RPMI+, either one of 40 different heat-killed Cryptococcus strains [107 microorganisms/mL] or heat-killed Candida albicans [105
microorganisms/mL] is shown respectively. Mean values 6 SE (n = 5) of three independent experiments are presented.
doi:10.1371/journal.pone.0055579.g001
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inheritable factor is responsible for the difference in cytokine
production.
Quantitative comparison of cytokine induction between
environmental and clinical strains within the
Cryptococcus species complex
Sixteen clinical C. gattii isolates (isolates 10,12,14,18,19–21,23–
29,39,40), of which six isolates belonging to the genotype AFLP6/
VGII which was involved in the Vancouver Island outbreak, were
compared to four environmental C. gattii isolates (isolates
13,15,16,17), as well as to four clinical C. neoformans isolates
(isolates 1,4,5,9), with regard to the cytokine induction (Figure 3).
Clinical C. gattii isolates induced significantly higher IL-1b and IL-
6 amounts compared to environmental isolates. Moreover, clinical
C. gattii isolates also induced higher IL-1b, IL-6, TNF-a, IL-1Ra
and IL-17 than clinical C. neoformans isolates. The C. gattii genotype
Figure 2. Comparison of C. gattii isolates and interspecies hybrids with C. neoformans isolates and hybrids between both C.
neoformans varieties. The forty heat-killed Cryptococcus isolates are grouped according to (sub)species. Cytokine production by human PBMCs
after 24 h (IL-1b, TNF-a, IL-6 and IL-1Ra) and 7 d (IL-17 and IL-22) incubation is shown. Mean values (n = 5 to 7) 6 SE of three independent
experiments are presented. *, p 0.01 to 0.05; **, p 0.001 to 0.01; ***, p,0.001. The horizontal line represents the lower detection limit.
doi:10.1371/journal.pone.0055579.g002
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AFLP6/VGII, however, induced no higher amounts of other
cytokines compared to the other clinical C. gattii isolates.
In a different panel of Cuban C. neoformans var grubii isolates,
comparison of clinical with environmental isolates showed no
significant difference (P value for IL-6 and IL-22: 0.19 and 0.07
respectively) in cytokine production (Figure 4). The induction of
low levels of cytokines by C. neoformans var grubii isolates, as seen in
the panel of 40 isolates, was confirmed.
Involvement of different Pattern Recognition Receptors
(PRRs) in cytokine production induced by C. gattii
To assess which PRRs are involved in recognizing C. gattii, we
performed experiments in which PBMCs were preincubated for
Figure 3. Comparison of cytokine production by PBMCs induced by clinical or environmental cryptococcal isolates. Heat killed clinical
isolates of C. gattii are compared to environmental C. gattii isolates and to clinical isolates of C. neoformans. The clinical isolates of C. gattii genotype
AFLP6/VGII are depicted separately. Mean values (n = 5 to 7)6 SE values of three independent experiments are presented. *, p 0.01 to 0.05; **, p 0.001
to 0.01; ***, p,0.001. The horizontal line represents the lower detection limit.
doi:10.1371/journal.pone.0055579.g003
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one hour with specific PRR blocking reagents prior to stimulation
with heat-killed C. gattii or, as a control, culture medium.
Stimulation with culture medium showed undetectable levels for
all cytokines (not shown). Blocking TLR2 had no effect on
cytokine production by C. gattii, whereas this antibody significantly
inhibited IL-1beta production after stimulation with Pam3cys (a
known TLR-2 ligand) (Figure S1). Blocking TLR4 significantly
diminished IL-1b induction by C. gattii, with a trend towards
significance for TNF-a (P=0.06). Interestingly, blocking TLR9 led
to significantly higher concentrations of IL-1b induced by C. gattii
compared to its control, and a trend towards significance (P=0.06)
was found for TNF-a. Blocking TLR9 had a negative effect
(P=0.03) on IL-17 production induced by C. gattii (Figure 5 for the
effect on IL-1b and IL-17).
We performed these experiments also with C. neoformans var
grubii (H99). The latter isolate did not elicit a substantial pro-
inflammatory cytokine response in PBMCs, as shown in previous
experiments with other strains. Moreover, we did not observe an
increase in IL-1b and TNF-a production induced by C. neoformans
var grubii when blocking TLR9 (results not shown).
Discussion
In the present study we investigated the in-vitro cytokine
production of human PBMCs incubated with 40 different heat-
killed isolates of the Cryptococcus neoformans species complex. We
demonstrate that C. gattii isolates induces higher concentrations of
pro-inflammatory and Th17/22 cytokines compared to C. neofor-
mans var. neoformans and C. neoformans var. grubii. In addition, we
found that clinical C. gattii isolates were able to induce higher
amounts of cytokines than environmental isolates or clinical C.
neoformans isolates. Furthermore, we demonstrated a contribution
of TLR4 and TLR9, but no role for TLR2, in the host’s cytokine
response to C. gattii.
Our results indicate that Cryptococcus neoformans species complex
seems to induce mainly a IL-22 response, with surprisingly low IL-
17 production. This argues against a Th17 response to crypto-
coccal infection as we hypothesized, but rather to an exclusively
IL-22 producing subset of Th-cells. A candidate for this areTh22
cells. These cells have not been found in mice so far; therefore only
studies with human cells can be used to determine the role of this
Th subset in host defense against cryptococcal infections. The aryl
hydrocarbon receptor is identified to mediate IL-22 production
without mediating IL-17 and seems to be critical in differentiation
of naı¨ve T cells to Th22 cells [16]. IL-22 is a unique cytokine in
that it acts only on non-immune cells including keratinocytes,
myofibroblasts and epithelial cells in tissues of the respiratory
Figure 4. Comparison of cytokine production by PBMCs induced by clinical or environmental C. neoformans var grubii isolates.
Cytokine production by human PBMCs after 24 h (IL-6) and 7 d (IL-22) incubation with heat-killed isolates is shown. Mean values (n = 7) 6 SE of three
independent experiments are presented. ns, not significant.
doi:10.1371/journal.pone.0055579.g004
Figure 5. The role of TLR2, TLR4 and TLR9 in IL-1b and IL-17
induction by C. gattii. Cytokine production by human PBMCs
preincubated for one hour with culture medium (white bar) or PRR
blocking reagents (dark gray bars) or their control (light gray bar) prior
to stimulation with heat-killed C. gattii (strain B5742) [107/ml]. IL-1b is
determined after 24 h incubation, IL-17 is determined after 7 d
incubation. Mean values 6 SE of eight individuals in 4 independent
experiments (IL-17) or six individuals in 5 independent experiments (IL-
1b) (with exclusion of additional four individuals with undetectable
cytokine induction by C. gattii) are presented. *, p 0.01 to 0.05. The
horizontal line represents the lower detection limit.
doi:10.1371/journal.pone.0055579.g005
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Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species
ystem, skin and digestive tract, which express receptors for this
cytokine [17]. IL-22 promotes the production of antimicrobial
agents called b-defensins by epithelial cells and serves in mucosal
defenses against pathogens. It is tempting to speculate that IL-22 is
important for the initial anti-cryptococcal defense because it has a
function at the place of entrance of this yeast, namely the epithelial
surface of the respiratory system. However, to confirm these
speculations, further research should be attempted to identify the
role of IL-22 and Th22 cells in clinical patients with cryptococ-
cosis.
Higher amounts of the pro-inflammatory cytokines IL-1b,
TNFa, IL-6, IL-17 and IL-22 by human PBMCs were induced by
C. gattii compared to both varieties of C. neoformans, indicating that
certain (virulence) factors of C. gattii are responsible for a more
pronounced inflammatory reaction. This finding is strengthened as
the same trend was seen in the hybrids containing C. gattii as a
partner of the mating pair. Therefore we suggest that an
inheritable factor is responsible for the difference in cytokine
production.
Our finding that C. gattii induces a more powerful pro-
inflammatory response aimed at more efficient defense against
the pathogen is supported by the work of Ngamskulrungroj et al
[18]. The authors compared the pathogenesis of the two
Cryptococcus species in mice using an inhalation model and they
found that in naive mice, C. gattii grew significantly slower in blood
than C. neoformans. Infection with C. gattii was restricted to the
lungs, while C. neoformans dissimenated to the brain causing
meningoencephalitis. When mice were infected intravenously with
low inoculums of yeast, C. neoformans was more virulent than C.
gattii. Apparently, in this murine model the host’s peripheral
immune cells are able to clear C. gattii infection more efficiently,
probably by a more adequate cytokine response. However, in
humans, C. gattii species seem to be more virulent, as they are able
to cause disease in apparently immunocompetent hosts. Large-
scale environmental colonization for C. gattii was found during the
Vancouver Island outbreak, whereas only relatively few people
developed overt disease [6]. It can be hypothesized that a specific
defect in the innate immune system of affected hosts predisposes
them to infection with C. gattii. Furthermore, other factors such as
intracellular survival, outgrowth or dissemination may also be
important for virulence of C. gattii, independent of the initial pro-
inflammatory cytokine response [19]. In our experiments we used
PBMCs of healthy individuals who are expected to have an
adequate immune response to C. gattii. These cells reflect the
second line of defense when the yeast enters the host after
inhalation. Our results showed a less optimal recognition and
initial cytokine induction of C. neoformans var. grubii and var.
neoformans, which suggests that in a host with inadequate cellular
immunity this less optimal innate cytokine response leads more
easily to infection with C. neoformans var. grubii and var. neoformans
compared to C. gattii. Clinical data support this, since infections of
immunocompromised hosts with C. neoformans var grubii is far more
prevalent than infection with C. gattii [20].
A potential limitation of our study is that heat-killed instead of
live cryptococci were used. However, at the temperatures used for
heat-killing, most virulence factors (capsular polysaccharide,
lipoproteins) are retained. Moreover, in number of previous
studies, heat-killed cryptococci were used and significant inflam-
matory responses specific for capsulated and unencapsulated
cryptococci were found [21,22]. One study investigated lympho-
cyte proliferation after stimulation with live and heat-killed
cryptococci and found no difference [23]. Thus, we feel that in
this study, the use of heat-killed crytococci is justified.
Our experiments using a virulent C. gattii strain in stimulating
PBMCs that were pre-incubated with specific PRR-blocking
reagents indicate a role for TLR4 and TLR9 in recognizing
Cryptococcus and subsequently modulation of the pro-inflammatory
cytokine response. TLR4 seemed to be involved in mounting a
pro-inflammatory cytokine response. Previous studies suggest that
glucuronoxylomannan, the major capsular component [15] or
other cryptococcal cell wall elements [24] are involved in binding
to TLR4. In this study we did not design experiments in order to
identify which cell wall components are involved in the initial
cytokine response. Cytokine responses appeared to be independent
of TLR2 recognition, since blocking of this receptor had no effect
on cytokine concentrations. This contrasted with what is found in
mice by Biondo et al. who demonstrated a key role of TLR2, but
not of TLR4 [12]. Other studies, however, found no major role for
TLR2 in survival of cryptococcal infections in a murine model
[11,13].
Based on our results, a special role in Cryptococcus recognition
can be ascribed to TLR9. Unmethylated CpG-rich DNA is the
best-known ligand for this receptor. Nakamura et al. have shown
that TLR9 recognizes cryptococcal DNA [14]. We found that this
receptor mediates IL-17 production, without any effect on IL-22.
Conversely, blockade of TLR9 resulted in increased IL-1b
Table 2. Details of 11 additional C. neoformans var grubii isolates, arranged by Microsatellite Complex (MC) [29].
Number in
experiment Isolate Other specification Species Serotype MC Origin Reference/Source
I 37-07-17 Cuba 617-05 C. neoformans var grubii A MC1 Clinical Illnait Zaragozi et al., 2010
II 44-08-52 Cuba CA 1-5 C. neoformans var grubii A MC1 Environmental Illnait Zaragozi et al., 2010
III 37-07-03 Cuba 24-2b C. neoformans var grubii A MC1 Environmental Illnait Zaragozi et al., 2010
IV 36-10-01 Cuba CH-2 C. neoformans var grubii A MC2 Environmental Illnait Zaragozi et al., 2010
V 44-08-16 Cuba 569-06 C. neoformans var grubii A MC2 Clinical Illnait Zaragozi et al., 2010
VI 36-09-16 Cuba 225-99 C. neoformans var grubii A MC2 Clinical Illnait Zaragozi et al., 2010
VII 36-09-32 Cuba 227-01 C. neoformans var grubii A MC3 Clinical Illnait Zaragozi et al., 2010
VIII 36-09-57 Cuba 0119 C. neoformans var grubii A MC3 Clinical Illnait Zaragozi et al., 2010
IX 36-10-46 Cuba 30-2D C. neoformans var grubii A MC3 Environmental Illnait Zaragozi et al., 2010
X 36-10-56 Cuba 315-01 C. neoformans var grubii A MC4 Clinical Illnait Zaragozi et al., 2010
XI 36-09-53 Cuba 098 C. neoformans var grubii A MC6 Clinical Illnait Zaragozi et al., 2010
doi:10.1371/journal.pone.0055579.t002
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production in response to C. gattii. The latter effect opposes the
possible effect of TLR4. However, a specific combination of PRRs
that bind available fungal PAMPs lead to pathways that interact
with each other because of a limited set of shared adaptor molecules
and transcription factors, and converge to a tailored response [25].
Likely, TLR9 and TLR4 work together in recognizing Cryptococcus
and their signaling pathways interact downstream. Interestingly, we
did not see TLR9 dependent negative modulation of C. neoformans
var. grubii, indicating that the TLR9 dependent recognition of
Cryptococcus is species-dependent. Negative modulation of immune
responses to fungal pathogens mediated by TLR9 have been
observed in other studies [26]. As the host’s response to C. gattii relies
on an initial pro-inflammatory cytokine response more than in C.
neoformans infections, it can be speculated that susceptibility to C.
gattii is influenced by subtle TLR polymorphisms and not necessarily
by a defective adaptive immune response.
In the present study we investigated the in-vitro cytokine
production of human PBMCs incubated with 40 different heat-
killed isolates of Cryptococcus neoformans species complex. We
demonstrated that isolates of C. gattii induce higher concentrations
of the pro-inflammatory cytokines IL-1b, TNF-a and IL-6 and the
Th17/22 cytokines IL-17 and IL-22 compared to C. neoformans var
neoformans and C. neoformans var grubii. In addition, we found that
clinical C. gattii isolates induced higher amounts of IL-1beta and
IL-6 than environmental isolates. Furthermore, we demonstrated
a likely contribution of TLR4 and TLR9, but no role for TLR2, in
the host’s cytokine response to C. gattii. In conclusion, clinical C.
gattii isolates induced a more pronounced inflammatory cytokine
response compared to other Cryptococcus species and non-clinical C.
gattii that is dependent on TLR4 and TLR9 as cellular receptors.
Materials and Methods
Cryptococcal strains
Forty cryptococcal isolates from the CBS Fungal Biodiversity
Centre (Utrecht, the Netherlands) were used in this study. These
isolates were obtained from laboratory, clinical, environmental
and veterinary sources. A detailed overview of the origin, sero- and
AFLP genotype of these isolates is provided in Table 1. Twenty-
three isolates were identified as C. gattii, 5 C. neoformans var.
neoformans, 5 C. neoformans var. grubii and 7 hybrids, 3 of which were
interspecies hybrids between C. gattii and C. neoformans var.
neoformans and 4 hybrids between both C. neoformans varieties. In
addition, 11 Cuban isolates were used in separate experiments, all
identified as C. neoformans var grubii (Table 2).
Prior to the experiments, the strains were freshly grown on
Sabouraud dextrose agar plates. A suspension of each strain was
prepared in sterile phosphate buffered saline (PBS), heat-killed
overnight at 56uC and quantified by spectrophotometry at a
wavelength of 530 nm. The suspensions were checked for fungal
and bacterial growth on a Sabouraud dextrose agar plate and a
blood agar plate respectively. No growth was observed after 5
days. All strains were stored at 4uC until used.
Candida strain
Heat-killed Candida albicans ATCC MYA-3573 (UC 820), a well
described clinical isolate, suspended in sterile PBS, was used as a
positive control.
Reagents and antibodies
Bartonella LPS, a penta-acylated LPS which is an antagonist of
TLR4-dependent signaling, was obtained as previously described
[27]. An anti-TLR2 monoclonal antibody from eBioscience (San
Diego, CA, USA) was used, and an irrelevant isotype-matched
murine IgG1 k isotype (Biolegend, San Diego, CA, USA) as
control. TLR9 inhibitory oligonucleotides ODN TTAGGG (anti
TLR9) [28] and its negative control were obtained from
InvivoGen (San Diego, CA, USA).
Isolation and stimulation of PBMCs
Human peripheral blood mononuclear cells (PBMCs) were
collected from buffy coats of healthy donors after written informed
consent had been obtained. PBMCs were isolated using density
gradient centrifugation on Ficoll-Hypaque (GE Healthcare,
Uppsala, Sweden). The cells from the interphase were aspirated
and washed three times in sterile PBS and resuspended in culture
medium RPMI 1640 Dutch modification (Sigma-Alderich, St
Louis, MO, USA) supplemented with 1% L-glutamine, 1%
pyruvate and 1% gentamicin. Cells were counted in a Coulter
Counter ZH (Beckman Coulter, Fullerton, CA, USA), and adjusted
to 56106 cells/ml. Thereafter, they were incubated in a round-
bottom 96-wells plate (volume 200 ml/well) at 37uC and 5% CO2
with either one of the heat-killed cryptococcal strains (final
concentration of 107/ml), or heat-killed C. albicans (final concen-
tration of 105/mL, which is known to induce substantial amounts
of cytokines) or culture medium alone. After 24 hours or 7 days (in
the presence of 10% human pool serum) supernatants were
collected and stored at 220uC until being assayed.
In a subsequent experiment, PBMCs were preincubated for one
hour with inhibitory ligand for TLR4 (Bartonella quintana LPS
(200 ng/ml) or culture medium as control, anti-TLR2 or control
antibody (10 mg/ml), TLR9 inhibitory oligonucleotides and its
negative control (25 mg/ml). After preincubation, C. gattii B5742,
isolate 27 in the previous experiment, or specific TLR ligands were
added, such as Pam3cys or E.coli LPS (10 mg/ml and 10 ng/ml
respectively] and PBMCs were incubated as described.
Cytokine assays
Tumor necrosis factor-a (TNF-a), Interleukin-1b (IL-1b), IL-6
and IL-1 receptor antagonist (IL-1Ra) concentrations were deter-
mined from the culture supernatant after 24 hours of incubation
using commercially available ELISA kits (TNF-a, IL-1b and IL-
1Ra: R&D systems, Minneapolis, MN, USA. IL-6: Sanquin,Am-
sterdam, the Netherlands) according to the manufacturer’s instruc-
tions. T-cell derived cytokines IL-17 and IL-22 concentrations were
determined in the supernatant after 7 days of incubation using
ELISA kits (R&D systems). Lower detection limits were 78 pg/ml,
39 pg/ml, 15 pg/ml, 200 pg/ml, 40 pg/ml and 78 pg/ml for
TNF-a, IL-1b, IL-6, IL-1Ra, IL-17 and IL-22 respectively.
Ethics statement
Written informed consent of healthy donors was provided. The
study was approved by the Medical Ethical Committee Arnhem-
Nijmegen in the Netherlands.
Statistical analysis
Results from at least three different experiments with a range of
5–7 donors were pooled and analyzed using GraphPad Prism 5
software (GraphPad, San Diego, CA). Data are given as mean 6
SE. The Mann-Whitney U-test for unpaired, nonparametrical
data was used to compare differences in cytokine production
between two groups. The Kruskal-Wallis test with Dunn’s multiple
comparison test was used when more than two groups were
compared. The Wilcoxon matched-pairs signed rank test was used
to analyze differences in cytokine production between inhibitors
and their controls in the inhibition experiments. The level of
significance was set at p,0.05.
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Supporting Information
Figure S1 IL-1b induction by Pam3cys and E. coli LPS
after blocking of TLR2 and TLR4 respectively. IL-1b
production by human PBMCs is shown (A) induced by pam3cys
[10 mg/ml] after preincubated for one hour with anti-TLR2 or
control antibody [10 mg/ml] and (B) by E. coli LPS [10 ng/ml]
after preincubation for one hour with TLR4 antagonist Bartonella
quintana LPS [200 ng/ml] or culture medium. Mean values
(n = 10) 6 SE of five independent experiments are presented.
(TIF)
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Chapter 12
Currently the genus Cryptococcus includes about 100 species but the C. neoformans/C. 
gattii species complex is most prominently associated with human disease (Fonseca et 
al., 2011). The expanding knowledge of these yeasts has allowed to identify the existence 
of two species comprising seven serotypes and different genetic groups: C. neoformans 
has been segregated into C. neoformans var. grubii (serotype A; AFLP1/VNI, AFLP1A/
VNB/VNII, and AFLP1B/VNII), C. neoformans var. neoformans (serotype D; AFLP2/
VNIV) and the intervarietal serotype C. neoformans AD (AFLP3/VNIII); the other 
species, C. gattii, has been divided into five distinct genotypes (AFLP4/VGI, AFLP5/
VGIII, AFLP6/VGII, AFLP7/VGIV, and AFLP10/VGIV). While serotype B strains are 
found in each of the five C. gattii AFLP genotypes, serotype C strains are restricted to 
genotypes AFLP5/VGIII and AFLP7/VGIV. It was found that C. gattii and C. neoformans 
can also form interspecies hybrids: genotype AFLP8 (C. neoformans var. neoformans 
AFLP2/VNIII serotype D × C. gattii AFLP4/VGI serotype B) and AFLP9 (C. neoformans 
var. grubii AFLP1/VNI serotype A × C. gattii AFLP4/VGI serotype B) (Bovers et al., 
2006; Bovers et al., 2008a; Bovers et al., 2008b; Meyer et al., 2009; Ngamskulrungroj et 
al., 2009; Springer and Chaturvedi, 2010). These aspects, although basic, are vital for 
understanding the disease. 
The natural history of infection due to the C. neoformans/C. gattii species complex has 
been well documented. Although there are occasional reports of cases that took up to 
22 years of evolution, it leads inexorably to death if appropriate and timely treatment 
is not administrated. Once symptoms emerge, 86% of the patients will die during 
the first year of which 70% during the first three months even when properly treated 
(Casadevall and Perfect, 1998, Friedman et al., 2005). These alarming statistics about 
the poor prognosis of the disease become even more worrisome with the knowledge 
that the estimated annual incidence exceeds one million cases (Armstrong et al., 2014; 
Park et al., 2009). 
This background was enough motivation to write this thesis, compilation of eleven 
publications grouped in three main parts. This last chapter contains a comprehensive 
view of the work included in the thesis: 1. molecular characterization of clinical and 
environmental C. neoformans species complex isolates from Cuba and The Netherlands, 
2. the antifungal susceptibility of Cuban and worldwide cryptococcal strains, 3. the 
analysis of C. neoformans/C. gattii species complex isolated from humans, animal and 
the environment and 4. attempts to elucidate some pathogenic differences between C. 
neoformans and C. gattii.
Molecular characterization of clinical and environmental C. neoformans species 
complex isolated from Cuba and the Netherlands
So far, attempts to characterize Cuban Cryptococcus isolates were restricted to 
conventional and serological typing studies by means of the commercial kit Crypto 
Check (Iatron Laboratories, Tokyo, Japan) in a limited number of specimens. The 
collaborative work between Instituto Pedro Kouri (IPK), Canisius Wilhelmina 
Ziekenhuis (CWZ) and Centraalbureau voor Schimmelcultures (CBS) allowed a step 
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forward since all specimens of this genus in the collection at the IPK in Havana were re-
identified and their genotypic patterns were defined using high resolution techniques. 
These criteria were used for comparative analysis of isolates according to their origin 
(clinical versus environmental) and to assess the isolates of patients with recurrent 
neurocryptococcosis. The re-identification by AFLP and sequencing D1/D2 and 
ITS1/5.8S/ITS2 fragments allowed confirmation of the dominance of C. neoformans 
var. grubii in Cuba. The mating-type of Cuban C. neoformans var. grubii isolates was 
determined for the first time and results showed that all isolates were MATα (Illnait-
Zaragozí et al., 2010). This result coincides with the current international literature. 
It is generally recognized that the C. neoformans/C. gattii species complex can exist as 
both the yeast and filamentous phase without being regarded as a dimorphic pathogen. 
Hyphae are not considered essential for virulence. The role of these infectious particles 
remains unclear; they are either the dried yeasts or the sexual basidiospores. However, 
the mating-type analysis in these organisms is important since it has been shown that 
MATα cells, present in both clinical and environmental samples in a greater proportion, 
are associated with increased virulence and are prone to spread to the CNS. Molecular 
analyzes indicate that genes involved in sexual reproduction of C. neoformans/C. gattii 
species complex are closely related to those encoding for virulence markers (capsular 
polysaccharide, melanin synthesis, thermotolerance, etc) (Litvintseva and Mitchell, 
2009; Lin, 2009; Metin et al., 2010; del Poeta and Casadevall, 2011). 
AFLP has been well standardized (Boekhout et al., 2001; Meyer et al., 2009). It was used for 
the initial characterization of all isolates (190 from Cuba and 300 from the Netherlands) 
and as reference in the evaluation of a set of nine microsatellite markers selected from 
the nucleotide sequence of the type strain H99. The analysis of Cuban clinical and 
environmental C. neoformans var. grubii suggests the existence of alternative sources of 
infection other than pigeon droppings. Clinical Cuban C. neoformans complex isolates 
showed a high genetic diversity in 19 of the 20 microsatellite clusters. In contrast, 
specimens obtained from pigeons droppings showed a low genetic variability (80% of 
them gathered in two of the 20 clusters) (Illnait-Zaragozí et al., 2010). There are few 
publications related to this topic. They generally show a close relationship between 
clinical and environmental genotypes (Boekhout et al., 2001; Trilles et al., 2003). 
Findings of other investigators are in line with our conclusions (Zhu et al., 2010).
Although studies suggests that serotype D is the most prevalent in Europe (Viviani et 
al., 2006), the majority of the Dutch studied isolates were serotype A and MATα, just 
as in Cuba, and microsatellite typing revealed a high genetic diversity among isolates 
belonging to this serotype. The genetic diversity of the Dutch clinical C. neoformans 
var. grubii population was even slightly higher than that observed in Cuba with 196 
genotypes among 259 studied isolates. This result could be due the time span of the 
study was 30 years (which is longer than the 20-year time frame of the Cuban study). The 
composition of the Dutch population, characterized by extensive immigration, which 
includes people from the former overseas colonies of Surinam, Netherlands Antilles, 
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and Indonesia, as well as immigrants from northern Africa and eastern Europe, may be 
another explanation for these surprising results (Hagen et al., 2012 (a)). 
When multiple isolates (sampled on the same day but from different clinical specimens 
or at different time points) from 38 Dutch and 7 Cuban patients were analyzed, 
microsatellite profiles of most of them were found to be identical. However, some 
Dutch patients and 70% of the Cuban patients were found to be infected by multiple 
C. neoformans isolates including interspecies hybrid isolates of C. neoformans var. 
neoformans and C. gattii (genotype AFLP8) (Illnait-Zaragozí et al., 2010; Hagen et al., 2012 
(a)). These findings confirm the broad genetic variability among clinical isolates from 
both countries and urges to hypothesize about the possible mechanism of recurrence 
of this fungal pathogen due to multiple genotypes. Acquisition of several genotypes at 
the initial infection or during the course of the disease. Previous studies have shown 
the ubiquity of the C. neoformans/C. gattii species complex that may coexist in the 
same ecological niche and, in turn, may result in simultaneous infection by different 
isolates (Lazera et al., 2000; Mandal et al., 2005; Kidd et al., 2007). Another mechanism 
that can explain this observation is a possible microevolution process since it is known 
that microorganisms constantly adjust and modulate their behavior in order to survive 
in different environments, thereby generating diversity in clonal populations. All these 
aspects together may stimulate the selection of certain variants which favors chronic or 
recurrent infection (Jain and Fries, 2008).
The use of selected markers for microsatellite typing has a high discriminatory power and 
serves as a technique of genetic characterization (de Valk et al., 2009; Illnait-Zaragozí et 
al., 2010; Hagen et al., 2012 (a)). High resolution technologies such as MLST, are currently 
available and have been proposed as reference method in genotypic characterization 
of the C. neoformans/C. gattii complex. However, its complex implementation that 
requires the sequencing of at least seven loci, makes it impractical for most laboratories 
(Meyer et al., 2009).
In conclusion we demonstrated for the first time that the prevalence of C. neoformans 
var. grubii MATα isolates in Cuba and its wide distribution in both clinical 
and environmental samples. The present studies provide new insights into the 
pathogenesis and epidemiology of cryptococcal disease and its causative agent. The 
genetic segregation between clinical and environmental isolates suggests the presence 
of additional hitherto unstudied niches of C. neoformans var. grubii. It can also be 
used to identify the recurrence or persistence of a cryptococcal infection caused by co-
infection with different genotypes. In this sense, the panel of selected markers showed 
a high discriminatory power and the microsatellite typing revealed its superiority as 
genetic characterization technique with respect to AFLP for molecular epidemiology 
studies for C. neoformans var. grubii. To expand these studies the development of in 
vitro and in vivo pathogenicity experiments will contribute significantly to corroborate 
the results.
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Antifungal susceptibility of Cuban and worldwide cryptococcal strains
During the last decades the incidence of fungal infections has raised, which has favored 
the frequent use of systemic antifungals and the occurrence of isolates with decreased 
susceptibility or even resistance to antifungal drugs (Vandenbossche et al., 2002; 
Cuenca-Estrella, 2010). Most of the studied C. neoformans species complex strains 
from Cuba and the Nederlands showed quite uniform patterns of susceptibility to the 
tested antifungal agents. Both species, regardless to their origin, were susceptible to 
amphotericin B, itraconazole, voriconazole, posaconazole, and isavuconazole. When 
all of the isolates were considered overall, the lowest MICs ranges were found for 
isavuconazole, voriconazole, and posaconazole while the widest ranges and highest 
MICs were seen for flucytosine and fluconazole (Illnait-Zaragozí et al., 2008; Illnait-
Zaragozí et al., 2010; Hagen et al., 2012 (a)). 
It is becoming evident that differences exist between genetic groups among C. 
neoformans and C. gattii species. The current study shows that there is a trend toward 
lower MIC values of amphotericin B for C. neoformans genotype AFLP2 isolates, similarly 
to that observed in Croatian and Spanish studies (Guinea et al., 2010; Mlinaric-Missoni 
et al., 2011). On the other hand, C. gattii strains belonging to AFLP6 had significantly 
(P ≤ 0.05) higher geometric mean MICs than strains belonging to genotype AFLP4 for 
six of the antifungal compounds tested. However, these genotypes had almost identical 
geometric mean MICs of posaconazole. These results are comparable with those for a 
recently reported collection of 43 North American C. gattii isolates (Iqbal et al., 2010). 
The development of new antifungal drugs, such as the novel triazoles and the 
reported increase in antifungal resistance, highlight the importance of monitoring the 
susceptibility profiles of clinical isolates. Most of the studied C. neoformans and C. 
gattii isolates, cultured either at the same time from different body sites or at different 
time points generally showed the same pattern of MIC values and were not resistant 
for the seven antifungal compounds tested. However, in serial isolates from two Cuban 
and two Dutch patients, MICs values of triazoles increased 4-5 log2 dilutions over time. 
Failures could be attributed to the excessive use of this agent, as well as to the use of 
suboptimal doses for long periods of time, especially among AIDS patients (Govender 
et al., 2011).
Its excellent pharmacokinetic and toxicity profile were the bases for the extensive 
use of fluconazole in some groups of patients. This has undoubtedly resulted in an 
increase of fluconazole-resistant strains of C. neoformans/C. gattii species complex as 
illustrated by case reports on therapeutic failures in AIDS patients who undergo long-
term maintenance therapy (Pfaller et al., 2004; Cuenca-Estrella et al., 2010). In line with 
previous studies, the current work corroborated that fluconazole and flucytosine have 
the lowest levels of activity against C. neoformans and C. gattii isolates. Among the 
studied isolates, environmental isolates seem to be less susceptible to fluconazole and 
flucytosine than the clinical ones, in harmony with previous reports (Brandt et al., 2001; 
Pfaller et al., 2004; Souza et al., 2005). Isolates obtained from HIV-negative patients 
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showed lower MIC90s compared to those from AIDS patients (Illnait-Zaragozí et al., 
2008; Illnait-Zaragozí et al., 2010; Hagen et al., 2012 (a)). 
Azole resistance has been primarily reported in patients with systemic mycosis who 
received long-term azole therapy. Microorganisms may develop resistance through three 
major pathways: (i) reduction of the accumulation of the drug within the fungal cell, 
(ii) decrease of the affinity of the drug to its target, and (iii) change in the metabolism 
to counterbalance the drug effect (Cuenca-Estrella, 2010; Vandeputte et al., 2012). 
In some highly resistant isolates, several mechanisms appear to act simultaneously. 
The increasing resistance during antifungal treatment has been attributed to the 
sequential acquisition of different mechanisms (Cannon et al., 2009). It is also known 
that some isolates may carry heteroresistance, especially against fluconazole; particular 
subpopulations within each colony display a greater tolerance to high concentrations 
of antifungal. This event is independent of prior exposure to antifungals and has been 
described for both species of the C. neoformans/C. gattii complex (Sionov et al., 2009; 
Varma and Kwon-Chung, 2010). 
Additionally, for bacteria it is known that significant risks are involved in the 
environmental route of development of resistance. In fungi, the relation between the 
use of antimicrobial agents outside human medicine and the development of resistance 
to clinically used compounds has been shown. Similarly, the widespread use of azole-
based fungicides, herbicides, and plant growth regulators is a potential risk factor for 
the development of resistance in human medical practice (Seifert et al., 2007). Although 
the hypothesis of a fungicide-driven route of azole resistance development in fungi is 
controversial, there is some evidence that such a route may exist. Therefore, regular 
surveillance of cultures as well as in vitro susceptibility testing of human isolates is 
strongly recommended (Snelders et al., 2012).
Each of the different classes of antifungals has limitations in comparison with an ideal 
agent. The polyenes are limited by their toxicity; echinocandins are only available 
for intravenous therapy and lack activity against Cryptococcus as well as endemic 
mycoses, and azoles are limited by their drug-drug interactions and development of 
resistance. These limitations promote searching to identify new targets of antifungal 
drugs (Cuenca-Estrella et al., 2010). Several published antifungal susceptibility studies, 
including this thesis, indicate that the newer azoles have excellent potency against 
each isolate and all AFLP genotypes, inclusive of those with reduced fluconazole 
susceptibilities. Both voriconazole and posaconazole show strong antifungal activity 
against all Cryptococcus strains, while isavuconazole displays even lower MIC values 
(Illnait-Zaragozí et al., 2008; Illnait-Zaragozí et al., 2010; Hagen et al., 2012). The latter, 
a water-soluble triazole suitable for oral and intravenous administration, has shown in 
vitro a broad spectrum of activity against all major opportunistic and true pathogenic 
fungi. Its pharmacokinetic and pharmacodynamic (PK/PD) characteristics, are slow 
elimination, low plasma clearance, and extensive tissue distribution (Odds et al., 2006; 
Seifert et al., 2007; Schmitt-Hoffmann et al., 2006(a); Schmitt-Hoffmann et al., 2006(b)), 
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which makes isavuconazole a promising candidate to replace the current drugs, given 
their potential side effects. 
The main goal of susceptibility testing is to predict with some reliability the clinical 
outcome when an infected patient is treated with the specific agent evaluated. This 
in vitro susceptibility is expressed as the clinical breakpoints (CBPs). Such values are 
based on the correlation of in vitro data with clinical and microbiological outcomes 
in order to differentiate between a treatable or non-treatable organism (Dalhoff et 
al., 2009). So far, a major concern has been the lack of CBPs of any antifungal agent 
for both C. neoformans and C. gattii infections due to the paucity of data on PK/PD 
and clinical outcomes in comparison with measured MICs. Species identification and 
antifungal susceptibility testing emphasize the utility of wild type (WT) cutoffs as a 
practical tool to detect triazole resistance among Cryptococcus isolates. Recently the 
epidemiologic cutoff values (ECVs) of amphotericin B (0.5 to 1 µg/ml) and flucytosine 
(4 to 16 µg/ml) versus both species were established (Espinel-Ingroff, et al., 2012 (a)). 
With these data it has become possible to relate the ECVs of these agents to those of 
fluconazole (8 to 32 µg/ml), itraconazole (0.25 to 1 µg/ml), posaconazole (0.25 to 0.5 
µg/ml) and voriconazole (0.12 to 0.25 µg/ml). Proposed ECVs for the C. neoformans/C. 
gattii species complex appear to be species- and molecular type-specific, but these 
differences are mostly within one dilution. Further investigations should determine the 
relationship between molecular mechanisms of triazole resistance and the proposed 
non-WT values (Espinel-Ingroff, et al., 2012 (b)).
In conclusion, this thesis offers the largest study of antifungal susceptibility on Cuban 
isolates where the MIC values of seven antifungal agents used in first-line treatment 
were compared with a substantial representation of isolates collected over 25 years. 
Data obtained from the Cuban strains were included in the study of a large collection 
of C. gattii which helped to establish ECVs for this species complex against the major 
triazoles. These promising results still need to be correlated with clinical outcome. 
Continuous surveillance should corroborate and expand the information provided in 
the present study. 
Analysis of C. neoformans/C. gattii species complex isolated from humans, 
animal and the environment in Cuba and pathogenic differences between C. 
neoformans and C. gattii isolates
In Cuba, cryptococcosis was first reported in the early 1950s (Curbelo, 1951). Since then 
sporadic cases were associated with alcoholism, organ transplants and immunological 
disorders. In 1986 with the beginning of the AIDS epidemic in Cuba, the amount of 
individuals suffering from this mycosis had increased with an average of eight new 
cases each year (Illnait-Zaragozi et al., 2010). This still might be an underrepresentation 
since a retrospective autopsy study of HIV/AIDS patients performed during a 10-year 
period showed that disseminated or central nervous system cryptococcosis was a 
serious disorder in 29% of the cases (Arteaga et al., 1998). These results concur with 
those reported by Cox et al. who conducted a six month prospective study to describe 
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and compare the clinical and autopsy-verified causes of death in hospitalized HIV-
infected and HIV-uninfected patients in Uganda. The study showed that cryptococcal 
infection was after tuberculosis the most frequent cause of death reaching more than 
20% among the 53 autopsies performed (Cox et al., 2012).
As shown before,  epidemiological studies on clinical- and pigeon droppings isolates, 
carried out in different regions in Cuba, revealed that most of were C. neoformans var. 
grubii. It was also established that only few microsatellite genotypes from environmental 
isolates were linked to genotypes from human isolates, suggesting that some clinical 
isolates may originate from additional ecological niche(s) (Illnait-Zaragozi et al., 2010). 
At present, it has become clear that Cryptococcus isolates, in addition to bird excreta 
(Kielstein et al., 2000) are present on trees and cacti (Chowdhary et al., 2012; Hagen et 
al., 2010 (b)). Hence, a search for the occurrence of this yeast in relation to different 
species of trees and cacti in Havana, Cuba was carried out.
A total of 662 samples were collected from 331 trees and cacti. Initial selection of the 
isolates was done by conventional techniques. They were further characterized using 
a combination of AFLP and DNA sequence analysis. Identification by conventional 
methods yielded 121 C. neoformans and 61 C. gattii isolates while molecular analyses 
showed that none of these isolates was C. gattii and only one proved to be C. neoformans 
var. grubii MATα. A total of 27 different other species were identified, and the most 
prevalent being C. heveanensis (33%). Moreover, 65 unidentifiable isolates were 
segregated into ten potentially novel species (Illnait-Zaragozí et al., 2012). This finding 
is in strong contrast with India, for example, where C. gattii can be isolated from up to 
50% of investigated trees (Chowdhary et al., 2013).
Analyzing the structure of the environmental population of C. neoformans and C. gattii 
can significantly increase our knowledge of their ecology, evolution and epidemiology 
(Hagen et al., 2010 (b)). However, the low prevalence of this yeast found on the 
studied plants does not allow a valid epidemiological evaluation and environmental 
niches responsible for human cryptococcal infections in Cuba remain to be identified. 
Additionally, these results suggest that conventional methods have a low specificity for 
the C. neoformans/C. gattii species complex and molecular analyses need to be applied 
to confirm identification of isolates from environmental sources.
Although there was no evidence for the environmental presence of C. gattii in Cuba, we 
included two reports of fatal infections due to this species, one from a cheetah at the 
National Zoo in Havana and one from a HIV-negative patient. The animal was imported 
from South Africa and the patient had a history of travel to Central America. Both died 
due to cryptococcal infection after 16 months and 2 years, respectively (Polo et al., 2010; 
Illnait-Zaragozi et al., 2011; Illnait-Zaragozi et al., 2013). 
There are three main arguments to support the hypothesis that both, animal and human 
patient, had a dormant infection: i) there was no evidence suggesting environmental 
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presence of this species in Cuba despite multiple attempts to recover C. gattii from 
trees and cacti (Illnait-Zaragozí et al., 2012); ii) it has been demonstrated that the time 
interval between exposure to C. gattii and the development of the disease is highly 
variable being either an acute infection or reactivation of a longstanding subclinical 
infection depending on the immunological status of the patient (Hagen et al., 2010 (a); 
Hagen et al., 2012 (b)); iii) both had a history of travel to C. gattii endemic regions and 
AFLP and the bootstrap Maximum Likelihood phylogenetic analysis after sequencing 
of the molecular analysis (Hagen et al., 2012 (b)) showed that the C. gattii strain from 
the cheetah was genotype AFLP4, nearly identical to a strain isolated from an unknown 
source in Kenya, and the C. gattii strain from the patient was genotype AFLP5 also 
closely related with two clinical and two environmental strains from Colombia (Illnait-
Zaragozi et al., 2011; Illnait-Zaragozi et al., 2013). Although genotype AFLP5 was originally 
reported from India, the current literature suggests that it has spread throughout Latin-
American countries (Argentina, Brazil, Colombia, Guatemala Mexico, and Venezuela), 
the west coast of the U.S.A., as well as over Asia and Australia (Chowdhary et al., 2013).
Infections due to C. gattii genotypes AFLP4 and AFLP6 usually occur in patients without 
detectable predisposing factors while genotypes AFLP5, AFLP7 and AFLP10 appear to 
be more associated with an impaired immune system, similar to C. neoformans (Hagen 
et al., 2010 (a); Hagen et al., 2012 (b)). Interestingly no underlying diseases, previously 
associated with C. gattii genotype AFLP5 infections, could be demonstrated in our 
patient.
Cryptococcus gattii infection usually requires longer treatment, is associated with a poor 
therapeutic response, development of neurological complications and high mortality 
(Kozubowski and Heitman, 2011; Kwon-Chung et al ., 2011, Marr et al., 2011). The human 
patient passed away one year after the diagnosis was made despite a prolonged treatment 
with amphotericin B, fluconazole, voriconazole and gamma interferon even when the 
isolate did not show in vitro resistance to these antifungal agents (Illnait-Zaragozí et al., 
2013). The animal died before any diagnosis could be made (Polo et al., 2010).
Until a decade ago, cryptococcosis caused by the primary pathogenic yeast C. gattii was 
a rarely encountered infection outside tropical and subtropical regions (Springer and 
Chaturvedi, 2010). However, this has changed due to an unprecedented outbreak that 
emerged in the temperate climate of Vancouver Island (British Columbia, Canada) and 
subsequently expanded further into the Pacific Northwest (Byrnes et al., 2009). 
Even though C. neoformans and C. gattii share most of the properties that confers 
pathogenicity, the lather species seems to be more virulent, as it has been held 
responsible for disease in apparently immunocompetent hosts (Illnait-Zaragozí et al., 
2013; Hagen et al., 2010 (a); Hagen et al., 2012 (b)). Although significant environmental 
colonization by C. gattii was found during the Vancouver Island outbreak, relatively 
few people developed overt disease (Kidd et al., 2007). This led to the hypothesis that 
a specific defect in the innate immune system predisposed the patients to infection 
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with this agent. In addition, other factors such as intracellular survival, outgrowth or 
dissemination may play an important role in their virulence (Ma et al., 2009). 
Our study on the in vitro cytokine production of human PBMCs demonstrated that 
i) Cuban clinical and environmental C. neoformans var. grubii isolates did not show 
significant difference in cytokine induction; ii) C. gattii induce higher concentrations 
of the pro-inflammatory cytokines (IL-1β, TNF-α and IL-6 and the Th17/22 cytokines 
IL-17 and IL-22) compared to C. neoformans var. neoformans and C. neoformans var. 
grubii; iii) clinical C. gattii isolates induced higher amounts of IL-1β and IL-6 than 
environmental isolates; iiii) a contribution of TLR4 and TLR9, but not of TLR2 was 
observed in the ex-vivo cytokine response to C. gattii (Stoffelen et al., 2013). 
The current study was not designed to identify which components of the cell wall are 
involved in the initial cytokine response. This reaction appeared to be independent 
of TLR2 recognition, since blocking of this receptor had no effect on cytokine 
concentrations (Stoffelen et al., 2013). This contrasted with what Biondo et al. found 
in mice; they demonstrated a key role of TLR2, but not of TLR4 (Biondo et al., 2005). 
Conversely, other studies found no major role of TLR2 in survival of cryptococcal 
infections in a murine model (Yauch et al., 2004; Nakamura et al., 2006).
To summarize it was not possible to demonstrate the presence of local isolates of C. 
gattii in Cuba. Attempts to recover this species from environmental samples have been 
fruitless and isolates from clinical cases (human and animal) seem to originate from 
dormant infections imported from endemic regions. These findings agree with evidence 
points at the relationship between development of infection and a visit to areas with 
higher C. gattii prevalence. A comprehensive prospective study in Cuba is necessary 
to get an estimation of the environmental prevalence of C. neoformans and C. gattii, 
not only in decayed wood but also in other natural substrates. Finally, knowledge of 
the host’s immune response to different Cryptococcus spp. can provide further insight 
that will lead to a better understanding of the pathogenesis of cryptococcosis and its 
management.
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Final remarks
It is widely accepted that fungal pathogens have an enormous influence on plant and 
animal life. Recent reports described the extraordinary and frightening impact of these 
agents on species extinction, food security, and ecosystem disturbances. In contrast, 
the effect that fungal infections have on human health is not widely recognized and 
deaths resulting from these infections are often overlooked. During their life most 
people will suffer from a superficial fungal infection. Such infections are generally easy 
to cure, but millions of individuals worldwide will contract life-threatening invasive 
infections that are much harder to diagnose and to treat. Of particular concern is the 
high mortality rate associated with such infections. It often exceeds 50% despite the 
availability of several antifungal drugs (Brandt and Park, 2013; Brown et al., 2012; Frey-
Klett et al., 2011; Wang et al., 2011). Cryptococcal infections are not an exception in this 
context. Our studies, on molecular, clinical-epidemiological and in vitro susceptibility 
aspects in relation with the C. neoformans/C. gattii species, have been conducted to 
improve our understanding of the disease and its causative agent.
126
Chapter 12
References
Armstrong-JD, Meintjes G, Brown GD. A neglected epidemic: fungal infections in HIV/AIDS. 
Trends Microbiol 2014; 22: 120-7.
Arteaga E, Capó De Paz V, Pérez-Fernández-Terán ML. Micosis oportunistas invasivas en el sida. 
Un estudio de 211 autopsias. Rev Iberoam Micol 1998; 15: 33-5.
Biondo C, Midiri A, Messina L, Tomasello F, Garufi G, Catania MR, Bombaci M, Beninati C, Teti G, 
Mancuso G. MyD88 and TLR2, but not TLR4, are required for host defense against Cryptococcus 
neoformans. Eur J Immunol 2005; 35: 870-8.
Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Dromer F, Meyer W. Hybrid genotypes in the 
pathogenic yeast Cryptococcus neoformans. Microbiology 2001; 147: 891-907.
Bovers M, Hagen F, Boekhout T. Diversity of the Cryptococcus neoformans-Cryptococcus gattii 
species complex. Rev Iberoam Micol 2008; 25: S4-12. (a)
Bovers M, Hagen F, Kuramae EE, Boekhout T. Six monophyletic lineages identified within 
Cryptococcus neoformans and Cryptococcus gattii by multi-locus sequence typing. Fungal Genet 
Biol 2008; 45: 400-21. (b)
Bovers M, Hagen F, Kuramae EE, Diaz MR, Spanjaard L, Dromer F, Hoogveld HL, Boekhout 
T. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus 
gattii. FEMS Yeast Res 2006; 6: 599-607.
Brandt ME, Park BJ. Think fungus–Prevention and control of fungal Infections. Emerg Infect Dis 
2014; 19: 1688-9.
Brandt ME, Pfaller MA, Hajjeh RA, Hamill RJ, Pappas PG, Reingold AL, Rimland D, Warnock 
DW, Cryptococcal disease active surveillance group. Trends in antifungal drug susceptibility of 
Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob 
Agents Chemother 2001; 45: 3065-9.
Brown GD, Denning DW, Gow NAR, Levitz SM, Netea MG, White TC. Hidden killers: human 
fungal infections. Sci Transl Med 2012; 4. doi: 10.1126/scitranslmed.3004404.
Byrnes EJ, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, Heitman J. Molecular evidence that the 
range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the 
Pacific Northwest in the United States. J Infect Dis 2009; 199: 1081-6.
Cannon RD, Lamping E, Holmes R, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, 
Monk BC. Efflux-mediated antifungal drug resistance. Clinical Microbiol Rev 2009; 22: 291-321.
Casadevall A, Perfect JR. Cryptococcus neoformans. ASM Press, Washington DC 1998.  
Chowdhary A, Prakash A, Randhawa HS, Kathuria S,  Hagen F, Klaassen CH, Meis JF. First 
12
127
General discussion and future directions
environmental isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review. 
Mycoses 2013; 56: 222-8.
Chowdhary A, Randhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus 
neoformans and C. gattii in India: an update. Crit Rev Microbiol 2012; 38: 1-16.
Cox JA, Lukande RL, Nelson AM, Mayanja-Kizza H, Colebunders R, van Marck E, Manabe YC. 
An autopsy study describing causes of death and comparing clinico-pathological findings among 
hospitalized patients in Kampala, Uganda. PLoS One 2012; 7: e33685. 
Cuenca-Estrella M. Antifúngicos en el tratamiento de las infecciones sistémicas: importancia del 
mecanismo de acción, espectro de actividad y resistencias. Rev Esp Quimioter 2010; 23:169-76.
Curbelo A. Septicemia y meningitis a Cryptococcus neoformans. Arch Hosp Univ (Cuba) 1951; 
9:324-30.
Dalhoff A, Ambrose PG, Mouton JW. A long journey from minimum inhibitory concentration 
testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving 
breakpoints. Infection 2009; 37: 296-305.
de Valk HA, Meis JF, Bretagne S, Costa JM, Lasker BA, Balajee SA, Pasqualotto AC, Anderson 
MJ, Alcázar-Fuoli L, Mellado E, Klaassen CH. Interlaboratory reproducibility of a microsatellite-
based typing assay for Aspergillus fumigatus through the use of allelic ladders: Proof of concept. 
Clin Microbiol Infect 2009; 15: 180-7.
del Poeta M, Casadevall A. Ten challenges on Cryptococcus and Cryptococcosis. Mycopathologia 
2012;173:303-10. 
Doering TL. How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in 
Cryptococcus neoformans. Annu Rev Microbiol 2009; 63: 223-47.
Espinel-Ingroff A, Aller AI, Canton E, Castañón-Olivares LR, Chowdhary A, Cordoba S, Cuenca-
Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd 
S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez 
T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. Cryptococcus neoformans-
Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint 
distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole and 
voriconazole. Antimicrob Agents Chemother 2012; 56: 5898-906. (b)
Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, 
Guarro J, Johnson E, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MSC, Ostrosky-
Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J. Cryptococcus neoformans-
Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint 
distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob 
Agents Chemother 2012; 56: 3107-13. (a)
Fonseca A, Boekhout T, Fell JW. Cryptococcus Vuillemin (1901). In: Kurtzman CP, Fell JW, 
Boekhout T. (Eds.) The yeasts: a taxonomic study. Elsevier Science & Technology, Amsterdam, 
2011; p: 1665-741.
128
Chapter 12
Frey-Klett P, Burlinson P, Deveau A, Barret M, Tarkka M, Sarniguet A. Bacterial-fungal interactions: 
hyphens between agricultural, clinical, environmental, and food microbiologists. Microbiol Mol 
Biol Rev 2011; 75: 583-609.
Friedman GD, Fessel WJ, Udaltsova NV, Hurley LB. Cryptococcosis: the 1981–2000 epidemic. 
Mycoses 2005; 48: 122-5.
Govender NP, Patel J, van Wyk M, Chiller TM, Lockhart SR. Trends in antifungal drug susceptibility 
of Cryptococcus neoformans isolates obtained through population-based surveillance in South 
Africa in 2002–2003 and 2007–2008. Antimicrob Agents Chemother 2011; 55: 2606-11.
Guinea J, Hagen F, Peláez T, Boekhout T, Tahoune H, Torres-Narbona M, Bouza E. Antifungal 
susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected 
during 18 years in a single institution in Madrid, Spain. Med Mycol 2010; 48: 942-8.
Hagen F, Boekhout T. The search for the natural habitat of Cryptococcus gattii. Mycopathologia 
2010; 70: 209–11 (b). 
Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, 
Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout 
T.  Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 2012; 
18: 1618-24 (b).
Hagen F, Illnait-Zaragozí MT, Meis JF, Chew WH, Curfs-Breuker I, Mouton JW, Hoepelman AI, 
Spanjaard L, Verweij PE, Kampinga GA, Kuijper EJ, Boekhout T, Klaassen CH. Extensive genetic 
diversity within the Dutch clinical Cryptococcus neoformans population.J Clin Microbiol 2012; 
50: 1918-26 (a).
Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA. Activated dormant Cryptococcus 
gattii infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular 
epidemiological approach. Med Mycol 2010; 48: 528-31 (a).
Illnait-Zaragozí MT, Hagen F, Fernández CM, Martínez GF, Polo JL, Boekhout T, Klaassen CH, 
Meis JF. Reactivation of a Cryptococcus gattii infection in a cheetah (Acinonyx jubatus) held in 
the National Zoo, Havana, Cuba. Mycoses 2011; 54: e889-92 (b).
Illnait-Zaragozi MT, Martínez-Machín GF, Curfs-Breuker I, Fernández-Andreu CM, Boekhout 
T, Meis JF. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other 
antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents 
Chemother 2008; 52: 1580-2.
Illnait-Zaragozi MT, Martínez-Machín GF, Fernández-Andreu CM, Boekhout T, Meis JF, Klaassen 
CH. Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii 
isolates from Cuba shows multiple genetic lineages. Plos One 2010; 5: e9124. 
Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM, Perurena-Lancha MR, 
Theelen B, Boekhout T, et al. Environmental isolation and characterization of Cryptococcus 
species from living trees in Havana City, Cuba. Mycoses 2012; 55: 138-44. 
Illnait-Zaragozí MT, Ortega-Gonzalez LM, Hagen F, Martínez-Machin GF, Meis JF. Fatal 
12
129
General discussion and future directions
Cryptococcus gattii genotype AFLP5 infection in an immunocompetent Cuban patient. Med 
Mycol Case Report 2013;2:48-51.
Iqbal N, DeBess EE, Wohrle E, Sun B, Net RJ, Ahlquist AM, Chiller T, Lockhart SR. Correlation 
of genotype and in vitro susceptibilities of Cryptococcus gattii from the Pacific Northwest of the 
United States. J Clin Microbiol 2010; 48:539-44.
Jain N, Fries BC. Phenotypic switching of Cryptococcus neoformans and Cryptococcus gattii. 
Mycopathologia 2008; 166: 181-8.
Kidd SE, Chow Y, Mak S, Bach PJ, Chen H, Hingston AO, Kronstad JW, Bartlett KH. 
Characterization of environmental sources of the human and animal pathogen Cryptococcus 
gattii in British Columbia, Canada, and the pacific northwest of the United States. Appl Environ 
Microbiol 2007; 73: 1433-43.
Kielstein P, Hotzel H, Schmalreck A, Khaschabi D, Glawischnig W. Occurrence of Cryptococcus 
spp. in excreta of pigeons and pet birds. Mycoses 2000; 43: 7-15.
Kozubowski L, Heitman J. Profiling a killer, the development of Cryptococcus neoformans. FEMS 
Microbiol Rev 2011; doi:10.1111/j.1574-6976.2011.
Kwon-Chung KJ, Boekhout T, Wickes BL, Fell JW. Systematics of the genus Cryptococcus and its 
type species C. neoformans. In: Cryptococcus: From human pathogen to model yeast. Heitman J. 
et al. (eds) ASM Press, Washington, DC. 2011; p: 3-15.
Lazera MS, Salmito MA, Londero AT, Trilles L, Nishikawa MM, Wanke B. Possible primary 
ecological niche of Cryptococcus neoformans. Med Mycol 2000; 38: 379-83.
Lewis RE, Pharm D. Current concepts in antifungal pharmacology. Mayo Clin Proc 2011; 86: 805-
817.
Lin X. Cryptococcus neoformans: Morphogenesis, infection, and evolution. Infect Genet Evol 
2009; 9: 401-16.
Litvintseva AP, Mitchell TG. Most environmental isolates of Cryptococcus neoformans var. grubii 
(serotype A) are not lethal for mice. Infect Immun 2009; 77: 3188-95.
Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T, May RC. The 
fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism 
driven by mitochondrial regulation. Proc Natl Acad Sci U S A 2009; 106: 12980-5.
Mandal P, Banerjee U, Casadevall A, Nosanchuk JD. Dual infections with pigmented and albino 
strains of Cryptococcus neoformans in patients with or without human immunodeficiency virus 
infection in India. J Clin Microbiol 2005; 43: 4766-72. 
Marr KA, Datta K, Pirofski LA, Barnes R. Cryptococcus gattii infection in healthy hosts: a sentinel 
for subclinical immunodeficiency? Clin Infect Dis 2012 54: 153-4.
Metin B, Findley K, Heitman J. The mating type locus (MAT) and sexual reproduction of 
130
Chapter 12
Cryptococcus heveanensis: Insights into the evolution of sex and sex-determining chromosomal 
regions in fungi. PLos Genet 2010; 6: e1000961.
Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz MR, Esposto MC, Fisher M, Gilgado F, 
Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-
Chung J. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and 
Cryptococcus gattii. Med Mycol 2009; 47: 561-70.
Mlinaric-Missoni E, Hagen F, Chew WH, Vazic-Babic V, Boekhout T, Begovac J. In vitro antifungal 
susceptibilities and molecular typing of sequentially isolated clinical Cryptococcus neoformans 
strains from Croatia. J Med Microbiol 2011; 60:1487-95.
Nakamura K, Miyagi K, Koguchi Y, Kinjo Y, Uezu K, Kinjo T, Akamine M, Fujita J, Kawamura I, 
M, Adachi Y, Ohno N, Takeda K, Akira S, Miyazato A, Kaku M, Kawakami K. Limited contribution 
of Toll-like receptor 2 and 4 to the host response to a fungal infectious pathogen, Cryptococcus 
neoformans. FEMS Immunol Med Microbiol 2006; 47: 148-54.
Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, Tsui KM, Mitchell TG, 
Vainstein MH, Meyer W. Genetic diversity of the Cryptococcus species complex suggests that 
Cryptococcus gattii deserves to have varieties. Plos One 2009; 4: e5862.
Odds, F. C. Drug evaluation: BAL-8557, a novel broad-spectrum triazole antifungal. Curr. Opin. 
Investig. Drugs 2006; 7: 766-72.
Park BJ, Wannemuehler KA, Marston BJ, Govender N, Pappas PG, Chiller TM. Estimation of the 
current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 
2009; 23: 525-30.
Pfaller MA, Messer SA, Boyken L, Hollis RJ, Rice C, Tendolkar S, Diekema DJ. In vitro activities 
of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. 
and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal 
surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-5.
Polo JL, Fernández CM, Martínez GF, Illnait MT, Perurena MR. Cryptococcus gattii aislado de 
un guepardo (Acinonyx jubatus) del Parque Zoológico Nacional de Cuba. Rev Cubana Med Trop 
2010; 62: 257-60.
Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, 
Beglinger C. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum 
antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral 
administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. 
Antimicrob Agents Chemother 2006; 50: 279-85. (a)
Schmitt-Hoffmann A, Roos B, Maares J, Heep M, Spickerman J, Weidekamm E, Brown T, Roehrle 
M. Triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, 
in healthy volunteers. Antimicrob Agents Chemother 2006; 50:286-93. (b)
Schoffelen T, Illnait-Zaragozi MT, Joosten LAB, Netea MG, Boekhout T, Meis JF, Sprong T. 
Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. 
Plos ONE 2013; 8(1):e55579. 
12
131
General discussion and future directions
Seifert H, Aurbach U, Stefanik D, Cornely O. In vitro activities of isavuconazole and other 
antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 
51: 1818-21.
Shoham S, Huang C, Chen JM, Golenbock DT, Levitz SM. Toll-like receptor 4 mediates intracellular 
signaling without TNF-alpha release in response to Cryptococcus neoformans polysaccharide 
capsule. J Immunol 2001; 166: 4620-6.
Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. Heteroresistance to fluconazole in 
Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob Agents 
Chemother 2009; 53: 2804-15. 
Snelders E, Camps SMT, Karawajczyk A, Schaftenaar G, Kema GHJ, van der Lee HA, Klaassen CH, 
Melchers WJ, Verweij PE. Triazole fungicides can induce cross-resistance to medical triazoles in 
Aspergillus fumigatus. Plos One 2012; 7: e31801.
Souza LK, Fernándes OFL, Kobayashi CC, Passos XS, Costa CR, Lemos JA, Souza-Júnir AH, 
Silva MR. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus 
neoformans in Goiânia City, Goiás, Brazil. Rev Inst Med Trop Sao Paulo 2005; 47: 253-6.
Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis 
2010; 16: 14-20. 
Trilles L, Lazera M, Wanke B, Theelen B, Boekhout T. Genetic characterization of environmental 
isolates of the Cryptococcus neoformans species complex from Brazil. Med Mycol 2003; 41: 383-
90.
Vandenbossche I, Vaneechoutte M, Vandevenne M, De Baere T, Verschraegen G. Susceptibility 
testing of fluconazole by the NCCLS broth macrodilution method, E-test, and disk diffusion for 
application in the routine laboratory. J Clin Microbiol 2002; 40: 918-21.
Vandeputte P, Ferrari S, Coste AT. Antifungal resistance and new strategies to control fungal 
infections. Int J Microbiol 2012; Article ID 713687, doi:10.1155/2012/713687.
Varma A, Kwon-Chung KJ. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob 
Agents Chemother 2010; 54: 2303-11.
Viviani MA, et al. Molecular analysis of 311 Cryptococcus neoformans isolates from a 30-month 
ECMM survey of cryptococcosis in Europe. FEMS Yeast Res 2006; 6: 614-19.
Wang X, Li W, Sun S, Kozubowski L, Lee SC, Feretzaki M, Heitman J. Know your enemy: how to 
build and vanquish a global fungal scourge. Mycopathologia 2012;173: 295-301.
 Yauch LE, Mansour MK, Shoham S, Rottman JB, Levitz SM. Involvement of CD14, toll-like receptors 
2 and 4, and MyD88 in the host response to the fungal pathogen Cryptococcus neoformans in vivo. 
Infect Immun 2004; 72: 5373-82.
Zhu J, Kang Y, Uno J, Taguchi H, Liu Y, Ohata M, Tanaka R, Moretti MK, Mikami Y. Comparison 
of genotypes between environmental and clinical isolates of Cryptococcus neoformans var. grubii 
based on microsatellite patterns. Mycopathologia 2010; 169: 47-55. 

1Chapter 3
Summary
Samenvatting
Resumen
134
Chapter 13
Summary
Cryptococcosis ranks among the three most common life-threatening opportunistic 
infections in persons with AIDS. Other patient groups with impaired T-cell function 
have an up to 6% lifetime risk to develop clinical cryptococcosis. Although about 100 
species belonging to the genus Cryptococcus have been described, members of the 
C. neoformans/C. gattii species complex are associated with the majority of human 
infections. This complex contains two pathogenic species: C. neoformans (serotypes 
A, D and AD), and C. gattii (serotypes B and C) and at least 10 monophyletic lineages 
representing these species and their serotypes as well as some hybrids. This thesis 
includes three main parts that compile eleven publications aimed to contribute to a 
better understanding of cryptococcosis and it causative agent. 
Studies of local and global epidemiology of Cryptococcus spp. have been hampered by 
the lack of rapid, discriminatory, and exchangeable typing methods. Part I of the thesis 
describes the molecular characterization of clinical and environmental C. neoformans 
species complex isolated from Cuba and the Netherlands. For this purpose a set of 190 
Cuban strains (122 clinical and 68 from pigeon guano) as well as 300 Dutch clinical strains 
were investigated by determining the mating type, serotype, AFLP and microsatellite 
genotype. For the last method nine microsatellite markers from the genome of C. 
neoformans var. grubii H99 were selected using the Tandem Repeats Finder software. 
All the Cuban and most of the Dutch isolates were serotype αA (demonstrated for the 
first time in Cuba). In general the most frequent genotype was AFLP1, distantly followed 
by AFLP2 and AFLP3. Microsatellite typing revealed multiple clusters of related 
genotypes which were assigned as microsatellite complexes. Dutch strains showed a 
high genetic diversity among serotype A isolates but a lower diversity within serotype 
D; most of the Cuban environmental isolates (70%) fell into one microsatellite complex 
containing only few clinical isolates (49 environmental versus 2 clinical) while clinical 
isolates were segregated over multiple microsatellite complexes. These findings led us 
to conclude that the selected panel of microsatellite markers was an excellent tool to 
study the epidemiology of C. neoformans var. grubii; that a large genotypic variation 
among these clinical isolates exist; and that the occurrence of additional source(s) of 
human cryptococcal infections beside pigeon guano in Cuba is possible.
AFLP genotyping revealed that one of the Dutch patients was infected by multiple 
genotypes, while genotyping with microsatellites of 19 isolates from seven Cuban 
patients with recurrent cryptococcal meningitis displayed 14 distinctive profiles: in 
three patients the infection was associated with identical isolates and the remaining 
patients had relapse isolates which were genotypically different. Antifungal 
susceptibility for amphotericin B, fluconazole, flucytosine, itraconazole, voriconazole, 
posaconazole and isavuconazole was tested by CLSI M27-A3 broth microdilution. 
Among the Dutch studied strains, one had high flucytosine MIC (>64 µg/mL), while 
decreased susceptibility (>16 µg/mL) of flucytosine and fluconazole was found in 9 and 
10 C. neoformans isolates, respectively. None of the Cuban strains were resistant to the 
studied drugs. These findings suggest that recurrence of cryptococcal meningitis in 
these patients was not associated with drug resistance of the original strain but with an 
initial infection with different strains or a re-infection with a new strain. 
13
135
Summary - Resumen
The management of cryptococcosis has been one of the most studied mycotic diseases 
but there are still many unresolved questions. Despite medical advances, the mortality 
rate during the first three months of treatment exceeds 20% and approaches 100% in 
patients who do not receive proper therapy. Part II of the thesis was devoted to the 
study of antifungal activity of isavuconazole (a new triazole) and six other antifungal 
drugs on a wide collection of cryptococcal strains isolated from human, veterinary, and 
environmental sources. 
One hundred sixty-five Cuban C. neoformans var. grubii and a worldwide collection 
of 350 C. gattii isolates were tested against amphotericin B, flucytosine, fluconazole, 
itraconazole, voriconazole, posaconazole and isavuconazole by CLSI M27-A3 broth 
microdilution. Of the seven antifungal compounds, voriconazole and posaconazole 
showed strong in vitro antifungal activity (up to 0.25 µg/mL) while isavuconazole 
displayed even lower MIC90 (up to 0.125 µg/mL). Amphotericin B had an acceptable 
MIC90 (up to 0.5 µg/mL), but flucytosine and fluconazole had higher MIC90s (up to 8 µg/
mL). The results indicate that, given the oral bioavailability and the well-tolerated nature 
of the new azoles, they might become an important addition to the armamentarium of 
antifungal agents against Cryptococcus strains. To the best of our knowledge this was 
the first report evaluating isavuconazole against Cryptococcus spp. which was the most 
effective antifungal drug in terms of in vitro activity. 
In addition C. gattii isolates were divided into seven AFLP genotypes, including the 
interspecies hybrids AFLP8 and AFLP9. Most of clinical isolates (n = 215) comprised 
genotypes AFLP4 (n = 76) and AFLP6 (n = 103). The latter had significantly higher 
geometric mean MICs of flucytosine and fluconazole than the first ones which 
suggested that susceptibility to antifungal drugs is species- and genotype-specific. This 
was corroborated by the international study of wild type (WT) susceptibility endpoint 
distributions and epidemiological cutoff values (ECV). Such parameters were recently 
established by Espinel-Ingroff and co-workers for amphotericin B and flucytosine versus 
C. neoformans/C. gattii species complex and here it was established for fluconazole, 
itraconazole, posaconazole, and voriconazole. The results highlight the utility of cutoffs 
as a practical tool to detect resistance among Cryptococcus isolates and that such values 
are species- and molecular type-specific: fluconazole (8 to 32 µg/mL), itraconazole 
(0.25 to 1 µg/mL), posaconazole (0.25 to 0.5 µg/mL), and voriconazole (0.12 to 0.25 µg/
mL). It was suggested to include these ECVs in the revised version of the CLSI M27-A3 
document and to continue susceptibility surveillance in order to corroborate or expand 
the information provided in this study as well as to start investigations to determine the 
relationship between molecular mechanisms of triazole resistance and the proposed 
ECV. 
C. neoformans and C. gattii have been worldwide isolated from environmental sources. 
Although the latter one used to have a more restricted distribution to tropical and 
subtropical climates the outbreaks in North America indicates the adaptation of 
this organism to new environments. This, together with the highly variable interval 
between exposure and development of clinical disease, makes it more difficult to arrive 
to conclusions of its epidemiology. Part III of the thesis involves the analysis of C. 
neoformans/C. gattii species complex isolated from humans, animal and plants in 
Cuba as well as studies about pathogenic differences between both species.
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Routinely only C. neoformans var. grubii used to be isolated from clinical samples 
and pigeon droppings and previous work provided strong evidence of an additional 
origin of exposure to this yeast in Cuba. This led to conduct an environmental study 
of 662 samples collected from 331 trees and cacti in Havana, Cuba. Initial selection of 
Cryptococcus spp. isolates by conventional techniques yielded 121 C. neoformans and 61 
C. gattii. Further characterization by AFLP and DNA sequence analysis showed that none 
of them was C. gattii; only one proved to be C. neoformans var. grubii; 27 were identified 
as other different species; and 65 unidentifiable isolates segregated into ten potentially 
novel species. Up to now attempts to recover C. gattii from environmental samples in 
Cuba have been fruitless, so these results highlight the need of more epidemiological 
studies to determine the exact distribution of C. neoformans and C. gattii in Cuba as 
well as the importance to apply molecular methods to confirm identification of isolates 
from environmental sources.
Part III also includes the description of the first two documented cases of C. gattii in 
Cuba: from a cheetah (Acinonyx jubatus) held at the National Zoo, in Havana and from 
a Cuban immunocompetent patient. Both cases had a travel history (South Africa and 
Central America respectively) and molecular analysis showed that the strains from the 
animal belong to genotype AFLP4 and those of the human to AFLP5. MLST sequences 
clustered with strains from Kenya and Colombia respectively which strongly suggests 
that both cases had a dormant infection when arrived to Cuba and that this method is 
an excellent approach to trace a clinical strain to its geographic origin. 
Although C. neoformans and C. gattii share most of the properties that confer 
pathogenicity, the latter species seems to be more virulent, as it has been the main 
causative agent of disease in apparently immunocompetent hosts. At the end of Part 
III a series of experiments is described aimed to demonstrate that the ability of C. gattii 
to cause disease in humans depends on a distinct innate cytokine response of the host. 
For this purpose an ex-vivo cytokine profile of human peripheral blood mononuclear 
cells of healthy individuals was determined, after stimulation with 40 different well-
defined heat-killed C. gattii, C. neoformans and several hybrid isolates. Furthermore, 
the involvement of TLR2, TLR4 and TLR9 in the pro-inflammatory cytokine response to 
C. gattii was investigated. The results suggested that clinical C. gattii isolates induced a 
more pronounced inflammatory response (IL-1b, TNF
α
 and IL-6) and Th17/22 cytokine 
response compared to non-clinical C. gattii and other Cryptococcus species which is 
dependent on TLR4 and TLR9 as cellular receptors. In this study it was not identified 
which cell wall components were involved in the initial cytokine response.
Since about a million persons worldwide contract cryptococcosis and its mortality 
exceeds 50% despite the availability of several antifungal drugs, we hope that these 
studies of the C. neoformans/C. gattii species complex have contributed to more 
understanding of these pathogenic yeasts and the infection they cause.
13
137
Summary - Resumen
Samenvatting
Cryptococcose behoort tot de drie meest voorkomende levensbedreigende 
opportunistische infecties bij mensen met HIV/AIDS. Andere patiëntengroepen met 
een verminderde T-celfunctie hebben een tot 6% hoger risico om gedurende hun leven 
cryptococcose te ontwikkelen. Hoewel er ongeveer 100 soorten gisten zijn beschreven 
die tot het genus Cryptococcus behoren, zijn soorten uit het C. neoformans/C. gattii 
species complex grotendeels verantwoordelijk voor infecties bij mensen en dieren. 
Het complex bevat twee pathogene soorten: C. neoformans (serotypen A, D en 
AD ) en C. gattii (serotypen B en C ) en valt uiteen in tenminste 10 monofyletisch 
clusters, daarnaast zijn er enkele hybriden beschreven. Dit proefschrift bestaat uit drie 
onderdelen die elf publicaties omvatten en die mogelijk bijdragen aan een beter begrip 
van de cryptococcose en de verwekker.
Onderzoek naar de lokale en globale epidemiologie van Cryptococcus soorten werd in 
het verleden gehinderd door een gebrek aan snelle, onderscheidende en uitwisselbare 
typeringstechnieken. Deel I van dit proefschrift beschrijft de moleculaire karakterisatie 
van klinische en omgevingsisolaten uit het C. neoformans species complex geïsoleerd 
in Cuba en in Nederland. Hiervoor is een set van 190 Cubaanse stammen (122 klinische 
en 68 uit duivenontlasting) en 300 Nederlandse klinische stammen onderzocht voor 
wat betreft het mating-type, serotype, AFLP en microsatelliet genotype. Voor de 
laatst genoemde methode werden negen microsatellietmarkers uit het genoom van 
C. neoformans var. grubii stam H99 geselecteerd met behulp van het softwarepakket 
Tandem Repeats Finder. Alle Cubaanse en de meeste Nederlandse isolaten waren 
mating- en serotype αA (dit is voor het eerst dat dit werd beschreven voor Cuba). Het 
meest voorkomende genotype bleek AFLP1 te zijn, gevolgd door AFLP2 en AFLP3. 
Microsatelliet typering liet meerdere clusters van verwante genotypes zien die 
microsatelliet-complexen worden genoemd. Nederlandse stammen hadden een hoge 
genetische diversiteit onder serotype A isolaten maar een lagere diversiteit binnen 
serotype D; de meeste Cubaanse omgevingsisolaten (70%) vielen in een microsatelliet-
complex met slechts weinig klinische isolaten (49 omgeving versus 2 klinische) terwijl 
klinische isolaten verspreid bleken te zijn over meerdere microsatelliet-complexen. Deze 
bevindingen leidde tot de conclusie dat het gekozen panel van microsatellietmarkers 
een uitstekend hulpmiddel is om de epidemiologie van C. neoformans var. grubii te 
onderzoeken; dat er grote genotypische verschillen tussen klinische isolaten bestaan ; 
en dat het mogelijk is dat er extra bron(nen) van menselijke Cryptococcus-infecties zijn 
in Cuba, buiten de al bekende duivenontlasting.
Genotypering middels AFLP liet zien dat één van de Nederlandse patiënten geïnfecteerd 
was met verschillende genotypen, terwijl microsatelliet genotypering van 19 isolaten 
van zeven Cubaanse patiënten met terugkerende cryptokokkenmeningitis 14 
moleculaire types liet zien: bij drie patiënten was de infectie geassocieerd met identieke 
isolaten terwijl de andere patiënten geinfecteerd waren met isolaten die genotypisch 
verschillend waren. Antifungale gevoeligheid voor amfotericine B, fluconazol, 
flucytosine, itraconazol, voriconazol, posaconazol en isavuconazole werd getest met 
de CLSI M27-A3 bouillon microdilutie-methode. Onder de Nederlandse stammen 
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was er slechts één met een hoge flucytosine MIC (> 64 µg/ml), terwijl verminderde 
gevoeligheid (> 16 µg/ml) van flucytosine en fluconazol werd gezien in respectievelijk 
9 en 10 C. neoformans isolaten. Geen van de Cubaanse stammen waren resistent tegen 
antifungale geneesmiddelen. Deze bevindingen suggereren dat een hernieuwde infectie 
van cryptokokkenmeningitis bij deze patiënten niet geassocieerd is met resistentie van 
de oorspronkelijke stam, maar met een initiële infectie met verschillende stammen of 
herinfectie met een nieuwe stam.
Cryptococcose is een van de meest bestudeerde schimmelziekten, maar er zijn nog veel 
onopgeloste vragen. Ondanks de medische vooruitgang is de sterfte in de eerste drie 
maanden van de behandeling nog steeeds meer dan 20% en loopt op tot bijna 100% bij 
patiënten die niet de juiste therapie krijgen. Deel II van dit proefschrift is gewijd aan 
de studie van de antifungale activiteit van isavuconazole (een nieuw triazool) en zes 
andere antimycotica op een brede verzameling van Cryptococcus stammen geïsoleerd 
van humane, veterinaire en ecologische bronnen .
Honderdvijfenzestig Cubaanse C. neoformans var. grubii isolaten en een wereldwijde 
verzameling van 350 C. gattii isolaten werden getest tegen amfotericine B, flucytosine, 
fluconazol, itraconazol, voriconazol, posaconazol en isavuconazole met de CLSI M27-
A3 bouillon microdilutie-methode. Van de zeven antischimmelmiddelen vertoonden 
voriconazol en posaconazol een sterke in vitro antifungale activiteit (tot 0,25 µg/ml) 
terwijl isavuconazole zelfs nog lagere MIC90 (tot 0,125 µg/ml) had. Amfotericine B 
had een aanvaardbare MIC90 (tot 0,5 µg/ml), maar flucytosine en fluconazol hadden 
hogere MIC90s (tot 8 µg/ml). De resultaten laten zien dat de nieuwe azolen, mede 
door de goede orale biobeschikbaarheid en goede verdraagzaamheid, een belangrijke 
toevoeging zijn aan het arsenaal van antischimmelmiddelen tegen Cryptococcus-
infecties. Dit onderzoek is de eerste evaluatie van isavuconazole tegen Cryptococcus 
spp. waarbij bleek dat het hoogste in vitro activiteit van alle antimycotica had. Tevens 
werden C. gattii isolaten verdeeld in zeven AFLP-genotypen, waaronder de interspecies 
hybriden met het genotype AFLP8 en AFLP9. De meeste klinische isolaten (n = 215) 
omvatten de genotypen AFLP4 (n = 76) en AFLP6 (n = 103). Deze laatste hadden 
significant hogere geometrisch gemiddelde MICs van flucytosine en fluconazol dan 
de eersten, wat suggereerde dat de gevoeligheid voor antimycotica soort- en genotype 
specifiek is. Dit werd bevestigd door een internationaal onderzoek van wild-type (WT) 
gevoeligheidsverdelingen en epidemiologische cut-off waarden (ECV). Dergelijke 
parameters zijn onlangs vastgesteld voor amfotericine B en flucytosine versus het 
C. neoformans/C. gattii species complex en hier beschreven is voor fluconazol, 
itraconazol, posaconazol en voriconazol. De resultaten benadrukken het nut van ECVs 
als een praktisch hulpmiddel om resistentie te detecteren voor Cryptococcus isolaten 
en dat deze waarden species- en genotype specifiek zijn: fluconazol (8 tot 32 µg/ml), 
itraconazol (0,25-1 µg/ml), posaconazol (0,25-0,5 µg/ml) en voriconazol (0,12-0,25 µg/
ml). Er werd voorgesteld om deze ECVs op te nemen in de herziene versie van CLSI 
M27-A3 document en door te gaan met gevoeligheidssurveillance om deze studie 
resultaten te bevestigen of uit te breiden en onderzoek te gaan doen naar de relatie 
tussen moleculaire mechanismen van triazool resistentie en de voorgestelde ECV .
C. neoformans en C. gattii zijn wereldwijd geïsoleerd uit het milieu. Hoewel C. gattii een 
meer beperkte distributie in tropische en subtropische klimaten had, laten de uitbraken 
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in Noord-Amerika zien dat dit micro-organisme zich goed aan heeft weten te passen 
aan nieuwe omgevingen. Samen met het zeer variabele interval tussen blootstelling 
en ontwikkeling van klinische ziekte, bemoeilijkt dit om harde conclusies te trekken 
over de epidemiologie. Deel III van dit proefschrift omvat een analyse van het C. 
neoformans/C. gattii species complex geïsoleerd van patienten, dieren en planten in 
Cuba alsmede studies over verschillen in pathogenese tussen beide soorten.
In het verleden werd alleen C. neoformans var. grubii routinematig geïsoleerd uit 
klinisch materiaal en uitwerpselen van duiven, eerder uitgevoerd onderzoek levert 
sterke aanwijzingen van een extra bron van blootstelling aan deze gist in Cuba. Dit 
gaf aanleiding tot een groot onderzoek van 662 monsters genomen van 331 bomen en 
cactussen in Havana, Cuba. Een eerste selectie van Cryptococcus spp. isolaten gedaan 
met conventionele technieken leverde 121 C. neoformans en 61 C. gattii stammen op. 
Verdere analyse van AFLP en DNA-sequentie data toonden aan dat er geen C. gattii 
aanwezig was en slechts één isolaat bleek C. neoformans var. grubii te zijn: 27 isolaten 
werden geïdentificeerd als andere soorten en en 65 niet-geïdentificeerde isolaten 
bestonden uit tien potentieel nieuwe soorten. Tot nu toe zijn pogingen om C. gattii te 
isoleren uit de omgeving in Cuba vruchteloos gebleken. Dit benadrukt de noodzaak 
van meer epidemiologisch onderzoek naar de exacte verspreiding van C. neoformans 
en C. gattii in Cuba en het belang van moleculaire methoden voor identificatie van 
omgevingsisolaten.
Deel III beschrijft ook de eerste twee gedocumenteerde gevallen van C. gattii in Cuba: 
een cheetah (Acinonyx jubatus) gehouden in de dierentuin in Havana en een Cubaanse 
immunocompetente patiënt. Beide gevallen hadden een relevante reisgeschiedenis 
(Zuid-Afrika en Midden-Amerika) en moleculaire analyse toonde aan dat de stam 
van het dier behoorde tot genotype AFLP4 en die van de patient tot AFLP5. MLST 
analyse toonde aan dat deze Cubaanse C. gattii-stammen clusterden met stammen uit 
respectievelijk Kenia en Colombia, wat suggereert dat beide gevallen mogelijk met een 
subklinische infectie naar Cuba zijn gereisd. MLST is een uitstekende benadering om 
van een klinische stam de geografische oorsprong op te sporen.
Hoewel C. neoformans en C. gattii beiden in het bezit zijn van virulentiefactoren die 
pathogeniciteit veroorzaken, lijkt de laatste soort meer virulent te zijn, omdat het 
de belangrijkste verwekker van de ziekte is in de immunocompetente gastheer. Aan 
het slot van deel III is een reeks experimenten beschreven met het doel om aan te 
tonen dat het vermogen van C. gattii om ziekte bij de mens te veroorzaken afhangt 
van een speciale aangeboren cytokine respons bij de gastheer. Daarom is een ex-vivo 
cytokine profiel bepaald van humane perifere bloed mononucleaire cellen van gezonde 
individuen na stimulatie met 40 verschillende goed gedefinieerde, door verhitting 
gedode, C. gattii, C. neoformans en verschillende hybride isolaten. Bovendien is de 
betrokkenheid van TLR2, TLR4 en TLR9 in de pro-inflammatoire cytokine respons 
tegen C. gattii onderzocht. De resultaten suggereerden dat klinische C. gattii isolaten 
een meer uitgesproken ontstekingsreactie (IL-1b, αTNF en IL-6) en Th17/22 cytokine 
respons induceerden dan niet-klinische C. gattii en andere Cryptococcus soorten die 
afhankelijk zijn van TLR4 en TLR9 als cellulaire receptoren. In dit onderzoek werden 
niet de celwand componenten geanalyseerd die betrokken zijn bij de oorspronkelijke 
cytokine respons.
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Ongeveer een miljoen mensen wereldwijd lopen cryptococcose op en de sterfte is hoger 
dan 50%, ondanks de beschikbaarheid van verschillende antimycotica. Ik hoop dat dit 
onderzoek naar het C. neoformans/C. gattii species complex zal bijdragen tot meer 
kennis van deze pathogene gisten en de infectie die ze veroorzaken.
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Resumen
La criptococosis constituye una de las tres infecciones oportunistas potencialmente 
mortales más frecuentes en las personas con sida. Otros grupos de pacientes con la 
función de las células T alterada tienen un riesgo de hasta el 6 % de desarrollar la forma 
clínica de esta infección. Aunque se han descrito alrededor de 100 especies pertenecientes 
al género Cryptococcus, los miembros del complejo de especies C. neoformans/C. gattii 
son los más frecuentemente asociados a infecciones humanas. Este complejo contiene 
dos especies patógenas: C. neoformans (serotipos A, D y AD) y C. gattii (serotipos B 
y C) y al menos 10 linajes filogenéticos que representan estas especies y sus serotipos, 
así como algunos híbridos. Esta tesis incluye tres partes principales que recopilan once 
publicaciones destinadas a contribuir a una mejor comprensión de la criptococosis y su 
agente causal.
Los análisis de epidemiología molecular local y global de Cryptococcus spp., se han visto 
obstaculizados por la falta de métodos de caracterización rápidos, discriminatorios 
e intercambiables. La Parte I de la tesis describe la caracterización molecular de 
aislamientos clínicos y ambientales de C. neoformans aislados en Cuba y los Países 
Bajos. Con este propósito fue investigada una colección de 190 aislamientos cubanos 
(122 clínicos y 68 recuperados de excretas de palomas), así como 300 aislamientos 
clínicos holandeses. A los mismos se les determinó el serotipo y el tipo de apareamiento 
mediante reacción en cadena de la polimerasa (PCR, de sus siglas en inglés), así como 
genotipificación mediante AFLP y fragmentos cortos repetitivos. Para este último se 
seleccionaron nueve marcadores microsatélites del genoma de C. neoformans var. grubii 
H99 utilizando el programa Tandem Repite Finder. Todos los aislamientos cubanos 
y la mayoría de los holandeses correspondieron con el serotipo Aα (demostrado por 
primera vez en Cuba). En general, el genotipo más frecuente resultó el AFLP1, seguido a 
gran distancia por AFLP2 y AFLP3. La tipificación empleando los microsatélites reveló 
múltiples grupos de genotipos relacionados que fueron denominados complejos de 
microsatélites. Los aislamientos holandeses mostraron una alta diversidad genética 
entre los especímenes del serotipo A, la cual fue menor para el serotipo D; la mayoría 
de aislamientos ambientales cubanos (70 %) quedaron agrupados en un complejo de 
microsatélites en el que sólo resultaron representados unos pocos aislamientos clínicos 
(49 ambientales vs 2 clínicos), mientras que los aislamientos clínicos se encontraban 
segregados en múltiples complejos de microsatélites. Estos hechos llevaron a la 
conclusión de que el panel seleccionado de marcadores de microsatélites resulta una 
excelente herramienta para el estudio de la epidemiología molecular de C. neoformans 
var. grubii; que existe una gran variación genotípica entre estos aislamientos clínicos; 
y a enunciar la hipótesis sobre la existencia de una fuente de criptococosis humanas 
adicional al guano de paloma en Cuba.
La caracterización mediante AFLP reveló que uno de los pacientes holandeses 
estaba infectado por múltiples genotipos, mientras que el empleo de microsatélites 
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demostró en una serie de 19 aislamientos de siete pacientes cubanos con meningitis 
criptocócica recurrente, 14 perfiles distintivos: en tres pacientes la infección se asoció 
con aislamientos idénticos y los restantes pacientes tuvieron recaídas por aislamientos 
que eran genotípicamente diferente. Se determinó la sensibilidad antifúngica frente 
a anfotericina B, fluconazol, 5-fluorocitosina, itraconazol, voriconazol, posaconazol e 
isavuconazol por el método de microdilución en caldo según el documento M27-A3 
del Instituto de Estándares para Laboratorios Clínicos (CLSI, de sus siglas en inglés). 
Entre todos los aislamientos holandeses estudiados, uno mostró alta concentración 
inhibitoria mínima (CIM) para 5-fluorocitosina (> 64 g/mL) y disminución de la 
sensibilidad (> 16 g/mL) para 5-fluorocitosina y fluconazol en 9 y 10 aislamientos de C. 
neoformans, respectivamente. Ninguno de los aislamientos cubanos resultó resistente 
a los fármacos estudiados. Estos hallazgos sugieren que la recurrencia de la meningitis 
criptocócica en estos pacientes no se asoció con resistencia del aislamiento original 
a los medicamentos, sino a una infección inicial con diferentes aislamientos o una 
reinfección con un aislamiento genotípicamente dierente.
El manejo de la criptococosis ha sido uno de los más estudiados entre las enfermedades 
fúngicas; no obstante, todavía hay muchos aspectos sin resolver. A pesar de los avances 
médicos, la tasa de mortalidad durante los primeros tres meses de tratamiento es 
superior al 20 % y se acerca al 100 % en los pacientes que no reciben la terapia adecuada. 
La Parte II de la tesis se dedica al estudio de la susceptibilidad de una colección amplia 
de aislamientos de Cryptococcus spp. de origen humano, veterinario y ambiental frente 
al isavuconazol (triazol de generación reciente) y otros seis fármacos antifúngicos.
Ciento sesenta y cinco C. neoformans var. grubii cubanos y una colección mundial de 
350 aislamientos de C. gattii fueron enfrentados a anfotericina B, 5-fluorocitosina, 
fluconazol, itraconazol, voriconazol, posaconazol e isavuconazol por el método de 
microdilución en caldo según el documento M27-A3 del CLSI. De los siete compuestos 
estudiados, voriconazol y posaconazol mostraron fuerte actividad antifúngica in vitro 
(hasta 0,25 g/mL) mientras que isavuconazol exhibió CIM90 aún más baja (hasta 0,125 
g/mL). La anfotericina B presentó un valor de CIM90 aceptable (hasta 0,5 g/mL), pero 
5-fluorocitosina y fluconazol mostraron MIC90s de hasta 8 g/mL. Los resultados indican 
que, dada la naturaleza de los nuevos azoles (voriconazol, posaconazol e isavuconazol), 
su biodisponibilidad oral y buena tolerancia, estos podrían llegar a ser una adición 
importante al arsenal de agentes antifúngicos para el tratamiento de la criptococosis. 
Hasta donde sabemos, estos constituyen los primeros informes de evaluación de 
isavuconazol frente a Cryptococcus spp., fármaco antifúngico que resultó más eficaz en 
términos de actividad in vitro.
Adicionalmente los aislamientos de C. gattii fueron divididos en siete genotipos 
mediante AFLP, incluyendo los híbridos interespecíficos AFLP8 y AFLP9. La mayoría de 
los aislamientos clínicos (n = 215) correspondieron a genotipos AFLP4 (n = 76) y AFLP6 
(n = 103). Los correspondientes a AFLP6 mostraron una media geométrica de los valores 
de CIM significativamente superiores para 5-fluorocitosina y fluconazol en comparación 
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con los del genotipo AFLP4. Esto sugiere que la susceptibilidad a los antifúngicos debe ser 
de tipo especie- y genotipo- específica. Esto fue corroborado por el estudio internacional 
de las distribuciones de punto final de la susceptibilidad antifúngica y los valores de 
corte epidemiológicos (ECV, de sus siglas en inglés) de aislamientos salvajes (WT, de 
sus siglas en inglés). Tales parámetros se establecieron recientemente por Espinel - 
Ingroff y colaboradores para la anfotericina B y 5-fluorocitosina frente al complejo de 
especies C. neoformans/C. gattii y en el presente trabajo se establecen para fluconazol, 
itraconazol, posaconazol y voriconazol. Los resultados ponen de manifiesto la utilidad 
de los puntos de corte como una herramienta práctica para detectar la resistencia entre 
los aislamientos de Cryptococcus, y se corrobora que dichos valores son específicos 
para cada especie y tipo molecular: fluconazol (8 a 32 µg/mL), itraconazol (0,25 a 1 
µg/mL), posaconazol (0,25 a 0,5 µg/mL) y voriconazol (0,12 a 0,25 µg/mL). Se sugirió 
incluir estos ECV en la versión revisada del documento M27-A3 del CLSI y mantener 
la vigilancia de la susceptibilidad a fin de corroborar o ampliar los datos ofrecidos en el 
estudio, así como llevar a cabo una investigación para determinar la relación entre los 
mecanismos moleculares de resistencia a los triazoles y el ECV propuesto.
C. neoformans y C. gattii han sido ampliamente aislados a partir de fuentes naturales. 
Aunque el último se caracteriza por tener una distribución más restringida a los climas 
tropicales y subtropicales, el brote ocurrido en América del Norte indica la adaptación 
de este organismo a nuevos ambientes. Esto, junto con el intervalo altamente variable 
entre la exposición al microorganismo y el desarrollo de la enfermedad clínica, hace más 
difícil llegar a conclusiones sobre la epidemiología de la criptococosis. La Parte III de la 
tesis consiste en el análisis de aislamientos del complejo de especies C. neoformans/C. 
gattii recuperados de humanos, animales y plantas en Cuba, así como estudios de 
patogenicidad ex-vivo de ambas especies. 
Rutinariamente sólo C. neoformans var. grubii suele ser aislado a partir de muestras 
clínicas y de las excretas de palomas en Cuba. Adicionalmente, evidencias moleculares 
recientes sugirieron la presencia de otras fuentes naturales de infección por esta 
levadura además de las investigadas. Estos hechos motivaron el estudio de 662 
muestras obtenidas de 331 árboles y cactus de La Habana, Cuba. La selección inicial 
de los aislamientos de Cryptococcus spp. se realizó mediante técnicas convencionales 
y arrojó 121 C. neoformans y 61 C. gattii. La caracterización posterior mediante AFLP y 
secuenciación de ADN, demostró que ninguno de los aislamientos correspondía a C. 
gattii; sólo uno resultó ser C. neoformans var. grubii; 27 fueron identificados como otras 
especies diferentes; y 65 aislamientos no identificables resultaron segregados en diez 
grupos genéticos no descritos anteriormente. Hasta ahora los intentos de recuperación 
de C. gattii en muestras ambientales en Cuba han sido infructuosos, por lo que estos 
resultados destacan la necesidad de continuar los estudios epidemiológicos para 
determinar la distribución exacta de C. neoformans y C. gattii en la isla, así como la 
importancia de aplicar los métodos moleculares para confirmar la identificación de los 
aislamientos recuperados de fuentes ambientales.
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La Parte III también incluye la descripción de los dos primeros casos de C. gattii 
documentados en Cuba: a partir de un guepardo (Acinonyx jubatus) del Zoológico 
Nacional, en La Habana y de un paciente inmunocompetente cubano. Ambos casos 
tenían antecedentes de viaje (África del Sur y América Central, respectivamente). El 
análisis molecular mostró que el aislamiento del animal pertenece al genotipo AFLP4 
y el del humano a AFLP5. Las secuencias genómicas obtenidas por secuenciación 
multilocus (MLST, de sus siglas en inglés) mostraron la semejanza con cepas de Kenia 
y Colombia, respectivamente, lo que sugiere que ambos casos tenían una infección 
latente en el momento de su arribo a Cuba y que este método es excelente para trazar el 
origen geográfico de los aislamientos.
Aunque C. neoformans y C. gattii comparten la mayoría de las propiedades que 
les confieren patogenicidad, esta última especie parece ser más virulentas, ya 
que es la principal responsable de la enfermedad en huéspedes aparentemente 
inmunocompetentes. Al final de la Parte III se describe una serie de ensayos con el 
objetivo de demostrar que la capacidad de C. gattii para causar enfermedad en los 
seres humanos depende de una respuesta innata distintiva de citoquinas. Con este fin, 
se evaluó el perfil de citoquinas producidas por células mononucleares de humanos 
obtenidas de sangre periférica de individuos sanos las cuales fueron estimuladas con 40 
aislamientos de C. gattii, C. neoformans y varios híbridos inactivados por calor. Además, 
se investigó la participación de TLR2, TLR4 y TLR9 en la respuesta de citoquinas pro-
inflamatorias durante la estimulación con C. gattii. Los resultados sugirieron que los 
aislamientos clínicos de C. gattii son capaces de inducir una respuesta de citoquinas 
inflamatorias (IL-1b, TNF α e IL-6) y Th17/22 más pronunciada en comparación con 
aislamientos de C. gattii no clínicos y otras especies de Cryptococcus, la cual parece ser 
dependiente de los receptores celulares TLR4 y TLR9. En este estudio no fue objetivo 
identificar qué componentes de la pared celular están implicados en la respuesta de 
citoquinas inicial lo que debe ser investigado más adelante. 
A pesar de los avances en el manejo de los pacientes con sida y el desarrollo de potentes 
antifúngicos, la tasa de morbimortalidad de la criptococosis a nivel mundial se mantiene 
por encima de límites aceptables. Esperamos que los estudios en relación con el complejo 
de especies C. neoformans/C. gattii comprendidos en esta tesis, contribuyan a mejorar 
la comprensión de estas levaduras patógenas y la infección que causan.
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